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Inflammatory bowel disease is a chronic, relapsing inflammation of the intestine. 
Approximately 0.5% of the western world is estimated to suffer from the disease. 
Crohn’s disease, a type of inflammatory bowel disease, consists of a patchy 
inflammation, that can occur throughout the entire gastrointestinal tract.  Due to 
the heterogeneous nature of Crohn’s disease, little is known about the 
mechanisms of disease pathogenesis. Compared to healthy individuals, patients 
with Crohn’s disease often have elevated levels of inflammatory T lymphocyte 
subsets, their associated effector cytokines, and higher intestinal permeability. 
Crohn’s disease has been associated with genetic risk factors, sedentary lifestyles, 
and a loss of tolerance to the commensal members of the microbiome.  
In this research, T lymphocytes from non-IBD and Crohn’s disease patient 
peripheral blood mononuclear cells (PBMCs) were analysed for comparison. 
Flow cytometry was used to fluorescently label cells and analytes of interest. 
Visual analytic tools, such as CytoAnalytics’ EarlyBird and viSNE were used to 
visualise patient variation within, and between groups. It was hypothesised that 
Crohn’s disease T lymphocytes would have a bias for inflammation-inducing T 
lymphocyte subsets, and that these cells would have a higher capacity for 
inflammation, than non-IBD controls. Indeed, inflammatory T lymphocytes were 
present at higher frequencies in Crohn’s disease patient blood samples. 
Furthermore, Crohn’s disease patient PBMCs had a higher capacity for 
proliferation in response to T lymphocyte stimulation. In responses to the 
commensal bacterium, Faecalibacterium prausnitzii, Crohn’s disease patient PBMC 
Tregs increased in frequency, whereas CD4+ inflammatory T lymphocyte subsets 
maintained their frequency. In contrast, non-IBD PBMC Tregs were not 
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influenced by co-culture with F. prausnitzii, and CD4+ inflammatory T 
lymphocyte subsets decreased in the presence of F. prausnitzii. Together, these 
data suggest that Crohn’s disease patient PBMCs respond abnormally to 
commensal bacteria, and this could play a role in disease pathogenesis. 
Intestinal organoids are derived from patient colonic biopsy stem cells. 
Organoids provide a unique in vitro model for the observation of intestinal 
interactions. In this thesis, a 2D intestinal monolayer was developed from the 
culture of 3D intestinal organoids. 2D monolayers emulate epithelial intestinal 
barrier cellular organisation. A difficult question to answer in Crohn’s disease 
research is whether intestinal permeability and inflammation is a cause or 
consequence of disease. As such, patient organoids and bacteria were integrated 
into the model stepwise, to analyse the influence each component has on the 
system, in the absence, or presence, on an active immune presence. Using this 
model, it was found that monolayers derived from Crohn’s disease patients were 
more permeable than non-IBD controls. Furthermore, Crohn’s disease patient 
monolayers had deleterious interactions in co-culture with F. prausnitzii, 
resulting in reduced epithelial integrity; in contrast to non-IBD patient 
monolayers which were unaffected. The addition of matched PBMCs into 
Crohn’s disease patient monolayers exacerbated epithelial degradation in the 
presence of F. prausnitzii.  
Taken together, it was found that Crohn’s disease patient PBMCs had greater 
inflammatory capacity than non-IBD control PBMCs. These data suggest that 
intestinal cells in patients with Crohn’s disease may have deleterious interactions 
with commensal bacteria, which could result in increased intestinal permeability. 
Furthermore, Crohn’s disease patient Treg responses to commensal bacteria 
suggest that intestinal areas of immune suppression may promote bacteria 
success, and potential dysbiosis. Translocation of the luminal microbiota into the 
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lamina propria, combined with excessive T lymphocyte inflammatory capacity, 
could be an initial driving factor for Crohn’s disease pathogenesis. 
Data in this thesis provide valuable insight into the initiation of epithelial 
degradation in patients with Crohn’s disease. These data suggest that epithelial 
degradation may occur in Crohn’s disease patients in response to commensal 
bacteria, even in the absence of an immune cell influence. With further 
development, the intestinal organoid monolayer model may provide insight into 
the mechanisms of epithelial degradation in individual patients. Further, the 
monolayer model may also provide a tool to optimise individual patient 
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The human immune system is a broad array of cell types, that maintain symbiosis 
with commensal members of the host microbiome and protect the host from 
invading pathogens and cancers. Inflammation is a critical process in immune-
based protection. Inflammation is a generic response to a stimulus, controlling 
the offensive agent through the use of chemical signals that induce the five signs 
of inflammation: pain, heat, redness, swelling, and loss of function. 
The human body is compartmentalised, organised as specialised niche areas, 
each with their own cellular response. The gastrointestinal tract is an organ which 
connects the mouth to the anus and is one of the few parts of the human body 
that directly interacts with the outside world. As such, the intestinal lumen is 
exposed to a variety of environmental microbes and allergens. Exposure to the 
microbiome is critical for the development of the human immune system. 
Foreign microbes and antigens enter the intestinal system, where they can be 
sampled by immune cells. The intestinal immune system is tolerant luminal 
antigens due to immune suppression in the surrounding intestinal tissues. Here, 
luminal antigens are sampled in a controlled environment via immune cell 
dendrites reaching through the lumen, and controlled antigen sampling via 
microfold (M) cells. 
Inflammatory Bowel Disease (IBD) is characterised by chronic inflammation of 
intestinal tissues. Chronic inflammation is a consequence of abnormal immune 
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cell responses to environments that would usually be tolerated in a healthy host. 
As such, IBD has been associated with a loss of suppression, excessive immune 
responses, and a loss of tolerance to commensal (healthy) microbes. Medical 
professionals diagnose IBD as Ulcerative Colitis (UC) - shallow lesions restricted 
to the colon, or Crohn’s Disease (CD) – deep lesions that can manifest anywhere 
in the gastrointestinal tract, often presenting as a cobblestone pattern. IBD affects 
up to 0.5% of the Western world and incidence is increasing in developing 
nations[1]. IBD symptoms can be debilitating and can include pain, diarrhoea, 
abdominal cramps, bloody stools, weight loss, and anaemia. CD has a 10-year 
risk of required intestinal resection, with a 34-86% chance of relapse within three 
years of surgery[2]. 
Due to the heterogeneous nature of IBD and a lack of knowledge of disease 
mechanisms, a cure, or even successful treatment for CD, remains difficult. 
Frontline CD treatments have limited efficacy in large groups of patients. For 
example, Infliximab, an anti-Tumour necrosis factor (TNF) antibody biologic 
treatment, is only effective in 60-87% of patients, 23-46% of whom will become 
non-responders within five years[3-5]. Mechanisms of IBD are yet to be 
elucidated and are difficult to pinpoint in individual patients, resulting in the 
inefficient selection of suitable patients for biologic treatments - reducing patient 
quality of life. This is exacerbated by the inability to accurately identify the 
mechanism of disease in an individual, as CD can be categorised into multiple 
subtypes, which dynamically change over time. However, it is generally 







1.1 The gastrointestinal tract 
The location of immune cells can directly affect their phenotype and response to 
stimuli. The gastrointestinal tract is exposed to the outside world. As a result, the 
gastrointestinal tract is an antigen-rich environment with a highly specialised 
immune system. The gastrointestinal tract is a tolerating environment, meaning 
that intestinal homeostasis is an immune-suppressed state[6]. The role of the 
immune system, in the gastrointestinal tract, is to prevent the invasion of 
microbes to deeper tissues, while also avoiding damaging inflammatory 
responses, and to tolerate commensal microbes. Uncontrolled inflammatory 
damage to the gastrointestinal tract can cause debilitating pain, reduction of 
absorbed nutrients, loss of water retention, and severe weight loss. As such, it is 
critical that the immune populations of the gastrointestinal tract maintain balance 
in their responses. In the following sections, this thesis will describe the basic 
roles of gastrointestinal cells, intestinal immune responses, and the intestinal 













Figure 1.1: The intestinal barrier in Crohn’s disease. 1) Areas of intestinal epithelial 
degradation allows the migration of luminal microbes and antigens across the intestinal 
epithelial barrier and into the lamina propria. This damage may be caused by pre-
existing inflammatory responses or inherent epithelial defects. Data in this thesis suggest 
Inflammatory bowel disease (IBD) patient intestinal cells may lose integrity upon contact 
with certain commensal bacteria 2) High permeability (low Transepithelial electrical 
resistance in monolayer model) in Crohn’s disease (CD) patient epithelial barriers may 
allow luminal microbes and antigens to migrate across the intestinal epithelial barrier in 
the absence of inflammation. 3) Presence of luminal microbes and antigens in the lamina 
propria initiates an immune response. Data in this thesis suggest that in the steady-state, 
CD patient T lymphocytes may not tolerate commensal bacteria and maintain their 
frequencies, whereas non-IBD T lymphocyte frequencies decrease. Dendritic cells can 
sample luminal antigens via dendrites in the absence of epithelial damage, which may 
trigger T lymphocyte responses in CD patients. Activation of immune cells leads to 
inflammation and further epithelial degradation 4) Immune cells recognise antigen and 
migrate towards the lymph node, via lymphatics, and potentiate immune response via 
recruitment of other immune cells. 5) Immune cells infiltrate from peripheral blood to 




1.1.1 The epithelial barrier 
The intestinal epithelial barrier is a complex structure that separates two vastly 
different environments. The intestinal mucosa is comprised of a single layer of 
intestinal epithelial cells, as well as the lamina propria (LP), a small underlying 
layer of connective tissue with a high concentration of immune cells. The 
intestinal epithelial barrier must: allow commensal colonisation, facilitate 
nutrient transport, regulate water migration, and respond to immune signals. 
The intestinal barrier is able to control each of these variables through complex 
cell-to-cell signalling, maintaining selective permeability, and possessing several 
key differentiated cell types. 
The gastrointestinal tract is constantly exposed to foreign materials and 
organisms. The intestinal epithelium is a single layer of cells which undergoes 
entire cell turnover every 2-6 days[7]. The stem cells responsible for this continual 
turnover are positioned within the base of crypts, tube-like invaginations that 
facilitate the protection of the stem cells from constituents of the luminal 
environment. The stem cells, which are identified by their expression of the Wnt 
Family Member 3A (Wnt3a)-target surface protein and the leucine-rich repeat-
containing G-protein coupled receptor (Lgr5), persist in a niche defined by the 
secretions of neighbouring cells within the crypts and underlying mesenchymal 
cells. Intestinal crypt stem cells are cultured with deep-crypt cell factors in 
specialized media to mimic the in vivo environment. Wnt3a, produced by both 
the underlying mesenchymal cells and flanking Paneth cells in the small 
intestine, is an inducer of Ascl2, a master regulator of stem cell phenotype. Lgr5+ 
stem cells proliferate and generate transit-amplifying (TA) cells. TA cells are 
highly proliferative cells that divide a finite number of times before 
differentiating into gut specialist cells[8]. As these cells are generated, they are 
pushed towards the lumen, distal to the crypt. As Paneth cells are found deep 
within crypts, the Wnt3a concentration lessens as TA cells ascend towards the 
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lumen, allowing TA cells to differentiate into their mature cell phenotypes. The 
large intestine does not contain Wnt3a-producing Paneth cells but receives 




Enterocytes are simple columnar epithelial cells and are the most abundant cell 
type comprising the intestinal epithelial barrier. Enterocytes in the large intestine 
are responsible for the majority of water absorption in the body. Enterocytes in 
the small intestine transport digested proteins, sugars, and other nutrients, from 
the lumen, into the underlying basement membrane. Microvilli extrude from the 
apical surfaces of enterocytes in the small intestine.  
Intestinal villi, found in the small intestine, are finger-like projections that extend 
into the lumen of the intestine. Villi are a collection of, enterocytes, goblet cells, 
and microvilli projections. The role of villi, in the intestine, is to increase surface 
area for greater absorption of digested nutrients and water. Villi can be damaged 
due to dysbiosis or excessive immune responses.  
 
1.1.1.2 Goblet cells 
Goblet cells are a polarised cell type that harbour and secrete a variety of mucins 
at its apical membrane[10]. Mucins are an important part of the intestinal defence 
system. Mucins, such as MUC2, are gel-forming glycosylated proteins, which 
contribute to the generation of mucin-comprised ‘biofilm-like’ coating that can 
prevent pathogen adhesion, colonisation, and invasion. Mucin coatings also 
harbour complement proteins, antimicrobial proteins, such as S100 family 
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proteins and defensins, and antibodies; each of which act to maintain bacterial 
numbers and prevent the translocation of microbes into the LP[11]. 
1.1.1.3 Microfold cells 
M cells endocytose luminal antigens and present them to immune cells in the 
lamina propria in a highly controlled manner. M cells take up samples of antigen, 
enclose them in vesicles, then deliver them to immune cells directly adjacent to 
their basolateral membrane. The intestinal lumen contains high concentrations of 
foreign antigens; thus, immune cells must be absent to ensure a tolerogenic 
environment. A tolerogenic environment is logical for an environment exposed 
to such high levels of foreign material but can also contribute to pathogenic 
success due to a lack of regulation. M cells allow for immune surveillance of the 
lumen without the requirement of a luminal immune presence. M cells are vital 
to immune preparation and stimulation. Presentation of pathogenic antigens to 
LP immune cells via M cells allows for the pre-emptive generation of an immune 
response. In an adoptive transfer model, Spib-/- mice, which lack M cells, showed 
a reduction in bacterial uptake and sampling in Payer’s Patches, and had a 
reduced immune response as a consequence[12]. Mechanisms of M cell-mediated 
antigen sampling are further discussed in Section 1.1.8 Gut-associated lymphoid 
tissues. 
 
1.1.1.4 The mucosal layer 
Antibodies, produced by B lymphocytes in the lamina propria, can be shuttled to 
the lumen via M cells[13]. Immunoglobulin (Ig)A can also be directly secreted 
into the mucus layer by enterocytes[14].  Once in the lumen, antibodies become 
trapped in the mucus layer, creating a ‘mucus trap’. Bacteria which encounter 
mucin have their movement restricted to the mucus layer, preventing pathogen 
attachment and invasion, while also allowing antibodies to target and neutralise 
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pathogenic bacteria. The mucus layer has been shown to keep bacteria in a ‘free-
swimming state’, preventing bacterial adhesion[15]. Antibodies not only 
neutralise pathogens but can also bind to certain beneficial commensal bacteria, 
such as Bacteroides fragilis, promoting their colonisation[16].   
 
1.1.1.5 Enteroendocrine cells 
Gastric enteroendocrine cells are rare, but potent producers of gastrointestinal 
hormones, enforcing their role as intestinal regulators[17]. Gastric 
enteroendocrine cells are scattered throughout the intestinal system, this allows 
for widespread information harvesting of luminal constituents[18]. In response 
to luminal alterations, gastric enteroendocrine cells produce hormones and 
release them into the bloodstream. Gastric enteroendocrine cells have profound 
effects on neighbouring cells and neural regulators. Gastrin, a peptide hormone, 
is secreted in response to food intake, stimulating the secretion of gastric acid to 
aid food digestion.  
 
1.1.1.6 The intestinal microbiome 
The gastrointestinal tract contains the highest abundance of microbes in the 
human body and is home to as many as 1014 bacterial cells, as well as innumerable 
fungi and viruses[19]. The human body is not inherently able to digest many of 
the foods it consumes. The food we consume is digested by commensal microbes 
into simple nutrients that we can absorb. This symbiotic strategy has allowed 
humans the ability to consume and digest a wide range of foods. However, this 
strategy also leaves humans vulnerable to dysbiosis (an imbalance of microbiome 




Most microbes in the gastrointestinal tract never invoke deleterious 
inflammatory responses. The intestinal epithelial barrier has a thick layer of 
mucus, saturated with antibodies and complement proteins[11]. Bacteria can live 
in this environment but not easily penetrate to reach the intestinal epithelial 
barrier surface.  
The intestinal microbiome is critical for human survival. As such, the human 
immune system has evolved to accommodate the presence of abundant microbial 
life. A number of physical barriers and complex immune:epithelial cross-talk 
work in tandem to ensure tolerance. 
 
1.1.1.7 Gut-associated lymphoid tissues 
Immune cells in the gastrointestinal tract sample antigens in gut-associated 
lymphoid tissues (GALT)[20]. GALT are compartmentalised lymphoid tissues, 
resembling small lymph nodes. GALT are small aggregates of lymphoid cells, 
located on the basolateral border of the intestinal epithelial barrier. GALT, like 
lymph nodes, contain a corona and a germinal centre. These regions are 
organised to control antigen presentation events. The corona is the outermost 
region of the GALT, comprised mostly of T and B lymphocytes. The germinal 
centre is comprised of both antigen-presenting cells (APC) and lymphocytes and 
is where most antigen presentation occurs. 
M cells lining the intestinal epithelial barrier take up luminal antigens and 
transport them to basolateral dendritic cells (DC) and macrophages, within the 
GALT[21, 22]. These antigens are processed and presented to naïve T 
lymphocytes and plasma cells, within the GALT. This organisation of cells 
encourages rapid detection and response to foreign antigens. Plasma cells are 
highly abundant in GALT and secrete large quantities of antibodies in response 
to luminal stimuli. T lymphocytes are present to amplify immune cell responses 
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and regulatory T lymphocytes (Treg) control inappropriate inflammatory 
responses. 
GALT in the small intestine also contain Peyer’s Patches (PP). PP are villus-like 
projections of GALT that extend into the lumen. In this way, PP are able to 
increase the surface area of GALT, increasing antigen sampling potential.  
Organised GALT are present during embryonic development and accumulate 
with age. GALT are dynamic and are essentially front-line mesenteric lymph 
nodes[20]. GALT are an elegant solution to the maintenance of intestinal 
tolerance. GALT provide a protected compartment for the identification of 
antigens - providing an internal environment, separate from the luminal 
microbiome, in which immune cells can determine if inflammation or 
suppression is appropriate. 
Simply, the gastrointestinal tract is the focal point for interactions between our 
internal and external environments. Maintenance of balance is critical to ensure 
proper digestion of food, absorption of nutrients and water, and healthy passage 
of waste. The intestinal immune system must be able to prevent deleterious 
dysbiosis and pathogenic success, while also maintaining tolerance for healthy 
microbes. To maintain this balance, the gastrointestinal tract is organised as a 
complex system of crosstalk and the exchange of information between intestinal 
epithelial and immune cells.
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1.2 The human immune system 
1.2.1 Antigen-presenting cells 
1.2.1.1 Pathogen identification 
APCs are innate responders to molecular stimuli. APCs use a variety of 
conserved Pattern Recognition Receptors (PRRs), which recognise molecules, 
such as Damage Associated Molecular Patterns (DAMPs) and Pathogen 
Associated Molecular Patterns (PAMPs)[23]. DAMPs are the molecular 
consequence of host cell damage or death. DAMPs are endogenous molecules 
released when host cells undergo necrosis, which can be caused by trauma, 
disease, or infection.  In contrast, PAMPs are pathogen-derived molecules which 
are recognised by innate immune cells. PAMPs and DAMPs are recognised by 
Toll-Like Receptors (TLRs) and nucleotide-binding oligomerization domain-like 
receptors (NOD)-Like Receptors (NLR) on the surface or in cytoplasmic domains 
of innate immune cells. For instance, TLR4 recognises lipopolysaccharide 
(LPS)[24], a gram-negative bacteria cell wall molecule, whereas TLR9 recognises 
unmethylated CpG motifs[25], which are of high abundance in bacterial 
genomes. NLRs, such as NOD1 and NOD2, recognise bacterial peptidoglycan 
derivatives[26].   
Once a PRR is stimulated, a signalling cascade occurs, generally resulting in the 
nuclear translocation of nuclear factor kappa-light-chain-enhancer of activated B 
cells (NFκB), in a MyD88-dependent pathway, inducing the production of 
inflammatory cytokines[27]. Activation of NLRs can induce the formation of the 
inflammasome, a cytosolic multi-protein PAMP and DAMP recognition complex, 
which upon activation, releases the inflammatory mediators Interleukin- (IL)1β 
and IL-18[28].  Activated TLRs can also induce expression of surface co-




1.2.1.2 Response to pathogens 
When a target has been identified as a pathogen, innate cells respond rapidly to 
control it. Macrophages are phagocytic, engulfing target organisms and 
microbial products. This process can be further enhanced by the complement 
protein C3b, which can bind to microbe surface molecules, opsonising the 
microbe[29]. Opsonisation of target surface molecules by C3b enhances 
macrophage-mediated phagocytosis via the binding of the macrophage C3b 
surface receptor, complement receptor 1, and microbe-bound C3b. Activation of 
complement receptor 1 promotes macrophage actin cytoskeleton rearrangement, 
promoting phagocytosis of the target.  Once phagocytosed, the ingested 
organism is contained in a phagosome created during phagocytosis[30]. The 
phagosome then merges with a lysosome, forming a phagolysosome. The 
digestive enzymes contained in the lysosome then facilitate the breakdown of the 
microbe and microbial products, providing nutrients for the immune cell, as well 
as a source of microbial proteins for display on surface receptors for antigen 
presentation. 
The activation of these pathways leads to the generation of proinflammatory 
cytokines and chemokines. Specific to the type, location, and number of the 
invading microbes, innate immune cells secrete inducers of inflammation. 
Cytokines, such as IL-1β and IFNγ are hallmark immune cell responses to 
pathogenic threat. IFNγ increases expression major histocompatibility complex 
(MHC)-II on APCs, recruits immune cells to the site of inflammation, and 
activates other immune cells[31]. IL-1β is a pyrogen and lymphocyte activation 
factor[32]. Together, innate cells can produce potent chemical inducers of 





1.2.1.3 Antigen presentation 
Professional APCs, such as DCs, phagocytose and process microbe-derived 
molecules[30]. Once degraded within an endosome, the endosome is then fused 
with a vesicle containing blocked-MHC-II. Once fused, the blocked-MHC II is 
liberated by human leukocyte antigen DM (HLA-DM), which facilitates the 
exchange of the blocker protein (CLiP) for the processed microbe-derived 
molecule[33]. This process is critical for the identification of foreign pathogens 
but is also used endogenously via loading on to MHC-I, for detection of 
intracellular bacteria and viruses. 
Once a molecule is presented on MHC-II, the MHC-II is loaded onto the cell 
surface, with the binding domain in the extracellular region. The APC is coated 
in the processed microbe-derived molecules, allowing for presentation to 
adaptive immune cells[33]. 
Antigen presentation is a communication bridge between the different cells that 
comprise the immune system. Successful adaptive responses require antigen 
presentation. By presenting processed antigen, APCs directly stimulate 
responder immune cells specific to the displayed antigen.  
Together, APCs are one of the first responders to insult. They rapidly respond to 
environmental stimuli, killing and phagocytosing pathogens and their 
derivatives, and packaging the products into a recognisable format for a primed, 
specific immune response via responder cell cooperation. 
 
1.2.1.4 Intestinal antigen-presenting cells  
Antigen-presenting cells, such as DCs and macrophages, are important sentinels 
of gut microbial and dietary antigens. DCs are situated in the lamina propria in 
GALT, Payer’s patches, and intestinal draining lymph nodes. DCs have long 
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dendrite projections which sample luminal antigens via paracellular spaces. DCs 
provide T lymphocytes with pro- or anti-inflammatory signals. There are two 
major types of DC found in the gut, CD103+ and CD103- DCs[34]. CD103 is a 
marker of immune cell residency; its ligand, E-cadherin, is a surface protein 
found on intestinal epithelial cells[35]. CD103+ DCs, broadly speaking, have a 
suppressive immune capacity, presenting antigen to lamina propria T 
lymphocytes and driving Treg differentiation. CD103- DCs in the gut can prime 
IFNγ+ and IL-17A+ T lymphocyte differentiation but are less commonly 
associated with gut tissues due to the absence of the CD103 integrin[36]. DCs in 
the gut respond to the presence of retinoic acid and transforming growth factor-
β (TGF-β), secreted by intestinal epithelial cell interactions with luminal 
microbes[37]. This DC-epithelial crosstalk drives intestinal tolerance by inducing 
a suppressive DC phenotype. Patients with IBD have been reported to have lower 
frequencies of CD103+ DCs in both inflamed and non-inflamed tissues and have 
reduced ability to induce Treg differentiation, compared to healthy controls[38]. 
 
1.2.2 Lymphocytes 
T lymphocytes and B lymphocytes are two major categories of adaptive immune 
cells. These cells are of lymphoid progenitor origin and generated in the bone 
marrow. A hallmark characteristic of T and B lymphocytes is their specificity to 
their target antigen.  
T lymphocyte progenitors are generated in the bone marrow and matured in the 
thymus. In the thymus, T progenitors undergo somatic V(D)J (Variable, diversity, 
joining) recombination[39]. The V(D)J regions, as well as a constant region (C), 
encode the building blocks of the T lymphocyte receptor (TCR). The TCR 
comprises an α and β chain (with some expressing conserved γ and δ chains). 
The TCR is the receptor responsible for identifying pathogen-derived peptides. 
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Recombination of the V(D)J segments involves the rearrangement and cutting of 
genetic segments to forge a unique binding domain[40].  
Once a new TCR is generated, T lymphocytes undergo selection by exposure to 
thymic cells expressing MHC-I, loaded with self-peptide[41]. T lymphocyte 
binding signal strength is tested to ensure the lymphocytes do not target host 
cells (autoimmunity). In the thymic cortex, TCRs that bind too weakly to thymic 
MHC undergo negative selection, eventually dying via apoptosis. A lymphocyte 
with a TCR that binds correctly becomes activated, survives, and proliferates. At 
this point, T lymphocytes, expressing both CD4 and CD8 co-signalling 
molecules, migrate to the thymic medulla[41]. CD4 is required for TCR 
interactions with MHC-II, whereas CD8 is required for MHC-I. During selection, 
the T lymphocyte will demonstrate a bias for MHC-I or MHC-II binding, 
resulting in the final downregulation of either CD4 or CD8. Within the thymic 
medulla, T lymphocytes undergo negative selection, in which they are exposed 
to self-proteins that would be expressed in other regions of the body. If cells are 
found to bind strongly to these proteins, they are captured and undergo 
apoptosis[41]. 
B lymphocytes develop in a similar way; however, their maturation occurs in the 
bone marrow. B lymphocyte B cell receptors (BCR) comprise similar V(D)J and C 
regions as TCRs. However, BCRs are fundamentally different. Where TCRs are 
comprised of α and β domains (or γδ domains), BCRs are comprised of two 
heavy chains (VDJ) and two light chains (VJ), resembling a membrane-bound 
Ig[42]. Igs, structurally identical to BCRs, further diversify via class switching - 
the genetic reassembly of conserved chain regions to optimise avidity. By this 
method, B cells can class switch from producing IgM pentamers to smaller IgA 
dimers, or IgE, IgD, or IgG monomers. 
Together, these processes facilitate the generation of a plethora of TCR and BCR 
variety, allowing for highly specific and optimised recognition of pathogens. 
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These processes are highly regulated, minimising inept or autoimmune T 
lymphocytes from leaving the thymus and B lymphocytes from leaving the bone 
marrow. Briefly, B lymphocytes share similar origins to T lymphocytes; however, 
BCR repertoires are far more diverse than TCRs and detect unprocessed peptides, 
whereas individual TCRs only detect a single peptide sequence, presented on 
MHC. 
 
1.2.2.1 T lymphocyte activation 
APCs display processed peptide sequences on MHC-II or endogenous molecules 
on MHC-I[43]. T lymphocyte activation requires at least two signals – a primary 
signal via the TCR, and a co-stimulatory signal via CD28.  
The primary signal is controlled by the binding of the specific TCR and its 
processed cognate antigen, displayed on MHC-II by an APC, or by MHC-I by 
host cells[43]. CD8+ T lymphocytes express a CD8 surface molecule, which 
secures binding between the TCR and MHC-I; similarly, CD4 secures the binding 
between the TCR and MHC-II. Upon recognition of a cognate antigen, a 
secondary signal, via CD28 binding to APC-CD80 or -CD86, is required for 
activation[44]. CD28 ligation complements TCR signalling by initiating 
signalling cascades and reorganising cytoskeleton arrangement for enhanced 
synapse contact. 
Lymphocyte activation enhances lymphocyte cytokine expression, induces the 
expression of anti-apoptotic molecules, increases proliferation, and induces 
expression of migratory chemokines. Activated CD8+ lymphocytes kill cells 
directly, through the release of the pore-forming molecule, perforin, and 
apoptosis-inducing granzyme A and B[45]. CD4+ T lymphocytes, while still able 
to directly kill target cells, mainly contribute to immune responses by enhancing 
the abilities of other immune cells. 
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T lymphocyte subsets are plastic – plasticity refers to a cell on a spectrum of 
transient cell identity. T lymphocytes are identified by key expression markers 
which are mainly associated with a certain cell type and their role. T lymphocyte 
differentiation is influenced by the cytokines present in their immediate area. 
Cytokines can be produced by many types of cells, which often makes plasticity 
a niche-specific change.  
The subtleties of T lymphocyte plasticity are beyond the scope of this thesis. 
However, in the following sections, I will describe the T lymphocyte subsets of 
interest in this study, their roles in immune responses, and their roles in the large 
and small intestine. 
 
1.2.2.2 T lymphocyte response 
CD4+ T lymphocytes propagate inflammatory responses through the activation 
and supplementation of other inflammatory cell subsets. CD4+ lymphocytes are 
typically associated with helping other types of immune cells via the secretion of 
cytokines. Upon presentation of cognate antigen by APCs, lymphocytes are 
activated and secrete cytokines appropriate to their stimulus and phenotype. For 
instance, an IFNγ+ T lymphocyte can promote the inflammatory capacity of a 
macrophage by secreting IL-1β and TNF[46]. When a connection is made 
between an APC and a lymphocyte, APCs produce cytokines which promote the 
survival and proliferation of responding lymphocytes; this is the third activation 
signal. 
CD8+ T lymphocytes are lymphocytes specialised in direct killing of intracellular 
bacteria and virus-infected cells[47]. CD8+ T lymphocytes recognise cognate 
antigen, derived from endogenous peptides, displayed on MHC-I. CD8+ T 
lymphocytes are potent producers of perforin and granzymes A and B. Perforin 
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forms pores in target cells, allowing entry of granzymes which induce apoptosis 
via activation of a caspase-cascade. 
 
1.2.3 T Lymphocyte subsets of interest 
There are many types of conventional and non-conventional T lymphocytes that 
are relevant to general immune responses. However, data in this thesis 
investigate three major T lymphocyte subsets of interest in CD, IFNγ+ T 
lymphocytes, IL-17A+ T lymphocytes, and Tregs. 
 
1.2.3.1 IFNγ+ T lymphocytes  
IFNγ+ T lymphocytes are described here as CD4- or CD8-expressing CD3+ 
lymphocytes, which also express IFNγ. IFNγ+ T lymphocytes are able to directly 
kill cells infected with intracellular viruses or bacteria, and also amplify immune 
responses by promoting the activation of other immune cell subsets. 
IFNγ+ T lymphocytes are defined by their production of IFNγ, controlled by the 
expression of the transcription factor, T-bet. IFNγ is a proinflammatory cytokine. 
IFNγ has been linked to increased disease severity in both mouse and human 
CD[48]. IFNγ is a broad-acting cytokine, implicated in many autoimmune 
diseases. IFNγ induces APC expression of MHC-I and MHC-II, and activates 
inflammatory cell subsets, such as macrophages and DCs, improving APC 
antigen presentation ability. This is a positive-feedback cycle, in which IFNγ+ T 
lymphocytes stimulate immune cells in their vicinity, which leads to further T 
lymphocyte stimulation and migration of other immune cells to the site of 
inflammation. IFNγ directly increases intestinal epithelial permeability by 
reducing expression of the tight junction protein, Zonula occludens-1 (ZO-1), and 
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perturbing apical actin organisation[49]. As such, IFNγ drives potent 
inflammatory responses and can disturb intestinal epithelial barrier integrity. 
In agreement with mouse models of colitis, early studies of human CD found that 
inflamed CD intestinal tissues had high frequencies of IFNγ+ and T-bet-
expressing CD4+ T lymphocytes[48]. CD patients also had high levels of serum 
IFNγ[50]. Early studies of CD in murine models identified that the development 
of colitis in IL-10-deficient mice was prevented with the administration of IFNγ-
blocking antibodies[51]. Other studies induced colitis via CD45RBHICD4+ T 
lymphocyte adoptive transfer from BALB/c mice into C.B-17 scid mice (lacking T 
and B lymphocytes). Colitis, in this context, displayed a polarised IFNγ+ T 
lymphocyte profile, characterised by high expression of IFNγ, which was 
abrogated with the administration of anti-IFNγ monoclonal antibodies 
(mAb)[52]. 
TNF is an inflammatory cytokine, primarily produced by activated macrophages 
but is also produced by IFNγ+ T lymphocytes, neutrophils, and NK cells. High 
concentrations of TNF in inflamed tissues is a hallmark of CD pathology[53]. In 
agreement, anti-TNF biologic therapies which neutralise the inflammatory effects 
of TNF, such as Infliximab, are frontline treatments for CD[54]. 
TNF recruits circulating inflammatory immune cells, activates T lymphocytes 
and neutrophils, and eventually induces apoptosis in responder cells[55, 56]. 
TNF is typically produced in response to bacterial derivatives, such as LPS and 
muramyl dipeptide (MDP), but is also expressed in response to IL-1β[56]. TNF 
induces the expression of IL-6, which in the presence of TGF-β, induces 
differentiation of naïve T lymphocytes and Tregs into IL-17A+ T lymphocytes.  
In most cells, TNF binds to the TNF receptor type (TNFR)1, which induces an 
inflammatory response. However, TNFR2 is preferentially expressed by 
activated Tregs, and to a lesser extent, other activated conventional T 
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lymphocytes. Activation of TNFR2 in Tregs promotes proliferation and survival, 
which suggests TNF also plays a role in immunosuppression[57]. 
 
Intestinal IFNγ+ T lymphocytes 
Many patients with CD have elevated frequencies of IFNγ+ (“Type 1”) T 
lymphocyte subsets, and a hallmark characteristic of these cells is that they are 
potent inducers of inflammation. Thus, anti-IFNγ treatment, in the form of 
Fontolizumab, has seen some success as a treatment option for CD patients[58]. 
Fontolizumab has a high-affinity for IFNγ, binding and neutralising the cytokine. 
However, Fontolizumab did not proceed past Phase II trials due to minimal 
success inducing remission of CD and high frequency of adverse events. It is also 
likely, that in many cases of CD, T lymphocytes are mediators of gut 
inflammation, but not the initial cause of disease. Nonetheless, adoptive transfer 
murine models of colitis have shown that T lymphocytes alone can cause IBD like 
pathology in nude mice (lacking thymus-dependent T lymphocytes)[59], and that 
suppression of T lymphocyte pathways can abrogate intestinal inflammation[60]. 
T lymphocytes are a major source of pro-inflammatory cytokines in intestinal 
immune responses.  Gut-resident T lymphocytes exist in a tolerogenic, 
suppressed environment. However, patients with CD have excessive intestinal T 
lymphocyte activation[61]. The cause of this T lymphocyte dysregulation is 
largely unknown, but is most likely a combination of genetic, environmental, and 
microbial effects. T lymphocytes which produce IFNγ have long been implicated 
in the onset of CD. IFNγ is a pro-inflammatory cytokine vital for inflammatory 






1.2.3.2 Regulatory T lymphocytes 
Tregs are, in this study, defined as either CD4+ or CD8+ T lymphocytes which also 
express high levels of the IL-2 receptor, CD25, and the transcription factor, 
forkhead box P3 (FOXP3). Tregs can be committed to Treg lineage in the thymus 
(tTreg) or induced in the periphery (iTreg). Tregs are a suppressive immune cell 
subset, responsible for the resolution phase of inflammation, ensuring that 
inflammatory responses subside once the threat is overcome. Tregs suppress 
other immune cell subsets via the release of TGF-β, IL-10, and IL-35, as well as 
inhibitory signalling molecules, such as PD-1 and CTLA-4, on the Treg cell 
surface[62]. Tregs are also able to directly kill IFNγ+ T lymphocytes via granzyme 
B-induced apoptosis[63]. 
iTregs are derived from the same lineage as IFNγ+ T lymphocytes. TGF-β is 
critical for the differentiation of naïve T lymphocytes into Tregs[64]. TGF-β 
induces the expression of FOXP3 in activated T lymphocytes. FOXP3 is a master 
regulator of a broad regulatory pathway. FOXP3 is expressed by many immune 
cells, on a spectrum, in which higher FOXP3 expression usually equates to higher 
suppressive function. Tregs produce TGF-β, which not only maintains their own 
differentiated state, but also induces a suppressive phenotype in cells around 
them[65].  
IL-10 is a pleiotropic cytokine which can induce suppression of multiple cell 
types. IL-10 downregulates MHC-II expression, inflammatory T lymphocyte 
cytokines, and reduces co-stimulatory molecules on the surface of APCs[66, 67]. 
IL-10 is an inhibitor of the NF-κB pathway, a pathway broadly associated with 
the propagation of inflammatory immune responses. Inhibition of NF-κB 
interferes with effector lymphocyte development, activation, and proliferation. 
Tregs propagate their suppressive effects through interactions with APCs via 
surface molecules, such as T cell immunoreceptor with Ig and ITIM domains 
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(TIGIT), Lymphocyte-activation gene (LAG3), and cytotoxic T-lymphocyte-
associated protein 4 (CTLA4). LAG3 is an inhibitor of MHC-II binding, reducing 
the antigen presentation capacity of APCs[68]. TIGIT induces APC expression of 
IL-10 and TGF-β[69]. CTLA-4 is a high-affinity competitor for the co-stimulatory 
molecule, CD28, preventing cellular activation[70]. Tregs also highly express 
CD25, the IL-2 receptor, which facilitates sequestration of IL-2 from the 
environment, ‘starving’ effector T lymphocytes of IL-2. 
Tregs are fundamental for maintaining gastrointestinal tract homeostasis and 
intestinal tolerance. In murine colitis models in which naïve CD4+ T lymphocyte 
adoptive transfer induced disease in the presence of bacteria, the transfer of Tregs 
reduced and cleared disease[52]. CD patient inflamed tissues are enriched for 
Tregs, compared to non-IBD controls[71]. Interestingly, a 2018 follow-up study 
found that Tregs from intestinal biopsies returned to non-IBD control levels in 
remitting patients; whereas Tregs remained at elevated levels in non-remitting 
CD patients[72]. These data suggest that Treg frequencies remain high in patients 
with CD to compensate for elevated inflammation. Further, Tregs from these 
studies appear to have normal suppressive function. Thus, dysfunctional Tregs 
are not typically considered to be a common cause of pathology in CD. However, 
Tregs exist in a state of plasticity and can differentiate into IFNγ+ and IL-17A+ T 
lymphocyte subsets upon exposure to specific cytokine influences. Inflammatory 
profiles from CD patients may have complex local interactions with Tregs. 
Therefore, Tregs are a subset of interest in the pathogenesis of CD. 
 
Intestinal regulatory T lymphocytes  
Tregs are critical in the regulation of the intestinal environment. Peripheral Tregs 
display TCRs specific for self-antigens, in contrast to intestinal Tregs, which 
express TCRs specific for both microbial and self-antigens[73]. Tregs are 
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abundant in the intestinal mucosa and are modulated directly by bacterial 
antigens. As recognition of cognate antigen activates Tregs, specificity for 
commensal bacteria helps to maintain intestinal tolerance. For example, 
Faecalibacterium prausnitzii and Bacteroides fragilis, both common gut commensals, 
induce Treg activation and differentiation via the surface proteins, microbial anti-
inflammatory molecule (MAM) and polysaccharide-A (PSA), respectively[74, 
75]. Both F. prausnitzii and B. fragilis have been reported as low abundance in 
patients with IBD, compared to non-IBD controls[76, 77]. Both MAM and PSA 
prevented DSS- and Trinitrobenzene sulfonic acid (TNBS)-induced colitis in 
murine models, reducing immune responses and promoting Treg production of 
IL-10 and TGF-β.   
In the context of intestinal epithelial cells, TGF-β is an inducer of epithelial–
mesenchymal transition (EMT)[78]. EMT is a process in which cells of the 
epithelial barrier lose their cellular polarity and transition into a mesenchymal 
phenotype. This process is a natural part of wound healing. In an immune 
context, TGF-β is recognised by TGFβ-receptors I and II, which initiate 
downstream signalling through SMAD1/3/4/6/7, resulting in suppression of 
inflammatory responses and induction of CD4+ T lymphocyte differentiation into 
Tregs[79]. The intestinal mucosa is a TGF-β-rich environment, which promotes 
barrier function and Treg phenotypes. TGF-β is an inducer of Treg differentiation 
in naïve T lymphocytes; however, in the presence of IL-6, naïve T lymphocytes 
transition into IL-17A+ T lymphocytes. This creates a transitional axis, in which T 
lymphocytes in the intestine are likely to have a Treg phenotype but transition to 
IL-17A+ T lymphocytes during infection.  Murine models broadly deficient in 
TGF-β or specifically blocked in T lymphocyte-TGF-β signalling, developed 
spontaneous autoimmune disease[80]. IL-10 suppression is mediated via 
interaction with the IL-10 receptor, expressed on hematopoietic cells, resulting in 
STAT3 phosphorylation and subsequent activation of a broad range of anti-
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inflammatory genes. Deficiency in IL-10 leads to spontaneous development of 
aggressive auto-immune disease in adoptive transfer models of murine 
colitis[81]. IL-10R polymorphisms have been associated with early-onset UC and 
impaired TGF-β signalling in IBD patients[82]. 
 
1.2.3.3 IL-17A+ T lymphocytes 
Historically, it was thought that IFNγ+ T lymphocyte subsets were the common 
link and causal agent of CD, whereas Type 2 T lymphocytes were responsible for 
UC inflammation. Type 2 T lymphocytes are characterised by their expression of 
IL-4, IL-5, IL-10, and IL-13, and are involved in defence against extracellular 
pathogens, such as helminths[83]. However, early studies of IBD were performed 
before the discovery of IL-17A+ (“Type 17”) T lymphocytes. New studies have 
revealed mucosal regions in murine colitis models are enriched for IFNγ+, IL-17+, 
and also IFN+IL-17+ double-positive CD4+ lymphocytes[84]. Indeed, human CD 
inflamed tissues and sera are also enriched for CD4+IL-17+ lymphocytes and IL-
17A protein[85-87]. 
IL-17A+ T lymphocytes exert their inflammatory effects by recruiting and 
activating macrophages and neutrophils to the site of inflammation[88]. 
However, treatment with the anti-IL-17A antagonist biologic, Secukinumab, 
resulted in more severe disease in patients with CD[89]; in contrast, rheumatoid 
arthritis, an IL-17-mediated autoimmune disease, Secukinumab was highly 
effective[90]. Thus, although IL-17A+ T lymphocytes do play a critical 
pathological role in the pathogenesis of CD, targeting this subset alone is not a 
viable treatment option. 
IL-17A+ T lymphocytes are either CD4+ or CD8+ T lymphocytes, defined by their 
expression of IL-17A, and the IL-17A-inducing transcription factor, RORγt. IL-
17A+ T lymphocytes are mainly associated with protection from fungi and 
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extracellular pathogens. IL-17A+ T lymphocytes are highly associated with 
pathogen clearance at mucosal surfaces, via interactions with neutrophils, 
natural killer (NK) cells, and cells that comprise mucosal surfaces. 
The main effector cytokines of IL-17A+ T lymphocytes are IL-17A, IL-17F, IL-
17A/F heterodimer, IL-21, and IL-22. IL-17A, IL-17F, and IL-17A/F heterodimer 
are potent inducers of neutrophil recruitment and activation[88, 91]. IL-21 
induces proliferation in NK cells and cytotoxic lymphocytes[92]. IL-22 is 
responsible for IL-17A+ T lymphocyte effects on mucosal protection. IL-22 
induces the expression of S100 antimicrobial proteins, defensins, and 
Regenerating Islet Derived Protein 3 Gamma (REG3γ), a bacterial peptidoglycan-
targeting receptor[93]. Both IL-17A and IL-22 play roles in mucosal cell healing 
and survival, which is a counterbalance to their ability to induce potent 
inflammatory responses at mucosal sites. Thus, IL-17A+ T lymphocytes mediate 
inflammation via the recruitment of other inflammatory immune cell subsets, as 
well as induction of protective responses from epithelial cells of the intestinal 
mucosa. 
 
1.2.3.4 Memory T lymphocytes 
T lymphocytes can exist as naïve, effector, or memory T lymphocytes.  Upon 
exposure to antigen, naïve T cells transition toward an effector phenotype[94]. 
Effector cells will typically perform their effector roles, then undergo apoptosis; 
however, a small fraction of these cells transition toward a memory phenotype. 
Memory T lymphocytes are long-lived, antigen-experienced cells. Memory T 
lymphocytes exist as rapid-response sentinels, primed to respond to antigenic-
stimulation.  
Memory T lymphocytes can be further divided into central memory and effector 
memory cells. Central memory T lymphocytes are similar to naïve T 
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lymphocytes; however, central memory cells have enhanced response to 
antigenic stimulation, are less dependent on co-stimulation, have elevated 
expression of the lymph node-homing molecule, CD62L, and have elevated 
expression of the APC-interacting co-stimulatory molecule, CD40L, compared to 
naïve T lymphocytes[94, 95]. In comparison, effector memory T lymphocytes are 
typically CD8+ T lymphocytes, have downregulated expression of lymph-node 
trafficking molecules, such as CD62L and CCR7, and have upregulated 
expression of perforin, compared to naïve T lymphocytes[95]. In general, central 
memory T lymphocytes respond to activation with an enhanced capacity for 
proliferation, whereas effector memory T lymphocytes respond with potent 
inflammation via cytolytic granules[94].  
Intestinal biopsies from patients with active IBD have been shown to have 
elevated frequencies of naïve T lymphocytes and central memory T lymphocytes 
but reduced frequencies of effector memory T lymphocytes, compared to non-
IBD controls[72]. Interestingly, T lymphocyte frequency profiles are similar to 
non-IBD profiles upon remission of disease. These data suggest IBD patient 
intestinal immune profiles may have a bias for rapid proliferation to antigenic 
stimulation, resulting in an abundance of naïve T lymphocytes and central 
memory T lymphocytes. As the intestine is a region of high antigenic load, it is 
possible that this skewed profile may cause IBD patients to be more at risk to the 





T lymphocyte populations which express IFNγ and/or IL-17 are often found at 
higher frequencies in human inflamed tissues of CD patients[96, 97]. Excessive T 
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lymphocyte activation in IBD could be caused by numerous pathways: 1) 
Inflammatory T lymphocyte subsets are resistant to Treg suppression[98]; 2) T 
lymphocytes may be specific for commensal bacterial species[99]; 3) unregulated 
activation of APCs in the gut[100]; 4) compromised intestinal barrier integrity, 
leading to recurring bacterial insult[101]. It is likely that IBD is just an umbrella 
term for gut inflammation, and the mechanisms of disease are much more 
complex than our current categorisation of CD and UC allows. It is also likely, 
that in many cases of IBD, T lymphocytes are mediators of gut inflammation, but 
not the initial cause of disease. Nonetheless, adoptive transfer murine models of 
colitis have shown that T lymphocytes alone, excluding Tregs, can cause IBD-like 




1.3 The pathogenesis of Crohn’s disease 
1.3.1 How disease occurs in Crohn’s disease 
CD is a heterogeneous disease with poorly understood aetiology in individuals. 
Human genome-wide association studies (GWAS) have identified hundreds of 
genetic risk loci associated with the onset of disease. Well-described risk loci, 
such as ATG16L1 and NOD2, are associated with CD in Caucasian patients but 
not Asian populations[103]. Furthermore, the relative risk of developing the 
disease is higher in monozygotic twins, compared to dizygotic twins; however, 
it is common for only one monozygotic twin to develop CD or UC. These 
inconsistencies in genetic abnormalities suggest that although genetics play a 
fundamental role in IBD susceptibility, environmental factors must also play a 
role. This is further evidenced by the rapid increase of IBD prevalence across 
countries adopting a ‘western-lifestyle’, as western countries typically have the 
highest prevalence of IBD[104]. The general consensus for the onset of IBD is that 
four susceptibility criteria must be involved: A genetic susceptibility to chronic 
inflammation, influence from luminal microbes and antigens, an immune 
response, and undefined environmental triggers[105]. 
CD is believed to be caused by abnormal immune cell responses to commensal 
bacteria at the intestinal mucosa. Patients with active CD have high intestinal 
permeability, however, it is still unclear whether inflammation in the intestine is 
a cause or consequence of epithelial degradation[101]. Translocation of microbes 
into the intestinal lamina propria generates an inflammatory immune response 
in both CD and non-CD patients. However, it is believed that patients with CD 
have a genetic susceptibility to the establishment of chronic inflammation. 
Polymorphisms in genetic regions associated with sensing of bacteria and 
autophagy have been linked to disease[106]. In general, the literature suggests 
that dysfunctional bacterial identification and clearance by innate immune cells 
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is the most probable cause of abnormal inflammatory responses in CD patients. 
However, the main cause of pathology in CD patients is by aggressive 
overstimulation of inflammatory T lymphocytes, and subsequent release of 
inflammatory cytokines. 
 
1.3.2 Loss of intestinal tolerance 
In this thesis, a loss of tolerance refers to the generation of an immune response 
against a bacterial species typically considered ‘commensal’ in healthy intestinal 
microbiomes. One of the leading hypotheses for the development of CD is the 
loss of tolerance to certain intestinal microbes. For instance, germ-free colitis-
susceptible mice do not experience colitis pathology but develop colitis when 
colonised with bacteria from colitis-free, specific pathogen-free mice[107]. 
Likewise, human CD patient PBMCs display commensal specificity, in which CD 
patient CD4+ T lymphocytes had potent responses to commensal derivatives, 
compared to non-IBD controls, and of these cells, CD responder cells had higher 
frequencies of cells that produce inflammatory cytokines[108]. Other studies 
have reported CD-specific immune responses to various other bacterial 
derivatives[109, 110]. 
It is not known if, in humans, loss of tolerance to commensal microbes is a cause 
of CD pathology, or a consequence of frequent LP exposure to commensal 
microbes caused by intestinal permeability. In any case, dysregulated immune 
responses to commensal bacteria contribute to the establishment of chronic 






1.3.3 Intestinal permeability in Crohn’s disease 
The mechanisms that can possibly lead to CD range from, but are not limited to: 
immune specificity to commensal bacteria, inflammatory and suppressive 
immune cell defects, polymorphisms in pattern-recognition receptors (NOD2, 
ATG16L1), defects in autophagy, and tight junction dysregulation and defects. 
Each mechanism is different in individual patients, but all have one trait in 
common – all mechanisms lead to permeability in the intestinal epithelial barrier. 
The LP, in contrast to the intestinal lumen, is a tightly regulated tissue, with little 
tolerance to bacterial, fungal, and viral presence. As such, there is an immune 
presence on the basolateral border of the intestinal epithelial barrier.  
Cells of the intestinal epithelial barrier express TLRs which lead to the production 
of inflammatory or anti-inflammatory responses to foreign materials. TLRs are 
activated by bacterial, viral, and fungal derivatives. For example, TLR9, a 
membrane protein complex, stimulates an anti-inflammatory, tolerogenic 
response upon recognition of bacterial unmethylated CpG dinucleotides on the 
apical surface (lumen) of enterocytes, whereas recognition of CpG on basolateral 
(lamina propria) TLR9 stimulates a pro-inflammatory response[111]. While this 
defence is effective at protecting against pathogens in healthy people, increased 
intestinal epithelial barrier permeability allows for luminal contents to migrate 
into the lamina propria. This in effect causes a positive feedback loop. Immune 
cells detect the unwanted foreign presence in the lamina propria and mount an 
immune response. Inflammatory cytokines, such as IL-6, IL-17A, IL-17F, IFNγ, 
and TNF are produced by resident immune cells in an attempt to control the 
invasion. While this immune response can contribute to increased epithelial 
turnover and pathogen clearance, it can also generate off-target cellular damage, 




1.3.4 Genes of risk in Crohn’s disease 
GWAS have uncovered over 163 single nucleotide polymorphisms (SNPs) 
associated with CD[112], such as NOD2 and ATG16L1[106].  NOD2 is a pattern 
recognition receptor expressed by a broad range of cells, including monocytes, 
DCs, macrophages, and enterocytes. NOD2 recognises MDP, a cell wall protein 
expressed by both gram-positive and gram-negative bacteria. Recognition of 
MDP by NOD2 induces a signalling cascade that leads to phosphorylation of IκB, 
which causes the release of active NF-κB, a broad inducer of inflammatory 
cytokine response[113, 114]. In healthy people, activation of the NOD2 pathway 
leads to immune cell activation, generation of pro-inflammatory cytokines, and 
eventual bacterial clearance[115]. NOD2-knockout mice have reduced bacterial 
clearance, reduced numbers of goblet cells, reduced protective mucins and anti-
microbial molecules, and increased abundance of non-commensal bacteria, such 
as Bacteroides vulgatus. Each of these effects can contribute to intestinal dysbiosis 
and onset of inflammation[116]. GWAS have shown between 30-50% of Crohn’s 
disease patients have NOD2 polymorphisms; however, it is still unclear if NOD2 
can directly cause disease in humans[114, 117]. Murine models and association 
studies in humans have provided an interesting theory for one mechanism of IBD 
pathogenesis, but more biologically relevant wet-lab work is required to validate 
this theory.  
The Atg16l1 gene is highly associated with the incidence of CD. Atg16l1 encodes 
a core structural protein of innate immune cell autophagosomes[118]. Bacteria, 
bacterial antigens, and cellular components are packaged within intracellular 
phagosomes for degradation. Phagosomes, loaded with products destined for 
degradation, fuse with degradative enzyme-containing lysosomes – forming an 
autophagolysosome[118]. In a healthy system, the autophagolysosome facilitates 
the degradation of cellular components into reusable products – 
macroautophagy. Atg16l1 polymorphisms have been shown to reduce the 
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formation of phagosomes. Campagne et al, 2014 showed that a disease variant in 
murine and human macrophage Atg16l1 had enhanced degradation of ATG16L1 
proteins by Caspase 3, resulting in defective bacterial clearance compared to 
wild-type controls[119]. The inability to degrade and recycle cellular and 
bacterial components can lead to their accumulation. Not only does this starve 
the immune cell of a vital source of recycled cellular components, but the 
accumulation of these products can also have potent inflammatory effects upon 
cell death. High concentrations of cellular debris, both host-derived and foreign, 
can be recognised as DAMPs and PAMPs, respectively. PAMPs can be 
recognised by a variety of PRRs, and the release of high concentrations of PAMPs 
from autophagy-deficient cells can be recognised as an infection – generating 
immune responses by other innate immune cells. DAMPs are potent ‘danger-
signals’ released from damaged tissues and can be recognised by a variety of 
immune cells, eliciting a potent pro-inflammatory response, leading to pathology 
and further cell death. Expression of TLR2, TLR4, and TLR9 are higher in 
inflamed tissue from CD patients, compared to matched non-inflamed tissues 
and non-IBD controls, which can exacerbate inflammatory responses to DAMP 
and PAMP accumulation[120]. 
 
1.4 Intestinal organoids 
Intestinal organoids are a three-dimensional in vitro model of the human 
intestinal epithelium that allows for robust, patient-specific in vitro research of 
the development and properties of the intestinal epithelium. Organoid cultures 
can be established either from individual Lgr5+ stem cells or isolated intestinal 
crypt-containing the stem cells. These are seeded into a supporting matrix, such 
as Matrigel®, which provides the high laminin levels characteristic of the stem 
cell niche[121].  
33 
 
Intestinal organoids are derived from the isolation and culture of primary stem 
cells of intestinal crypts or Induced pluripotent stem cells (iPSC)s. Intact 
intestinal crypts can be isolated from colonoscopy biopsy samples by Ca2+-
chelation[122]. While there are a number of different protocols for the isolation 
of the crypts [123, 124], a common feature is the incubation of the biopsy samples 
in Ca2+-free Ringer solution containing Ethylenediaminetetraacetic acid (EDTA) 
and dithiothreitol (DTT), followed by mechanical agitation. This results in the 
isolation of a relatively pure population of intact intestinal crypts containing 
Lgr5+ stem cells. When cultured in a suitable matrix, such as Matrigel®, stem cells 
within the intestinal crypts survive, avoid anoikis, and proliferate. The crypts 
then close and develop into a sphere-shaped organoid structure (spheroid). Over 
the next several days, the cells that compose the spheroids proliferate and 
differentiate into gut specialist cells. Lgr5+ stem cells migrate to different areas of 
the spheroid and undergo crypt-fission events, generating multiple sites of 
proliferation, thus expanding the culture[123]. Mature organoids (colonoids) can 
then be mechanically disrupted and passaged over months and maintain genetic 
similarity to their in vivo cell counterparts. 
 
1.4.1 In vitro niche for crypt-derived organoids 
In small intestinal organoids, the development of Paneth cells allows a reduction 
in exogenous Wnt3a levels, but the absence of mesenchymal and Paneth cells in 
colonic organoids requires the continued presence of relatively high levels of 
exogenous Wnt3a in the media to maintain the cultures. Cell fate is determined 
by exposure to different niche factors produced by sub-epithelial fibroblasts at 
the serosa surface of the crypts. Factors such as Noggin and Gremlin inhibit bone 
morphogenetic protein (BMP), inducing cellular differentiation[125, 126]. Wnt3a 
is an inducer of stemness, in contrast to BMP. Differentiation of crypt cells occurs 
in response to the inverse gradient relationship between Wnt3a and BMP. Wnt3a 
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concentrations are highest in the base of the crypt, as cells ascend towards the 
lumen, BMP concentration rises as Wnt3a concentration falls, inducing 
differentiation in ascending cells. This intestinal crypt design, coupled with 
mesenchymal and flanking cell chemical influences, allows the intestinal 
epithelial barrier to produce cells in a stochastic manner. This complex cell-to-
cell signalling enables neutral drift mechanics, ensuring a specific differentiated 
cell is generated when required and old cells are shed[127]. 
 
1.4.2 Organoids as a tool for immunological research 
The human intestine is a complex organ with a strict organization of structural 
domains. Current intestinal epithelial models, such as Caco2 cell lines (an 
immortalized cell line derived from human epithelial colorectal adenocarcinoma 
cells)[128], are useful for drug absorption screening but do not adequately 
replicate the physiology of the intestine. Organoids allow for in-depth analysis 
of pathogen-host cell interactions and investigation and validation of human cell 
mechanisms and pathways. However, in general, current organoid systems do 
not contain functioning immune cells, nor do they contain M cells, a critical cell 
for intestinal antigen sampling. The introduction of a functional immune system 
could change the way intestinal disease is modelled and investigated. 
The human immune system is difficult to study, as samples taken from donors 
are only a snapshot in time. The ability to culture patient tissues and co-culture 
with the same patient’s immune cells is, in theory, the gold standard for 
immunological research. In an organoid model, the researcher has control of the 
cells added to the culture, providing the ability to systematically observe the 
effect each cell type might have on a specific epithelium. For instance, CD 
patients often have low frequencies of intestinal CD103+ DCs, and CD103+ DCs 
promote intestinal tolerance. If patient DCs are isolated, expanded, and induced 
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to a tolerogenic phenotype: Can epithelial integrity be restored in vitro? How 
does the addition of specific immune subsets affect organoid permeability and 
growth? Does a beneficial effect require the addition of a combination of immune 
subsets? Can the addition of recombinant proteins improve model readouts? 
How does the addition of a microbiota affect these changes? Can immune cell 
subsets or cytokines of interest be identified to elucidate the most relevant 
treatment option for an individual? The organoid model provides a tool to 
address these questions by allowing a systematic approach to an overly complex 
immunological system.  
Recently, researchers have developed organoid assays for personalised screening 
systems that could reduce the impact of non-optimal therapy prescription[129]. 
For instance, organoids from rectal biopsies from two patients with cystic fibrosis 
had a positive response to ivacaftor, in a forskolin-induced swelling assay[130]. 
Theoretically, a high-throughput system could be designed, in which patient 
organoids are grown in a 96-well plate and tested with different treatments, 
immune cell compositions, and microbial species. This model design could lead 
to the optimisation of patient treatments before application, improving patient 
quality of life and reducing the chance of treatment failure. Recently, rectal 
organoids derived from patients with cystic fibrosis were successfully used to 
predict patient response to treatment[131]. This was particularly important as 
cystic fibrosis patients with rare genetic mutations are not examined in clinical 
trials, reducing optimal treatment application. Modern IBD treatments are 
designed to target multiple immune mediators, highlighting the value of high-
throughput in vitro personalised screening for identification of promising 
treatment targets.  
Organoid cultures could also be useful in understanding the mechanisms of CD, 
before the onset of inflammation. In some cases of CD, IL-17A+ T lymphocytes are 
responsible for excessive mucosal inflammation via the release of IL-17A, IL-17F, 
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and the heterodimer IL-17A/F[132]. If non-IBD control or CD patient organoids 
are co-cultured with CD patient IL-17A+ T lymphocytes, it may be possible to 
identify whether these cells have deleterious effects on organoid growth, 
proliferation, or permeability. In the same way, Tregs could be investigated for 
their ability to suppress other immune cells, in an inflammation positive control 
system. This could be further investigated with the addition of a functional 
microbiota in the apical compartment of the system. A loss of tolerance to gut 
commensals has been speculated to contribute to chronic inflammation in CD; 
however, the field still lacks the evidence required to elucidate which 
mechanisms of disease are the cause or a mere consequence of disease. The 
organoid model provides a unique opportunity to investigate CD in vitro, before 
chronic inflammation has been established, potentially providing answers to 
fundamental unknowns of CD. 
 
1.4.3 Rationale for organoid monolayers 
3D organoids contain no stromal tissues or LP. Recently, groups have generated 
2D monolayers from 3D organoid culture systems to research macrophage 
interactions with intestinal epithelial cells and bacteria[133]. This is an interesting 
model concept, sacrificing crypt-physiology, but gaining the ability to further 
manipulate the model system. Mechanically disrupted 3D organoids are seeded 
on Transwell® membrane plates, generating a polarised gut cell lining which 
emulated the intestinal epithelial barrier, separating the apical and basal 
compartments of the well. This effectively mimics in vivo physiology, providing 
a lumen (apical compartment) and a lamina propria (basal compartment). This 
model system has been shown to be effective for the investigation of pathogen-
epithelial-immune cell interactions. Noel et al., 2017 generated this system using 
human small intestine organoids co-cultured with macrophages and pathogenic 
Escherichia coli[133]. Macrophages were observed extending dendrites through 
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the monolayer to interact with E. coli in the ‘lumen’. Co-culture with 
macrophages also provided resistance to pathogenic E. coli-induced 
permeability. These data suggest that the organoid model is highly adaptable to 
experimental requirements, and relevant for the investigation of the immune 
system in the gut. Our lab began development of the 2D monolayer model prior 
to the Noel et al., 2017 publication[133]. The techniques and reagents used differ 
between monolayer protocols; however, both share the removal of the drivers of 
stemness, Wnt3A and R-spondin, to induce monolayer differentiation. 
 
1.4.4 The intestinal microbiota 
Multiple groups have introduced bacteria to organoids. For example, 
microinjection of Salmonella typhimurium into the lumen of intestinal organoids 
induced transcriptional changes relating to cytokine expression patterns[134, 
135]. After injection into the lumen, S. typhimurium penetrated host cell 
membranes and resided within host-cell vacuoles. These experiments suggest 
that the organoid model is capable of not only hosting microbial lifecycles, but 
also responding to their presence. Researchers could introduce a large fraction of 
the species found within an individual’s microbiota via microinjection of 
microbes isolated from patient-specific faecal material. However, faecal material 
will only provide live-facultative anaerobes, and the oxygen required for 
organoid culture will not facilitate obligate anaerobe survival. The addition of 
antibiotics, pH changes, antivirals, antifungals, recombinant cytokines, 
probiotics, or immune subsets, could provide valuable insight into responses to 
the microbiota and improve understanding of intestinal homeostasis. 
How the microbiota interacts with immune cells of the intestine remains largely 
unknown. Gut-resident immune cell subsets relevant to maintaining gut 
homeostasis exist, but little is known about the mechanisms of control. Short-
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chain fatty acid (SCFA) production by gut microbes is important for intestinal 
barrier homeostasis. A recent study showed that, in CD patients treated with 
anti-TNF, remitting IBD patient microbiomes converged toward a healthy 
control phenotype, whereas non-remitting IBD patient microbiomes did not[136]. 
Consequentially, non-remitting CD patients had lower expression of more 
intestinal metabolites than remitting CD patients and healthy controls.  
Probiotics are speculated to be an important emerging field for initiating 
intestinal homeostasis for patients with intestinal diseases; however, due to a lack 
of knowledge on microbe-barrier-immune cell interactions, probiotics remain 
ineffective as treatments. Theoretically, a high-throughput intestinal organoid 
system could provide insight into these interactions, allowing the 
production/selection of more biologically relevant probiotics that not only reduce 
dysbiosis, but promote immune tolerance and homeostasis. To achieve this, 
researchers could use co-culture experiments in which microbes of interest are 
introduced to organoid systems containing a functional immune system. Positive 
readouts could include improvement of epithelial integrity, production of 
tolerogenic cytokines, immune cell differentiation into tolerogenic phenotypes, 
or a reduction of pro-inflammatory cytokines.  
 
1.5 Hypothesis and Aims 
T lymphocytes are considered to be the main mediators of inflammation in CD 
pathology. CD patients often have elevated abundances of IFNγ+ and IL-17A+ T 
lymphocytes, and their associated cytokines, in serum and the intestinal mucosa. 
Therefore, it is hypothesised that CD patients will have T lymphocyte profiles 
distinct from non-IBD controls. Moreover, it is hypothesised that CD patient 
PBMCs will have a higher inflammatory capacity than non-IBD control PBMCs. 
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CD has been associated with a loss of tolerance to commensal microbes. Indeed, 
CD patients have been shown to have reduced abundances of commensal species 
such as B. fragilis and F. prausnitzii[137, 138]. Commensal microbes contribute to 
intestinal tolerance, and dysbiosis can lead to an immune response. It is unclear 
whether loss of tolerance to commensals is a cause or consequence of CD 
pathology. Furthermore, it is unclear if the loss of tolerance is a trait shared by all 
CD patients. It is hypothesised that co-culture of CD patient PBMCs with 
commensal bacteria would elicit an immune response, whereas non-IBD PBMCs 
would not. 
Intestinal organoids are derived from patient colonic biopsies and can be 
cultured indefinitely. Intestinal organoids provide a unique way to observe 
interactions between immune cells, intestinal epithelial cells, and commensal 
bacteria. Furthermore, research groups have recently developed methods to 
culture 3D intestinal organoids as 2D monolayers. 2D monolayers mimic 
intestinal epithelial barrier organisation. 3D Intestinal organoids from CD 
patients have elevated permeability, a trait which matches in vivo physiology of 
CD patient intestinal epithelial barriers. It is hypothesised that the development 
of CD patient monolayers would generate a tool useful for the investigation of 
CD patient immune responses to commensal bacteria. Moreover, CD patient 
PBMCs would be deleterious to matched intestinal monolayers, whereas non-





The specific aims of this thesis were to: 
• Characterise non-IBD and CD patient PBMC T lymphocyte profiles 
 
• Determine whether CD patient PBMCs have a higher inflammatory 
capacity than non-IBD controls 
 
• Determine if CD patient PBMCs generate an immune response to 
commensal bacteria 
 
• Develop a 2D intestinal organoid monolayer from patient colonic biopsies 
 
• Determine whether CD patient intestinal monolayer cells have a 
deleterious response to commensal co-culture 
 
• Determine whether CD patient PBMCs are deleterious to intestinal 








Materials and Methods 
2.1 Patient cohort 
2.1.1 Ethical approval 
Healthy participants obtained through the university were provided with an 
information sheet about the project and were led through the consenting process 
by me. Patients and healthy participants obtained through the Dunedin Hospital 
were consented by the nurse staff of the Gastrointestinal Unit of the Dunedin 
Hospital. All participants were allowed to ask questions and consider their 
participation, then written consent was obtained. Collection and analysis of 
patient peripheral blood and biopsies were approved by the Multiregion Ethics 
Committee (Ref# MEC/11/11/093). Ethical approval for the use of peripheral 
blood from healthy individuals was approved by the Otago Ethics Committee of 
the University of Otago (Ref# 12/036, 18/088). 
 
2.1.2 Patient samples 
Patient PBMCs and intestinal tissues were collected from patients at the Dunedin 
Hospital and students and staff at Otago University (Tables 2.5-2.7). All 
participants provided written informed consent prior to inclusion in the study. 
PBMCs and/or intestinal biopsies were obtained from IBD patients and control 
patients undergoing colonoscopies. Control tissues for this study were from 
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patients with a hereditary risk of developing colon cancer, but where no cancer 
was detected during colonoscopy. 
 
Patients who provided only peripheral blood 
Potentially suitable patients were identified on outpatient clinic lists by the 
research nurses of the gastroenterology research unit. These were approached by 
Professor M Schultz (co-supervisor) in the Dunedin Hospital IBD clinic when 
coming forward for an outpatient appointment and if interested led through the 
consenting process by a research nurse. Patients were given a Patient Information 
and Consent Form to read and sign and then blood was taken either through a 
phlebotomist from the Southern Community Labs or a research nurse. 
 
Patients who provided peripheral blood and colonic biopsies 
Potentially suitable patients were identified on outpatient clinic lists by the 
research nurses of the gastroenterology research unit. These were approached by 
Professor M Schultz (co-supervisor) or the research nurses in the 
Gastroenterology Department of Dunedin Hospital when attending for their 
colonoscopy appointment. If interested, patients were led through the consenting 
process by the research nurse. Patients were given a Patient Information and 
Consent Form to read and sign and blood was taken prior to the procedure. 




2.1.3 Cohort description 
Variable Patients with CD (n=25) 
Age mean [range] (SD) 40.32[22-78](17.1) 
Sex (%) Female 12 (48%)  
Male 13 (52%) 
Treatment at time of 
appointment (%) 
6MP + Azathioprine 1 (4%) 
 




Mesalazine 2(8%)  
Adalimumab + Methotrexate 1(4%)  
Azathioprine 2(8%)  
Adalimumab 4(16%)  
Prednisone 2(8%)  
Infliximab + Azathioprine 1(4%)  
Cholestyramine 1(4%)  
Adalimumab + Azathioprine 2(8%)  
No medication 7(28%) 
Table 2.1: CD cohort information for data used in Chapters 3 and 4 
Table 2.2: Non-IBD control cohort information for data used in Chapter 5  
 
Table 2.3 CD patient cohort information for data used in Chapter 5 
Variable Non-IBD controls (n=5) 
Age mean [range] (SD) 
 
52.2[51-55](6.83) 
Sex (%) Female 3(60) 
Male 2(40) 
Treatment at time of 
appointment (%) 
No treatment 5(100%) 
Variable Patients with CD (n=4) 
Age mean [range] (SD) 
 
50.5 [41-57](7.19) 
Sex (%) Female 3(75) 
Male 1 (25) 
Treatment at time of 
appointment (%) 
Mesalazine + 6MP 1 (25%) 
Steroids + Urosan 1(25%)  
No medication 2(50%) 
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2.1.4 PBMC processing 
Peripheral blood was collected in 10 mL heparin blood collection tubes 
(eBiosciences, San Diego, CA). Whole blood was then mixed 1:1 with PBS, then 
mixed several times. 15 mL of Ficoll-Paque Plus (GE healthcare, Piscataway, NJ) 
was added to the bottom compartment of a 50 mL SepMate (Stemcell 
Technologies, Vancouver, Canada) tube. PBS-mixed blood was then gently 
pipetted into the top compartment of the SepMate tube. The SepMate tube was 
then centrifuged at 1200xg, 4oC, for 10 minutes. PBMC-enriched supernatant was 
then poured into a 50 mL Falcon tube, then centrifuged at 582xg, 4oC for 4 
minutes. PBMCs were then washed twice with PBS, then counted using a 
haemocytometer. PBMCs were then ready for experimentation or resuspended 
in FCS + 10% Dimethyl sulfoxide (DMSO; Sigma-Aldrich, St Louis, MO, USA), 
then transferred to cryotubes and placed in a -80oC freezer for 48 hours, then into 
liquid nitrogen for long-term storage. 
 
2.2 Flow cytometry 
Flow cytometry was used throughout this thesis to identify immune cell subsets 
and quantify cytokine concentrations. Fluorophore-conjugated antibodies were 
titrated using healthy PBMCs to identify optimal dye antibody volumes. If 
intracellular cytokines were to be analysed, cells were stimulated with 
PMA/Ionomycin, then brefeldin A (BFA; Sigma-Aldrich), as described below. 
Patient PBMC samples were processed and cells of interest were isolated (Patient 
Samples 2.1.2) and resuspended in 1 mL RPMI-10 ((RPMI; Gibco, Green Island, 
NY, USA) + 10% foetal calf serum (FCS; PAA Laboratories, Morningside, 
Australia) + 100 µg/mL Penicillin, 100 µg/mL Streptomycin, 55 µM 2-
mercaptoethanol (2ME; Sigma-Aldrich). If stimulation was required, cells were 
incubated at 37oC, 5% CO2 in the presence of phorbol 12-myristate 13-acetate 
45 
 
(PMA; Sigma-Aldrich) and Ionomycin (Sigma-Aldrich), for 2 hours, then BFA 
was added for a further two hours. Cells were centrifuged at 58xg, 4oC, for 4 
minutes. Cells were resuspended in phosphate-buffered saline (PBS; Invitrogen, 
Carlsbad, CA, USA) and stained with a viability dye to distinguish live and dead 
cells. Cells were incubated in the dark, on ice, for 30 minutes, then washed twice 
with fluorescence-activated cell sorting (FACS) buffer (PBS + 0.5% FCS + 0.01% 
sodium azide (PROLAB, Geldenaakaeban, Leuven)). Cells were resuspended in 
100 μL total volume of antibody cocktail, containing all titrated extracellular 
antibodies (excluding CD4 – which was added intracellularly as CD4 is 
endocytosed post-stimulation[139]). Cells were incubated in the dark, on ice, for 
30 minutes. Following extracellular staining, cells were washed twice with 
FOXP3 transcription factor staining kit (eBioscience) fix/permeabilization buffer 
for 1 hour, centrifuged, then resuspended in FACS buffer. If cell sorting was 
required, cells were not fixed. 
For intracellular staining, extracellularly stained cells were centrifuged and 
resuspended in 100 μL total volume of antibody cocktail, containing all titrated 
intracellular antibodies in permeabilisation buffer (including CD4). Cells were 
incubated in the dark on a rocking platform, on ice, for 90 minutes. Following 
intracellular staining, cells were washed twice with permeabilisation buffer, once 
with FACS buffer, then resuspended in 150 μL FACS buffer. Cells were then 
ready to be analysed. 
Fluorescence minus one (FMO) controls were used in each experiment. For FMO 
controls, cells were stained as detailed above, but each ‘FMO’ tube consisted of 
all antibodies, excluding the FMO’s antibody of interest. Unstained controls 
underwent all outlined staining steps, excluding the additions of antibody and 
viability dye. 
Single drops of One Comp Beads (eBioscience) were stained as outlined above 
but were stained with a single antibody. 
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Cytometer setup and tracking was completed each day to account for machine 
variation. In each experiment, the unstained control was generated as a negative 
stain control. Photomultiplier tube (PMT) voltages were set on unstained cells to 
compensate for background cell fluorescence. Stained-One Comp Beads were 
used as positive controls to adjust PMT voltages and calculate compensation. 
Cytometric data were acquired on an LSR-FORTESSA II (Becton Dickinson, 
Franklin Lakes, NJ, USA). Cell sorting was performed on a FACSAria II (Becton 
Dickinson). Data was acquired using FACSDiva software (Becton Dickinson) and 
analysed using Flowjo software (version 10.6.0, Tree Star, Ashland, OR, USA). 
Data were analysed using the EarlyBird graphing tool, developed by 
Cytoanalytics (http://earlybird.cytoanalytics.com/). Cluster analyses were 
conducted using viSNE and SPADE analysis tools on the Cytobank database. 
All patient data analysis was performed under blinded conditions. Unblinding 
of clinical information occurred after experimentation was completed. Refer to 
2.1.3 Cohort description for patient demographics. 
 
2.2.1 Cytokine stimulation 
Human PBMCs (8x104) were added to individual wells of a 96-well plate 
(Corning, Corning, NY, USA), in 200 μL RPMI, in duplicate. Cells were 
stimulated with anti-CD3/28 beads (Sigma-Aldrich) at a 1:1 (cell:bead) ratio, or 
remained unstimulated, and incubated at 37oC, 5% CO2, for 48 hours. Cell 
supernatant (25 μL) was collected from the top-most region of a supernatant of 
interest. Cell supernatant were then treated with fluorescent beads, as per the 
LegendPlex human inflammation cytokine analysis kit methods (BioLegend, San 
Diego, CA, USA). Supernatants were then analysed using an LSR-FORTESSA II 
(Becton Dickinson). Data were acquired using FACSDiva software (Becton 
Dickinson), and cytokines were analysed using LegendPlex software 
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(LegendPlex, v 8.0, BioLegend). LegendPlex standard curves were calculated by 
Legendplex software using data obtained from LegendPlex panel standard 
cocktails. Samples of supernatant were run at undiluted, 1/4, and 1/10 diluted 
concentrations, in triplicate. 
 
2.2.2 Suppression assays 
PBMCs were isolated and stained as detailed (Tables 2.4 and 2.5). PBMCs were 
extracellularly stained with CD3, CD4, CD25, and CD127 antibody to identify 
Treg (CD3+CD4+CD25HICD127-) and conventional T lymphocyte 
(CD3+CD4+CD25lo-intCD127+; Tconv) populations. Cells were then sorted into 
purified Treg and Tconv populations using a FACSAria II (Becton Dickinson). 
Tconvs were washed twice in PBS and resuspended in 1 mL PBS + 1 μL Cell Trace 
Violet (CTV), and incubated at 37oC, 5% CO2, for 20 minutes. CTV was then 
inactivated adding 3 mL FCS, centrifuged, and washed twice with RPMI 10. 1x104 
Tconvs and Tregs were then cultured at indicated ratios in a total volume for 200 
μL RPMI in a 96-well plate (Corning). Anti-CD3/28 beads were added to each 
well at a 1:10 (bead:cell) ratio, then incubated for 80 hours at 37oC, 5% CO2. Cells 
were then washed twice with PBS, then stained for CD3 and CD45, then analysed 
on an LSR-FORTESSA II (Becton Dickinson). Data were acquired using 
FACSDiva software (Becton Dickinson) and analysed using Flowjo software 




The proliferation index and precursor frequencies were calculated using the 
following equations: 
 
2.2.3 Bacterial co-culture 
PBMCs were isolated as outlined in 2.1.4 PBMC processing. PBMCs were then 
co-cultured with laboratory strains (provided by Professor Gerald Tannock, 
University of Otago) of heat-killed non-toxigenic bacteria, F. prausnitzii DSM 
17677 or B. fragilis ATCC 25285T, at a 1:1 (cell:bacteria) or 1:10 ratio, or no bacteria 
was added, in RPMI 10. Cell:bacteria ratios were determined by optimisation of 
a range of ratios between 0.5:1 – 1:100 and comparison with commensal co-




2.2.4 Flow cytometry antibodies 
Table 2.4: Flow cytometry panel 1 - T lymphocyte characterisation 
 
Table 2.5: Flow cytometry panel 2 – Tconv and Treg sorting 
Antibody Fluorophore Clone Amount (μL) Company 
Viability dye ZOMBIE NIR  0.10 eBioScience 
CD3 AF700 WCHT1 1.25 BioLegend 
CD4 PAC BLUE SK3 1.25 BioLegend 
CD8 V500 RPAT8 1.25 BD 
CD25 PE/CY7 BC96 2.50 BioLegend 
IL-2 BV605 MQ1-17H12 2.50 BioLegend 
IL-13 APC JE510-SA2 1.25 BioLegend 
IL-17 PE/DAZZLE BL168 1.25 BD 
IL-22 PE BG/IL22 1.25 BioLegend 
IFNγ PerCP/Cy5.5 45.B3 2.50 BioLegend 
FOXP3 AF488 150D/E4 5.00 BioLegend 
Antibody Fluorophore Clone Amount (μL) Company 
Viability dye ZOMBIE NIR  0.10 BioLegend 
CD3 APC/Cy7 HIT3a 1.25 BioLegend 
CD4 BV605 OKT4 1.25 BioLegend 
CD25 PE/Cy7 BC96 2.50 BioLegend 
CD45 PerCP/Cy5.5 HI30 1.25 BioLegend 
CD127 APC A019D5 1.25 BioLegend 
Cell-Trace Violet   1.00 Thermo Fisher 
Science 





RNA was isolated using the RNeasy Plus Micro Kit (Qiagen, Hilden, Germany). 
PBMC samples were lysed and filtered to purify the lysate using a gDNA 
eliminator column (Qiagen). The resulting solution was then treated with 70% 
ethanol, loaded into a MinElute column (Qiagen), then centrifuged. Samples 
were then washed with RW1 buffer (Qiagen), RWE buffer (Qiagen), and 80% 
ethanol, with centrifugation between each wash. Finally, RNA was liberated by 
transferring the RNA-containing filter into a fresh collection tube and adding 14 
μL of elution buffer (Qiagen), then centrifuging. RNA concentration and quality 
were determined by UV spectroscopy via NanoDropTM spectrophotometer using 
NanoDrop software version 3.0.1 (Thermo Fisher Scientific, USA). 
cDNA was generated using a SuperScriptTM III First-Strand Synthesis System Kit 
(Invitrogen) used as per manufacturer’s instructions. Briefly, in a MicroAmpTM 
Optical 8-Tube Strip, 0.2mL (Thermo Fisher), RNA (maximum 5 µg) was added 
to 1 μL primer (Oligo-dT) (Invitrogen) and 1 μL 10 mM dNTP mix (Invitrogen). 
RNA was diluted using elution buffer to ensure the mixture was a total volume 
of 10 μL. The tube was then incubated at 65oC for 5 minutes, then stored on ice 
for 1 minute. Meanwhile, a cDNA synthesis mix was created using contents from 
the SuperscriptTM III RT PCR kit (Invitrogen), 10 μL total volume per sample. 
Samples were then incubated at 50oC for 50 minutes, then 85oC for 5 minutes. 1 
μL RNase was added to each sample, then samples were incubated at 37oC for 20 
minutes. Complete cDNA was then stored at -20oC for future qPCR. 
PCR reaction mix was generated by mixing TaqMan® Universal Master Mix II 
(Thermo Fisher) with primers outlined in Table 2.3, RNase-free water 
(Invitrogen), and 5 μL of cDNA (diluted to account for the number of primers 
used). Samples were then incubated with Master Mix II for 2 minutes at 50oC, 
then 10 minutes at 95oC. Samples then underwent 40 cycles of denaturing at 95oC, 
15 seconds, and annealing cycles of 60oC, 1 minute. Completed qPCR products 
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were observed using ViiA7 software (version 1.2, Life Technologies). Relative 
quantity expression was calculated using the delta-delta CT equation and 
normalised to the housekeeping gene, Hypoxanthine-guanine 
phosphoribosyltransferase (HPRT1). 
 
Table 2.6: qPCR Probes 
 
2.4 Intestinal organoids 
2.4.1 Tissue processing and organoid generation 
Patient intestinal biopsies were obtained from IBD patients or control patients 
undergoing colonoscopies. Six random biopsies were taken from visually 
uninflamed regions of the transverse colon. Isolation of intestinal crypts and the 
generation of intestinal organoids were based on protocols designed by the Sato 
laboratory group[123]. 
Gene Catalogue ID Company 
HPRT1 4333768T Thermo Fischer Scientific 
IL-1β Hs00174097_m1 Thermo Fischer Scientific 
IL-2RA Hs00907777_m1 Thermo Fischer Scientific 
IL-10 Hs00174086_m1 Thermo Fischer Scientific 
IL-17A Hs00174383_m1 Thermo Fischer Scientific 
IL-17F Hs00369400_m1 Thermo Fischer Scientific 
IL-23R Hs00332759_m1 Thermo Fischer Scientific 
TGF-β Hs00171257_m1 Thermo Fischer Scientific 
TNF Hs00174128_m1 Thermo Fischer Scientific 
IFNγ Hs00174143_m1 Thermo Fischer Scientific 
FOXP3 Hs00203958_m1 Thermo Fischer Scientific 
RORc Hs00172858_m1 Thermo Fischer Scientific 
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Tissues were washed twice in Dithiothreitol (DTT; Gibco), then incubated in 0.5 
mM EDTA (Sigma-Aldrich) on ice, for 1 hour. After incubation, the EDTA was 
removed and PBS + 10% FCS was added to the tissues in a 15 mL Falcon tube 
(Corning). The tube was then gently shaken 5-10 times, until intestinal crypts 
were liberated. The crypt-enriched liquid was then removed, and the process was 
repeated until the tissues no longer released crypts. Intestinal crypts were then 
centrifuged at 40xg, 4oC, for 2 minutes. Crypts were then washed in Dulbecco's 
Modified Eagle Medium (DMEM/F-12; Gibco), centrifuged, then resuspended in 
Matrigel® (Corning). Crypt-containing Matrigel® was then added to a 
prewarmed 48-well plate as ~40 μL droplets. Crypts were then incubated at 37oC, 
5% CO2, for 10 minutes, the 500 μL organoid media (Table 2.4 Organoid media) 
(containing ROCK-inhibitor) was added to each well and placed back in the 







Final concentration Supplier 
N2 100X 1X Invitrogen 
B27 50X 1X Invitrogen 
Nicotinamide 250 mM 10 mM Sigma-Aldrich 
N-acetyl-L-cystine 500 mM 1 mM Sigma-Aldrich 
LY 2157299 0.5 mM 500 nM PeproTech (NJ, 
USA) 
SB 202190 1 mM 10 µM PeproTech 
PGE2 10 µM 0.01 µM PeproTech 
Human EGF 100 µg/mL 50 ng/mL Thermo Fisher 
Scientific 
Noggin 100 µg/mL 100 ng/mL PeproTech 
Gastrin 1000 µg/mL 1 µg/mL PeproTech 
Advanced DMEM/F-12  30% Thermo Fisher 
Scientific 
Glutamax 100X 1X Invitrogen 
HEPES 1M 10 mM Sigma-Aldrich 
Penicillin / Streptomycin 100 µg/mL 1% Invitrogen 
Normacin 50 mg/mL 0.1 mg/mL Invivogen 
Gentamycin  0.0025% (Total 
volume) 
Gibco 
Wnt-conditioned media  50% (Total volume) R&D Systems 
r-spondin-conditioned media  12% (total volume) PeproTech 







2.4.2 Organoid passage 
Organoids were passaged every 5-7 days. Briefly, organoid domes were 
resuspended in cold PBS and incubated on ice for 30 minutes. Organoids were 
then centrifuged at 40xg, 4oC, for 2 minutes. The supernatant was then removed, 
and organoids were resuspended in 1 mL PBS. Organoids were then 
mechanically disrupted using a 23G syringe 20-30 times, centrifuged, then re-
plated in Matrigel® domes (as outlined above). Organoids were then cultured in 
500 μL organoid media (containing ROCK-inhibitor). 
 
2.4.3 Monolayer generation 
Intestinal organoids were generated and passaged until at least passage 3. PET 
Transwell® plates, 48-well, 0.4 µM pore size were coated in 80 μL 1:30 
Matrigel®:DMEM/F-12, for 1 hour, then the excess liquid was removed and 
replaced with 150 μL organoid media (containing ROCK-inhibitor). Organoids 
were then incubated in TrypLE-express + EDTA (0.5 mM) on ice, for 30 minutes, 
then a 37oC water bath for 10 minutes. Organoids were then centrifuged, and the 
supernatant was removed. Organoids were then mechanically disrupted using a 
p1000 pipette ~30-50 times. Disrupted organoids were resuspended in organoid 
media then seeded on the Matrigel®-coated Transwell® membranes (50 μL per 
membrane). 
 
2.4.4 TEER reading 
Intestinal monolayers were monitored for confluence using an EVOM 2 
transepithelial resistance meter (TEER). Organoid media was refreshed, then an 
STX2 electrode was placed in the apical and basal compartments of an intestinal 
monolayer-containing Transwell® plate. A TEER reading was generated and the 
background ‘no monolayer’ reading was subtracted from the reading. 
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2.4.5 Monolayer processing for haematoxylin and eosin staining 
Transwell® inserts were washed with PBS, then 200 μL and 500 μL of 
paraformaldehyde (Sigma Aldrich) was added to apical and basal compartments, 
respectively, for 30 minutes. Transwell® membranes were then cut from 
Transwell® inserts using a sterile scalpel, inserted into a tissue cassette with foam 
inserts, then submerged in 70% ethanol. 
Samples were then processed for paraffin wax embedding. Fixed Transwell® 
membranes were treated with 70% ethanol for 60 minutes, then 95% ethanol/5% 
methanol for 60 minutes, then absolute ethanol for 90 minutes, a repeat bathing 
in fresh absolute ethanol for 90 minutes, then a final repeat bathing in fresh 
absolute ethanol for 120 minutes. Samples were then treated with xylene (Leica 
Biosystems, Wetzlar, Germany) for 60 minutes, then treated with Paraplast X-tra 
wax (Sigma Aldrich) at 50oC for 60 minutes, twice. Samples were then embedded 
in paraffin wax blocks. 
Samples in paraffin wax blocks were sectioned into 5 μm-thick ribbons using a 
microtome. Ribbon samples were then laid flat on a glass slide in preparation for 
H&E staining. Sections were dewaxed via two xylene baths for 2 minutes, 
followed by two baths in absolute ethanol for 2 minutes, followed by a water 
wash. Sections were then stained in Gill II Hematoxylin (Leica Biosystems) for 4 
minutes, washed in water for 2 minutes, treated with Scott’s Tap Water (Leica 
Biosystems) for 2 minutes, washed in water for 2 minutes, stained with Surgipath 
Eosin (Leica Biosystems) for 30 seconds, washed with water for 1 minute, then 
dehydrated and covered with a coverslip. 
2.5 Statistical analysis 
All statistical analyses are provided within the legends of each figure. Statistical 
analyses were calculated using GraphPad Prism version 7.00 for Windows 






Functional analysis of T lymphocyte responses in 
Crohn’s disease patients 
3.1 Introduction 
CD is a chronic, relapsing inflammation of the intestine. PBMCs and intestinal 
immune cells from patients with CD often have elevated frequencies of IFNγ+ 
and IL-17A+ T lymphocytes, and their associated effector cytokines[48]. 
Furthermore, CD has been associated with a loss of tolerance of commensal 
microbes (Section 1.3.2).  
Patients with CD often have a more permeable intestinal epithelial barrier than 
healthy people[101]. Intestinal leakiness allows for the migration of luminal 
antigens and bacteria to invade the LP. Due to this, it is unclear whether 
inflammation in CD is initiated by microbial translocation into the LP, or if 
uncontrolled inflammation is the cause of intestinal permeability. Faecal samples 
from patients with CD often have low abundances of commensal bacteria, such 
as B. fragilis and F. prausnitzii[141]. These commensals have been shown to 
contribute to intestinal homeostasis via the production of anti-inflammatory 
molecules, such as PSA[142] and MAM[74], and also through the production of 
butyrate[143]. PSA and MAM directly induce the activation of Tregs in the 
intestine (Section 1.2.3.2). Thus, the lack of commensal microbes in CD patients 
may cause a reduction in intestinal tolerance. However, it is unclear whether the 
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lack of commensals in CD patients is due to excessive inflammation, host genetic 
abnormalities, or initial dysbiosis. It is also unclear whether the lack of 
commensal microbes in CD patients contributes to pathogenesis or is just a 
consequence of intestinal inflammation. 
It is known that inflammation in CD is heavily influenced by T lymphocytes. 
Thus, more information regarding immune cell responses to stimulation and 
commensal bacteria are required for a better understanding of the mechanisms 
of pathology in CD. 
 
3.2 Aims 
The aims of this chapter were to elucidate CD patient PBMC T lymphocyte 
responses to stimulation and commensal bacteria. Experiments were designed to 
provide a functional analysis of IFNγ+ T lymphocytes, IL-17A+ T lymphocytes, 
and Tregs (CD3+CD4/8+CD25HIFOXP3+). It was hypothesised that CD PBMCs 
would have a higher inflammatory capacity in response to stimulation, than non-
IBD controls. Furthermore, it was expected that CD patient PBMCs would have 
inflammatory responses to co-culture with commensal bacteria. 
The specific aims of this chapter were to: 
• Identify differences between non-IBD and CD patient PBMC profiles 
 
• Identify differences between non-IBD and CD PBMC responses to 
stimulation 
 
• Identify differences between non-IBD and CD PBMC responses to 
commensal bacteria 
 




3.3.1 Development of a flow cytometry panel for T lymphocyte identification 
A flow cytometry panel was established for the analysis of T lymphocyte subsets 
of interest in non-IBD and CD patient PBMCs. Lymphocytes are a well-
characterised lineage, which provided information for accurate identification via 
size (FSC-A) and granularity (SSC-A). Cells can clump together to form 
‘doublets’, causing inaccuracies in the analysis. Doublet cells were excluded by 
removing outlier-sized cells using FSC-H against FSC-A, and FSC-H against FSC-
W. Live-CD3+ lymphocytes were selected as cells positive for CD3 and negative 
for the viability dye, ZOMBIE NIR. Cells were then categorised into two major 
arms of T lymphocytes, based on their expression of either CD4 or CD8 (Figure 
3.1a). Of CD4- and CD8-expressing cells, cells were further identified by their 
expression of either IFNγ, IL-17A, or high expression of CD25 and FOXP3 (Tregs) 
(Figure 3.1b-c). PBMCs were stimulated using PMA and ionomycin. Ionomycin 
is an ionophore which binds Ca2+ ions and transfers these Ca2+ ions into the 
immune cell. In a cellular context, ionomycin stimulates immune cells by 
increasing the intracellular concentration of Ca2+. PMA crosses the cellular 
membrane to directly activate protein kinase C (PKC). By directly activating 
PKC, an activating surface signal is not required to activate the cell. In 
combination, PMA and ionomycin work together to induce non-specific immune 
cell activation via the transcription factors, NFκB and NFAT, without the 
requirement of surface signalling. As T lymphocytes are functionally plastic, it is 
difficult to assign T lymphocytes into subsets when cells are at rest. 
PMA/ionomycin are primarily used in flow cytometry to induce the expression 
of intracellular cytokines, allowing for detection, without de novo gene expression 
(Figure 3.2a). In theory, immune cells will become activated and express their 
unique cytokine profiles, allowing categorisation of subsets. However, 
PMA/ionomycin stimulation can induce the endocytosis of extracellular CD4, 
59 
 
which prevents detection of CD4+ immune cells[144]. As such, when 
PMA/ionomycin stimulation was used, CD4 staining was conducted 
intracellularly, rather than extracellularly (Figure 3.2c). For T lymphocyte-
specific stimulation, anti-CD3/28 beads were used (Figure 3.2b). Activation of 
CD3 and CD28 emulated the primary and secondary stimulation signals (usually 
provided by antigen-presenting cells) required to activate T lymphocytes, 
respectively. Anti-CD3/28 beads provide a specific T lymphocyte response, 





Figure 3.1: Flow cytometry panel for T lymphocyte subset characterisation. PBMCs 
were isolated from non-inflammatory bowel disease (IBD) and Crohn’s disease (CD) 
patient peripheral blood, processed and analysed as described in Material and Methods. 
a) Gating strategy for identification of T lymphocyte subsets by granularity (SSC-A) and 
size (FSC-A), doublet exclusion, selection of live CD3+ cells, and selection of CD4+ and 
CD8+ T lymphocytes. b-c) CD4+ (b) and CD8+ (c) T lymphocytes were then selected on 
their expression of IL-17 (left), CD25 and FOXP3 expression (Tregs; middle), or IL-2 and 
IFNγ (right). Gates identify cells positive for the indicated marker. Gates were placed 
according to FMO control expression. Data are shown from an individual non-IBD 






Figure 3.2: Optimisation of T lymphocyte stimulation. a-b) Non-inflammatory bowel 
disease control Peripheral blood mononuclear cells (PBMC) were either plated alone 
(left) or stimulated with either Paraformaldehyde/ionomycin (a; top middle) or anti-
CD3/28 beads (b;  bottom middle) as described in Materials and Methods (CD4 was 








3.3.2 Crohn’s disease patient PBMCs display high frequencies of T lymphocyte 
subsets  
Patients with CD suffer from sporadic chronic inflammation throughout the 
gastrointestinal tract. Inflammation in CD is typically considered to be mediated 
by excessive lymphocyte immune responses. To identify the mechanisms of 
inflammation and to compare these data to data in the literature, I initially sought 
to characterise the differences between non-IBD and CD patient PBMC T 
lymphocyte populations of interest. Non-IBD and CD patient PBMC IFNγ+ T 
lymphocyte and Treg frequencies were similar when observed as a percentage of 
total CD3+ and CD4+ cells (Figures 3.3-3.4). CD patients had significantly higher 
frequencies of CD4+IL-17A+ T lymphocytes than non-IBD controls when observed 
as total CD3+ cells but not when observed as total CD4+ cells (Figure 3.5a; p = 
0.415). There was no significant difference between non-IBD and CD patient CD8+ 
T lymphocyte populations (Figure 3.3-3.5).  
These data showed that CD patient peripheral blood had higher frequencies of 
CD4+IL-17A+ lymphocytes than non-IBD controls. These data also suggest that 
cytokine-producing CD8+IL-17A+ T lymphocytes and Tregs were rare 
populations, compared to CD4+ equivalents, and that CD8+ populations were not 
significantly different between non-IBD and CD patient blood samples.  
qPCR was conducted to further analyse PBMC expression profiles. mRNA 
expression profiles provide insight into the level of gene expression on a cell 
population-wide basis. RNA was harvested from frozen non-IBD and CD patient 
PBMCs and analysed using a TaqMan qPCR kit, in conjunction with primers of 
interest. CD patient PBMCs had a higher median expression of FOXP3, IL23R, 
and TNF, compared to non-IBD controls, but this was not significant (Figure 3.6). 
Median IL1B expression was lower in CD patient PBMCs, than in non-IBD 
controls, but this was not significant. There was no significant difference in the 
expression of IFNG, IL2RA, TGFB1, or IL10. 
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Although there was no significant difference between groups, comparison of 
median expression levels suggests that CD patient PBMCs expressed genes 
related to the Th17/Treg axis, more so than non-IBD controls. In combination 
with T lymphocyte population data, these data suggest that CD patient PBMC 
populations, in general, display a more inflammatory phenotype, than non-IBD 
control PBMCs. Due to reagent limitations, a single housekeeping gene, HPRT1, 
was used for mRNA analysis. In future experiments, more housekeeping genes 




Figure 3.3: No difference between non-IBD and CD patient PBMC regulatory T 
lymphocytes. Peripheral blood mononuclear cells (PBMC) were isolated from non-
inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). 
Samples were processed as described in the Materials and Methods, then analysed by 
flow cytometry. a) Frequency of regulatory T lymphocytes (CD4+CD25HIFOXP3+) of CD3+ 
cells. b) Frequency of regulatory T lymphocytes (CD8+CD25HIFOXP3+) of CD3+ cells. c) 
Frequency of regulatory T lymphocytes (CD4+CD25HIFOXP3+) of CD4+ cells. d) 
Frequency of regulatory T lymphocytes (CD8+CD25HIFOXP3+) of CD8+ cells.  Data shown 
are individual patients and the bar represents the median frequency. Non-IBD (n=15), 




Figure 3.4: No difference between non-IBD and CD patient PBMC IFNγ+ T 
lymphocytes. Peripheral blood mononuclear cells were isolated from non-inflammatory 
bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples were 
processed as described in the Materials and Methods, then analysed by flow cytometry. 
a) Frequency of CD4+IFNγ+ T lymphocytes of CD3+ cells. b) Frequency of CD8+IFNγ+ T 
lymphocytes of CD3+ cells. c) Frequency of CD4+IFNγ+ T lymphocytes of CD4+ cells. d) 
Frequency of CD8+IFNγ+ T lymphocytes of CD8+ cells.  Data shown are individual 
patients and the bar represents the median frequency. Non-IBD (n=15), CD (n=12). 






Figure 3.5: CD patients have a higher frequency of IL-17A+ T lymphocytes than non-
IBD controls. Peripheral blood mononuclear cells were isolated from non-inflammatory 
bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples were 
processed as described in the Materials and Methods, then analysed by flow cytometry. 
a) Frequency of CD4+IL-17A+ T lymphocytes of CD3+ cells. b) Frequency of CD8+IL-17A+ 
T lymphocytes of CD3+ cells. c) Frequency of CD4+IL-17A+ T lymphocytes of CD4+ cells. 
d) Frequency of CD8+IL-17A+ T lymphocytes of CD8+ cells.  Data shown are of individual 
patient samples and the bar represents the median frequency. Non-IBD (n=15), CD 





Figure 3.6: No difference in non-IBD and CD patient PBMC expression profiles. 
Peripheral blood mononuclear cells were isolated from non-inflammatory bowel disease 
(IBD) controls and patients with Crohn’s disease (CD). Samples were processed as 
described in the Materials and Methods. Samples were then analysed by qPCR. Data 
show the mRNA expression of indicated genes, shown as the relative expression of the 
indicated gene to HPRT1 (dotted line). Data are shown as individual patients and the 
bar represents the median relative expression. Non-IBD (n=7), IBD (n=8). Statistical 




3.3.3 High degrees of heterogeneity in non-IBD and CD patient PBMCs 
Functional analysis of PBMC data can result in observer bias of specific markers, 
which can result in failure to observe important cell types or responses. Cluster 
analysis tools, such as viSNE and SPADE, provide a visualisation of PBMC 
expression profiles across a broad range of cell identities. viSNE and SPADE can 
process concatenated PBMC data from patient groups and display them as 
clusters of cells with similar expression profiles using median-fluorescence 
intensity (MFI). These tools allow for the observation of group-wide cell profiles 
which can provide valuable phenotype data missed by using conventional gating 
techniques. It is important to note that expression data displayed by these 
techniques use MFI data relative to other cells within the same data set. For 
instance, viSNE plots displaying CD3 expression show clusters expressing low 
CD3. However, data were pre-gated on live CD3+ cells, thus, clusters that 
expressed low CD3 were still CD3+ but expressed lower CD3 than other cell 
clusters.  
viSNE plots showed a clear resolution of CD3, CD4, and CD8 T lymphocytes 
(Figure 3.7). The viSNE analysis showed non-IBD and CD patient PBMC 
expression profiles were similar. Interestingly, CD25 and IL-2 co-localised with 
clusters with high expression of CD4. In contrast, IFNγ co-localised with clusters 
with high CD8 expression. These data suggest that CD8+ cells are more associated 
with high expression of IFNγ, whereas CD4+ cells are more associated with high 
expression of CD25 and IL-2. However, both high CD4 and CD8 expression 
clusters had some clusters with high expression of each of these cytokines. IL-17 
and FOXP3 did not resolve clusters based on their expression, which may suggest 
their expression is not associated uniformly within specific clusters. These data 
more suggest a consistency of high expression within CD4 or CD8 populations, 
and their respective highly expressed cytokines. Interestingly, non-IBD and CD 




Figure 3.7 Heterogeneous cytokine expression in non-IBD and CD patient PBMCs. 
Peripheral blood mononuclear cells (PBMC) were isolated from non-inflammatory 
bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples were 
processed as described in the Materials and Methods, then analysed by flow cytometry. 
Figures show expression of a single indicated markers across individual clusters of cells 
with similar expression profiles as determined by viSNE analysis. Data were 
concatenated from 5 non-IBD and 5 CD patient PBMCs and pre-gated on live CD3+ T 
lymphocytes. Regional clusters represent cells of similar expression profiles across all 




SPADE is a spanning-tree progression analysis which used MFI data in a similar 
way to viSNE. However, SPADE visualisation of cell expression profiles groups 
clusters by similarity to each other. Simply, the length of the line connecting two 
clusters represents profile similarity – the closer, the more similar – however, 
distant nodes are not necessarily unrelated. Thus, it is important to work through 
SPADE plots stepwise to identify cell populations based on known phenotyping 
methods. As the data fed into the SPADE analyses were pre-gated on live CD3+ 
T lymphocytes, expression of CD3 was ubiquitous in all observed clusters but 
varied in the intensity of expression (Figure 3.8). High expression of CD3 co-
localised with expression of CD4 (Supplementary Figure 1) and CD8 (Figure 3.9). 
Clusters with high expression of CD8 were associated with high expression of 
IFNγ (Figure 3.10), this was true in both non-IBD and IBD patient PBMCs 
(Supplementary Figures 1-8). SPADE analysis identified a population of 
CD3+CD4/8-IFNγ+ cells in both non-IBD and IBD patient PBMCs (Figure 3.10, 
Supplementary Figure 4)).  However, this was not unexpected, as T lymphocytes 
can endocytose CD4 and CD8 upon activation[145]. High IL-2 expression was 
associated with clusters expressing high MFI of CD8 (Figure 3.11), in contrast to 
viSNE analysis which associated IL-2 expression with CD4-expressing clusters 
(Figure 3.7). IL-2 is expressed by both CD4+ and CD8+ cells (Figure 3.1). It is likely 
that IL-2 is not a strong candidate for cluster resolution as its expression is wide-



















Figure 3.8 PBMC CD3 expression visualised by SPADE analysis. Peripheral blood mononuclear cells (PBMC) were isolated from non-
inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples were processed as described in the Materials and 
Methods, then analysed by flow cytometry. Plot shows CD3 expression across live CD3+ PMBCs from concatenated data from 5 non-IBD controls. 


















Figure 3.9 PBMC CD8 expression visualised by SPADE analysis. Peripheral blood mononuclear cells (PBMC) were isolated from non-
inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples were processed as described in the Materials and 
Methods, then analysed by flow cytometry. Plot shows CD3 expression across live CD3+ PMBCs from concatenated data from 5 non-IBD controls. 















Figure 3.10 Subset of highly activated CD4/8- T lymphocytes in non-IBD and CD patient PBMCs. Peripheral blood mononuclear cells (PBMC) 
were isolated from non-inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples were processed as described 
in the Materials and Methods, then analysed by flow cytometry. Plot shows IFNγ expression across live CD3+ PMBCs from concatenated data 
from 5 non-IBD controls. Boxes indicate regions of CD4+, CD8+, and CD3+CD4/8- IFNγ+ T lymphocytes. IFNγ expression is relative to mean IFNγ 

















Figure 3.11 CD8+ T lymphocytes express high levels of IL-2. Peripheral blood mononuclear cells (PBMC) were isolated from non-inflammatory 
bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples were processed as described in the Materials and Methods, then 
analysed by flow cytometry. Plot shows IFNγ expression across live CD3+ PMBCs from concatenated data from 5 non-IBD controls. Boxes indicate 
regions of CD4+, CD8+, and CD3+CD4/8- IFNγ+ T lymphocytes. IL-2 expression is relative to mean IL-2 MFI within this data set. 
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3.3.4 Stimulated vs unstimulated PBMCs  
Inflammation in CD could be due to excessive immune responses from activated 
lymphocytes. Thus, I sought to compare T lymphocyte subset dynamics between 
non-IBD and CD PBMCs, in response to a non-specific T lymphocyte stimulus. T 
lymphocytes can be activated in vitro with anti-CD3/28 beads, which activate 
lymphocytes via the TCR, imitating the role of antigen presentation by APCs. 
Anti-CD3/28 beads are an effective method to activate lymphocytes as responses 
to beads are consistent and do not require the addition of live APCs. Non-IBD 
and CD patient PBMCs were stimulated for 48 hours with anti-CD3/28 beads to 
investigate differences in T lymphocyte profiles upon stimulation. 48 hours was 
determined, by time-course optimisation, to be the optimal incubation time for 
the secretion of cytokines (Supplementary Figure 9). 48 hour stimulation is in-
line with PBMC stimulation experiments in the literature[146]. 
Non-IBD and CD patient PBMCs increased in Treg (Figure 3.12a; CD p = 0.078), 
IFNγ+ T lymphocytes (Figure 3.12b; CD p = 0.0156), and IL-17A+ T lymphocyte  
population (Figure 3.12c; CD p = 0.0156) frequencies, in response to stimulation; 
however, only CD patient PBMC responses were significant, likely due to the 
larger sample size. Non-IBD and CD patient PBMC CD4+ and CD8+ Tregs had 
similar increases in Treg population frequencies in response to stimulation: CD4+ 
Tregs (Average change in frequency; non-IBD = +26.7%, CD = +28.5%) and CD8+ 
Tregs (Average change in frequency; non-IBD = +7.5%, CD = +9.7%). 
CD patient CD4+ IFNγ+ T lymphocytes increased with a greater magnitude than 
non-IBD control T lymphocytes (Figure 3.12b; p = 0.0156) (Average change in 
frequency; non-IBD = +9.1%, IBD = +16.4%). CD patient CD8+IFNγ+ T 
lymphocytes increased in frequency in response to stimulation (Figure 3.12b; p = 
0.078) (Average change in frequency; non-IBD = +4.8%, CD = +6.1%), whereas the 
non-IBD CD8+IFNγ+  T lymphocyte response was not significant. 
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CD CD4+IL-17A+ T lymphocytes increased in frequency in response to 
stimulation (Figure 3.12c; p = 0.0156) (Average change in frequency; non-IBD = 
+4.2%, CD = +7.1%). Interestingly, CD patient CD8+IL-17A+ T lymphocytes 
increased in frequency in response to stimulation, whereas there was not 
significant response in non-IBD CD8+IL-17A+ T lymphocytes (Average change in 
frequency; non-IBD = 0.5%, CD = +3.4%). Further, stimulated CD PBMC CD8+IL-
17A+ T lymphocyte frequencies were significantly higher than stimulated non-
IBD CD8+IL-17A+ T lymphocytes (Figure 3.12c; p = 0.0013). 
These data suggest that CD patient PBMC CD4+IFNγ+ T lymphocytes, CD8+IFNγ+ 
T lymphocytes, and CD8+IL-17A+ T lymphocytes were more responsive to anti-
CD3/28 bead stimulation than non-IBD controls (Figure 3.12a-c). 
Non-IBD and CD patient blood samples were stimulated with anti-CD3/CD28 
beads at a 1:1 cell:bead ratio, for 48 hours, and cytokines were quantified via 
LegendPlex. Due to reagent limitations, cytokines were measured as the total 
cytokine concentration after stimulation but were not compared to a baseline 
control. In future experiments, comparison to an unstimulated baseline control 
will provide a more accurate representation of the effects of stimulation on PBMC 
cytokine expression and the magnitude of change for individual samples. CD 
patient PBMCs secreted significantly higher concentrations of IL-17A (p = 
0.0077), TNF (p = 0.0472), and IL-6 (p = 0.0415) than non-IBD controls (Figure 
3.13). IL-1β and IL-12p70 secretion was, on average, higher in CD patient PBMCs 
than non-IBD control PBMCs but not significantly. IFNγ secretion by CD patient 
PBMCs could be stratified into high- and low-secretors. Low-secretors had lower 
expression of IFNγ than non-IBD controls, whereas high expressors of IFNγ 
produced higher concentrations of IFNγ than the assay could detect, however, 
this was not significant, possibly due to low numbers of samples in stratified 
groups (further expanded in 4.3.3 Stratification by age). There was no difference 
in the secretion of IL-2 and IL-23. IL-4 secretion, on average, was lower in CD 
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patient PBMCs, compared to non-IBD controls but was not statistically 




Figure 3.12: CD patient PBMC CD8+IL-17A+ T lymphocyte frequencies increase in 
response to stimulation Peripheral blood mononuclear cells were isolated from non-
inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). 
Samples were processed as described in the Materials and Methods, stimulated with 
anti-CD3/28 beads for 48 hours, then analysed by flow cytometry. a-c) Frequencies of 
CD4+ (left column) and CD8+ (right column) Tregs (a), IFNγ+ T lymphocytes (b), and IL-
17A+ (c) T lymphocytes. Data shown are of individual patient samples. Non-IBD (n= 5), 
CD (N=8). Statistical analyses were calculated using the Wilcoxon matched-pairs signed 
rank test, comparing baseline and stimulated T lymphocyte frequencies (* = p < 0.01), or 
a two-way ANOVA with Sidak’s multiple comparisons test, comparing matched values 
between non-IBD and CD groups (** = p < 0.01).  
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Figure 3.13: CD patient PBMCs secrete more inflammatory cytokine than non-IBD 
controls. Peripheral blood mononuclear cells (PBMC) were isolated from non-
inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). 
Samples were processed as described in the Materials and Methods, then 80,000 PBMCs 
were cultured with anti-CD3/CD28 beads at a 1:1 ratio for 48 hours. Cytokine 
supernatants were then analysed by flow cytometry. Data are shown as individual 
patients and the bar represents the median concentration (pg/mL). Non-IBD (n=7), CD 
(n=10). The dotted lines represent the upper and lower limits of detection of the assay. 






3.3.5 Crohn’s disease patient PBMCs have an abnormal response to 
commensal bacteria 
It has been theorised that patients with CD may have lost tolerance to commensal 
microbes in the intestine. To test this, non-IBD and CD patient PBMCs were co-
cultured with various doses of the commensal bacteria, F. prausnitzii or B. fragilis. 
Both F. prausnitzii and B. fragilis are common gut commensals and are suggested 
to have important roles in the induction of intestinal tolerance via the activation 
of intestinal Tregs. 
Non-IBD and CD PBMC responses to F. prausnitzii were highly consistent, within 
each test group. Non-IBD CD4+ and CD8+ Treg populations did not change in the 
presence of F. prausnitzii at a 1:1 ratio (PBMC:bacteria) (Figure 3.14a-b). In 
contrast, CD patient CD4+ Tregs were significantly higher when co-cultured with 
F. prausnitzii at a 1:1 ratio (p = 0.0005) but displayed a non-significant reduction 
from this increase when co-cultured at 1:10 ratio (Figure 3.14a). Non-IBD control 
CD4+IFNγ+ T lymphocytes were significantly reduced at a 1:1 ratio of F. prausnitzii 
(p = 0.0078) and maintained this reduction at a 10:1 ratio (p = 0.0078) (Figure 
3.15a). In contrast to non-IBD control data, 4/8 CD patient PBMC CD4+IFNγ+ T 
lymphocytes decreased in frequency and 3/8 increased in frequency, at a 1:1 ratio 
of F. prausnitzii (Figure 3.15a); overall there was no statistically significant change 
in frequency. There was no significant difference in non-IBD control CD8+IFNγ+ 
cells, whereas CD patient CD8+IFNγ+ cells decreased in frequency at a 1:1 ratio of 
F. prausnitzii (p = 0.0156) and maintained the reduction at 1:10 at a ratio (p = 
0.0078) (Figure 3.15b). Non-IBD control PBMCs showed a significant reduction 
of IL-17A+ T lymphocyte frequencies at a 1:1 ratio with F. prausnitzii (p = 0.0043), 
which was maintained at a 10:1 ratio (p = 0.0043) (Figure 3.16a). CD patient PBMC 
CD4+IL-17A+ T lymphocytes had a similar response at a 1:10 ratio (p = 0.001), but 
this was not significant at a 1:1 ratio of F. prausnitzii (Figure 3.16b). Non-IBD and 
CD CD8+IL-17A+ PBMCs did not have a significant response to the presence of F. 
prausnitzii at any ratio (Figure 3.16b). 
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Figure 3.14: CD patient Tregs increase in response to F. prausnitzii. Peripheral blood 
mononuclear cells (PBMC) were isolated from non-inflammatory bowel disease (IBD) 
controls and patients with Crohn’s disease (CD). Samples were processed as described 
in the Materials and Methods. PBMCs were co-cultured with F. prausnitzii at 1:1 or 1:10 
ratios, or no bacteria, for 72 hours, then analysed via flow cytometry. a-b) Frequency of 
regulatory T lymphocytes (a) CD4+CD25HIFOXP3+ (b) CD8+CD25HIFOXP3+ as a 
percentage of total CD3+ cells at indicated co-culture ratios. Data shown are individual 
patient PBMCs in each culture condition. Non-IBD (n=12), CD (n=15). Statistical analyses 







Figure 3.15: CD patient IFNγ+ T lymphocytes frequencies do not change in co-culture 
with F. prausnitzii. Peripheral blood mononuclear cells (PBMC) were isolated from non-
inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). 
Samples were processed as described in the Materials and Methods. PBMCs were co-
cultured with F. prausnitzii at 1:1 or 1:10 ratios, or no bacteria, for 72 hours, then analysed 
via flow cytometry. a-b) Frequency of T lymphocytes (a) CD4+IFNγ+ (b) CD8+IFNγ+ as a 
percentage of total CD3+ cells at indicated co-culture ratios. Data shown are individual 
patient PBMCs in each culture condition. Non-IBD (n=9), CD (n=8). Statistical analyses 







Figure 3.16: CD and non-IBD IL-17A+ T lymphocytes have similar response to F. 
prausnitzii. Peripheral blood mononuclear cells (PBMC) were isolated from non-
inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). 
Samples were processed as described in the Materials and Methods. PBMCs were co-
cultured with F. prausnitzii at 1:1 or 1:10 ratios, or no bacteria, for 72 hours, then analysed 
via flow cytometry. a-b) Frequency of T lymphocytes (a) CD4+IL-17A+ (b) CD8+IL-17A+ 
as a percentage of total CD3+ cells at indicated co-culture ratios. Data shown are 
individual patient PBMCs in each culture condition. Non-IBD (n=15), CD (n=12). 
Statistical analyses were calculated using the Wilcoxon matched-pairs signed-rank test 






Non-IBD and CD patient PBMC CD4+ and CD8+ Tregs had similar responses to 
co-culture with B. fragilis. CD4+ Tregs significantly increased in both non-IBD and 
CD patient groups in response to co-culture with 1:1 B. fragilis (non-IBD p = 
0.0005), CD p = 0.0015), compared to no bacteria conditions (Figure 3.17a), in 
agreement with the literature regarding B. fragilis-induced Treg activation[142]. 
Interestingly, CD patient CD8+ Treg frequencies had a greater fold-increase than 
non-IBD CD8+ Tregs (Figure 3.17b). Non-IBD control CD4+IFNγ+ T lymphocytes 
were significantly reduced in the presence of B. fragilis at a 1:1 ratio of B. fragilis 
(p = 0.0117) (Figure 3.18a). Of note, 2/10 CD patient CD4+IFNγ+ T lymphocytes 
increased in frequency in co-culture with B. fragilis. 7/10 CD patients had low 
frequencies of CD4+IFNγ+ T lymphocytes. IFNγ expression was low in most CD 
patient PBMCs, compared to non-IBD controls (Figure 3.18a). However, samples 
run in the same experiment had higher frequencies of IFNγ+ cells, suggesting that 
the stain was functional in this data set; therefore, these are true values and not a 
failed stain. The discrepancy in IFNγ expression may have been due to 
differences between patient treatments. CD patient CD8+IFNγ+ T lymphocytes 
were significantly reduced at a 1:1 B. fragilis ratio (p = 0.0088), non-IBD 
CD8+IFNγ+ responses were similar, but not statistically significant (Figure 3.18b). 
Non-IBD CD4+IL-17A+ T lymphocytes had a significant reduction in frequency in 
co-culture with 1:1 (p = 0.0081) and 1:10 ratios of B. fragilis (p = 0.0105) (Figure 
3.19a). In contrast, CD patient CD4+IL-17A+ T lymphocytes had a significant, 
lesser reduction in frequency at 1:1 ratio (p = 0.0006) and no change at 1:10 ratio 
(Figure 3.19a). Non-IBD control and CD patient PBMC CD8+IL-17A+ T 
lymphocytes frequencies did not significantly change in response to B. fragilis 
(Figure 3.19b). Interestingly, non-IBD controls had higher frequencies of CD8+IL-
17A+ T lymphocytes than CD patients. CD patient CD8+IL-17A+ T lymphocytes 
were almost undetectable at all co-culture conditions. 
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Overall, non-IBD and CD patient PBMC T lymphocytes had different responses 
to co-culture with F. prausnitzii and B. fragilis. Broadly speaking, non-IBD control 
CD4+, and to a lesser degree CD8+IFNγ+ T lymphocytes, reduced in frequency in 
co-culture conditions, a response which is possibly impaired in CD patient CD4+ 
IFNγ+ T lymphocytes. Non-IBD control CD4+IL-17A+ T lymphocyte frequencies 
were reduced in co-culture conditions at 1:1 and 1:10 ratios, whereas CD patient 
CD4+IL-17A+ T lymphocytes had a lesser magnitude of reduction in co-culture 
conditions. Finally, in co-culture with F. prausnitzii, but not B. fragilis, CD patient 
CD4+ Tregs increased in frequency, whereas non-IBD control CD4+ Tregs did not.  
Furthermore, CD patient PBMCs displayed inconsistent responses to co-culture, 
whereas the non-IBD control group data were more consistent between patients, 
which may be due to varying degrees of disease severity. Together, these data 
suggest that CD patient PBMCs respond differently than non-IBD controls to the 





Figure 3.17: CD patient Tregs increase in co-culture with high dose of B. fragilis. 
Peripheral blood mononuclear cells (PBMC) were isolated from non-inflammatory 
bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples were 
processed as described in the Materials and Methods. PBMCs were co-cultured with B. 
fragilis at a 1:1 or 1:10 ratios, or no bacteria, for 72 hours, then analysed via flow 
cytometry. a-b) Frequency of regulatory T lymphocytes (a) CD4+CD25HIFOXP3+ (b) 
CD8+CD25HIFOXP3+ as a percentage of total CD3+ cells at indicated co-culture ratios. 
Data shown are individual patient PBMCs in each culture condition. Non-IBD (n=13), 
CD (n=15). Statistical analyses were calculated using the Wilcoxon matched-pairs 






Figure 3.18: No difference between non-IBD and CD patient IFNγ+ T lymphocyte 
responses to B. fragilis. Peripheral blood mononuclear cells (PBMC) were isolated from 
non-inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). 
Samples were processed as described in the Materials and Methods. PBMCs were co-
cultured with B. fragilis at a 1:1 or 1:10 ratios, or no bacteria, for 72 hours, then analysed 
via flow cytometry. a-b) Frequency of T lymphocytes (a) CD4+IFNγ+ (b) CD8+IFNγ+ as a 
percentage of total CD3+ cells at indicated co-culture ratios. Data shown are individual 
patient PBMCs in each culture condition. Non-IBD (n=9-15), CD (n=15). Statistical 
analyses were calculated using the Wilcoxon matched-pairs signed-rank test (* = p < 0.05, 





Figure 3.19: CD patient CD4+IL-17A+ T lymphocytes frequencies do not decrease in the 
presence of B. fragilis. Peripheral blood mononuclear cells (PBMC) were isolated from 
non-inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). 
Samples were processed as described in the Materials and Methods. PBMCs were co-
cultured with B. fragilis at a 1:1 or 1:10 ratios, or no bacteria, for 72 hours, then analysed 
via flow cytometry. a-b) Frequency of T lymphocytes (a) CD4+IL-17A+ (b) CD8+IL-17A+ 
as a percentage of total CD3+ cells at indicated co-culture ratios. Data shown are 
individual patient PBMCs in each culture condition. Non-IBD (n=13), CD (n=15). 
Statistical analyses were calculated using the Wilcoxon matched-pairs signed-rank test 







3.3.6 Cytokine profiles in response to F. prausnitzii 
Co-culture data suggested that CD patient PBMC T lymphocytes had abnormal 
responses to commensal bacteria. To identify differences in cytokine production 
capacity, non-IBD and CD patient PBMCs were co-cultured with F. prausnitzii 
and supernatants were analysed for a range of human inflammation-related 
cytokines. In conditions containing no bacteria, non-IBD and CD patient PBMC 
cytokine profiles were similar between groups (Figure 3.20). Secreted IL-6 (p = 
0.0078) and IL-10 (0.0156) concentrations were significantly higher in CD patient 
supernatants cultured at 1:1 and 1:10 ratios of F. prausnitzii, respectively, 
compared to non-IBD controls. Median concentrations of TNF were higher in CD 
patient PBMCs, but this was not statistically significant. IL-6 was significantly 
increased in CD patient PBMC supernatants when co-cultured 1:1 ratio with F. 
prausnitzii (p = 0.0078); however, there was a significant decrease in IL-6 at a 1:10 
ratio F. prausnitzii when compared to 1:1 ratio conditions (p = 0.0078) (Figure 
3.20). In contrast, non-IBD control PBMCs displayed no difference in IL-6 
secretion when co-cultured at a 1:1 ratio with F. prausnitzii, whereas 3/6 increased 
when co-cultured with 1:10 ratio of F. prausnitzii, however, this was not 
significant. CD patient PBMCs secreted higher median concentrations of TNF 
when cultured at a 1:1 ratio F. prausnitzii, whereas there was no change in non-
IBD control TNF secretion, however, this was not significant. There were no 
significant changes in the secretion of IL-2, IL-4, IL-5, IL-10, IL-21, IL-17A, or 






Figure 3.20: CD patient PBMCs secrete IL-6 and IL-10 in response to F. prausnitzii.  
Peripheral blood mononuclear cells (PBMC) were isolated from non-inflammatory 
bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples were 
processed as described in the Materials and Methods, then 80,000 PBMCs were cultured 
with either F. prausnitzii at a 1:1 or 1:10 ratio, or cells alone, for 48 hours. Cytokine 
supernatants were then analysed by flow cytometry using a LegendPlex assay. a) Data 
are shown as individual patients across each condition as the concentration of the 
indicated analyte (pg/mL). Non-IBD (n=6), CD (n=8). Statistical analyses were calculated 
using the Mann-Whitney U test (* = p < 0.05, ** = p < 0.01). 
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3.3.7 Treg suppression assay  
CD patient CD4+ Tregs increased in frequency in the presence of F. prausnitzii, 
whereas non-IBD CD4+ Tregs did not (Figure 3.14). CD8+ Tregs displayed no clear 
response to F. prausnitzii in either group. CD4+ Tregs play a critical role in the 
induction of a tolerogenic environment. The lumen of the intestine is home to 
vast arrays of microbes and antigens, as such, a tolerogenic environment is vital 
for the preservation of intestinal tissues. To maintain this balance, suppressive 
immune cells, such as CD4+ Tregs (among others), are activated by cellular 
components from symbiotic commensals. However, CD is a disease which stems 
from uncontrolled inflammation, whereas these co-culture data inferred that CD 
patient PBMCs may generate more Tregs in the presence of F. prausnitzii; thus, 
suggesting the potential to create a more tolerogenic environment than non-IBD 
CD4+ Tregs. As such, I sought to determine and compare the suppressive capacity 
of CD patient CD4+ Tregs to non-IBD controls. 
Briefly, conventional T lymphocytes (Tconvs) (CD3+CD4+CD25lo-intCD127+) and 
CD4+ Tregs (CD3+CD4+CD25HICD127-) were isolated from non-IBD and CD 
patient PBMCs. Tconvs were stained with Carboxyfluorescein succinimidyl ester 
(CFSE), a cytoplasmic dye that halves in fluorescent intensity with each 
successive division event. Tconvs and Tregs were co-cultured at various ratios 
and stimulated with anti-CD3/28 beads at a 1:10 (cell:bead) ratio, for 80 hours. 
After incubation, the number of Tconv divisions could be determined via CFSE 
intensity. However, CFSE did not resolve separate division events, in any dosage 
of CFSE (Supplementary Figure 9). Instead, Cell-Trace Violet (CTV) was used 
and successfully resolved individual proliferation peaks (Figure 3.21). Moving 
forward, fluorophores for the sorting of Tconvs and Tregs were altered to 
accommodate the switch between CFSE and CTV. 
The proliferation index of each Treg:Tconv co-culture ratio was calculated to 
determine the capacity for the average Tconv cell to undergo division in the 
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presence of Tregs. The proliferation index is a calculation that accounts for the 
number of cells that are present in a proliferation peak and normalises back to 
initial population numbers (ie. If 10 cells of a total initial population of 100 
divided twice, then the second peak would contain 40 cells) (Table 3.1). In 
contrast, the precursor frequency represents the average number of divisions a 
cell from the initial pool of cells that proliferated underwent. Simply, precursor 
frequency represents total cell division capacity, whereas proliferation index 
represents the average number of divisions responder cells underwent (Table 
3.2). This distinction is important as these readouts represent different ways 
Tregs can influence the ability for a Tconv to respond to a stimulus. For example, 
Tregs could reduce the number of divisions the average cell undergoes (reducing 
proliferation index) but a higher frequency of total cells may have still 
proliferated at least once (higher precursor frequency). 
Suppression assay data suggested differences in both precursor frequencies 
(Figure 3.22a) and proliferation indexes (Figure 3.22b) between non-IBD and CD 
patient Tconvs. The average CD patient precursor frequency was 0.61, compared 
to non-IBD precursor frequency of 0.37 (Figure 3.22a). Similarly, the average CD 
patient proliferation index was 2.27, compared to the non-IBD index of 2.00 
(Figure 3.22b). Unfortunately, Tconvs were not suppressed by Tregs, at any ratio. 
However, the values for Treg co-culture ratios are similar to both CD and non-
IBD Tconv cultures which contain no Tregs (proliferation index: 2.28 and 2.00, p 
= 0.0223; and precursor frequencies: 0.64 and 0.37, p = 0.0490, respectively). These 
data suggest that CD patient Tconvs were more prone to division and divided 
more than non-IBD equivalents, on average, but these effects did not seem to be 






Figure 3.21: Treg suppression assay gating. a) Non-inflammatory bowel disease (IBD) 
and Crohn’s disease (CD) patient peripheral blood mononuclear cells were sorted into 
Tconv (CD3+CD4+CD25lo-intCD127+) and Treg (CD3+CD4+CD25HICD127-) populations. b) 
Tconvs and Tregs were co-cultured at various ratios [as indicated] (Treg:Tconv) for 80 
hours, at a 1:1 ratio of cell:anti-CD3/28 bead ratio, as described in Materials and Methods. 
Tconvs were stained with Cell-trace Violet (CTV) before co-culture for tracking of 
division events.  Individual proliferation peaks were gated and labelled by division 
number and the frequency of total CTV+ events. Data are representative of 7 non-IBD 
and 7 CD patient samples.  
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Figure 3.22: CD patient PBMCs have elevated proliferation indices and precursor 
frequencies compared non-IBD. a-b) Non-inflammatory bowel disease (IBD) and 
Crohn’s disease (CD) patient peripheral blood mononuclear cells were sorted into Tconv 
(CD3+CD4+CD25lo-intCD127+) and Treg (CD3+CD4+CD25HICD127-) populations. Tconvs 
and Tregs were co-cultured at various ratios [as indicated] (Treg:Tconv) for 80 hours, at 
a 1:1 ratio of cell:anti-CD3/28 bead ratio, as described in Materials and Methods. Tconvs 
were stained with Cell-trace Violet before co-culture for tracking of division events. a) 
Precursor frequency was calculated by (N/2i)/(Total number of events /2i)*100 = %P. 
Precursor frequency was determined by the sum of %P of all peaks where division 
occurred (peaks 1-4). b) Proliferation index was calculated by ((N/2i)*N)/(Total number 
of events); where N indicates the number of events within a proliferation peak and 2i 
indicates the number progeny per division stage. Individual patient data can be viewed 
in Table 3.1 and Table 3.2. Non-IBD (n=7 - blue), CD (n=7 - red). Statistical analyses were 
calculated using the Mann-Whitney U test (* = p < 0.05).
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Table 3.1 Proliferation indices. Non-inflammatory bowel disease (IBD) and Crohn’s disease (CD) patient peripheral blood mononuclear cells 
were sorted into Tconv (CD3+CD4+CD25lo-intCD127+) and Treg (CD3+CD4+CD25HICD127-) populations. Tconvs and Tregs were co-cultured at 
various ratios [as indicated – below green bar] (Treg:Tconv) for 80 hours, at a 1:1 ratio of cell:anti-CD3/28 bead ratio, as described in Materials 
and Methods. Tconvs were stained with Cell-trace Violet before co-culture for tracking of division events. Proliferation index was calculated by 
((N/2i)*N)/(Total number of events); where N indicates the number of events within a proliferation peak and 2i indicates the number of progeny 
per division stage. NA (red cells) refers to unreadable data.
 Proliferation Index 
 Treg:Tconv ratio 
Specimen Tconv 1:1 1:2 1:4 1:8 1:16 
Non-IBD 1 1.79 1.89 1.80 1.81 1.82 1.82 
Non-IBD 2 1.81 1.91 1.82 1.85 1.91 1.91 
Non-IBD 3 1.93 1.85 1.89 1.86 1.90 1.87 
Non-IBD 4 1.83 1.92 1.86 1.85 1.86 1.85 
Non-IBD 5 2.14 2.20 2.17 2.11 2.19 2.17 
Non-IBD 6 2.17 2.15 2.14 2.20 2.16 2.23 
Non-IBD 7 2.33 2.27 2.21 2.21 2.23 2.22 
  Tconv 1:1 1:2 1:4 1:8 1:16 
TCD 16 1.95 2.16 2.05 1.93 2.03 2.11 
TCD 17 2.16 2.00 2.16 2.14 2.15 2.11 
TCD 42 2.37 2.20 2.47 NA NA 2.38 
TCD 43 2.16 2.22 2.17 2.19 2.28 2.22 
TCD 44 2.34 2.29 2.40 2.45 2.22 2.28 
TCD 58 2.35 2.18 2.31 2.27 2.27 2.31 
TCD 64 2.64 2.56 2.60 2.62 2.48 2.70 
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Table 3.2 Precursor frequencies. Non-inflammatory bowel disease (IBD) and Crohn’s disease (CD) patient peripheral blood mononuclear cells 
were sorted into Tconv (CD3+CD4+CD25lo-intCD127+) and Treg (CD3+CD4+CD25HICD127-) populations. Tconvs and Tregs were co-cultured at 
various ratios [as indicated – below green bar] (Treg:Tconv) for 80 hours, at a 1:1 ratio of cell:anti-CD3/28 bead ratio, as described in Materials 
and Methods. Tconvs were stained with Cell-trace Violet before co-culture for tracking of division events. Precursor frequency was calculated 
by (N/2i)/(Total number of events /2i)*100 = %P. Precursor frequency was determined by the sum of %P of all peaks where division occurred 
(peaks 1-4). Non-IBD (n=7), CD (n=7). NA (red cells) refers to unreadable data.  
 Precursor Frequency 
 Treg:Tconv ratio 
Specimen Tconv 1:2 1:4 1:8 1:16 1:1 
Non-IBD 1 0.25 0.35 0.32 0.26 0.27 0.33 
Non-IBD 2 0.27 0.34 0.33 0.34 0.34 0.34 
Non-IBD 3 0.35 0.36 0.32 0.34 0.31 0.32 
Non-IBD 4 0.27 0.37 0.27 0.33 0.35 0.33 
Non-IBD 5 0.39 0.37 0.37 0.44 0.39 0.40 
Non-IBD 6 0.43 0.35 0.45 0.43 0.46 0.35 
Non-IBD 7 0.39 0.44 0.45 0.54 0.50 0.41 
  Tconv 1:1 1:2 1:4 1:8 1:16 
TCD 16 0.79 0.83 0.91 0.87 0.81 0.89 
TCD 17 0.94 0.86 0.90 0.93 0.93 0.93 
TCD 42 0.92 0.84 0.92 NA NA 0.89 
TCD 43 0.34 0.33 0.37 0.40 0.39 0.33 
TCD 44 0.34 0.26 0.38 0.40 0.27 0.30 
TCD 58 0.72 0.57 0.71 0.68 0.69 0.63 





In this chapter, it was demonstrated that CD patient PBMCs had distinct 
responses to anti-CD3/28 bead stimulation and stimulation with the commensal 
bacteria, F. prausnitzii and B. fragilis, compared to non-IBD control PBMCs. 
Stimulation of T lymphocytes with anti-CD3/28 beads showed CD patient 
PBMCs secreted more IL-6, IL-17A, and TNF, than non-IBD control PBMCs, each 
of which are cytokines associated with CD pathology. Co-culture of PBMCs with 
commensal bacteria suggested CD patient PBMCs and non-IBD PBMCs 
responded differently to the presence of commensal microbes. Data showed CD 
patient PBMC Tregs increased in frequency in the presence of F. prausnitzii; 
whereas CD4+IFNγ+ and CD4+IL-17A+ T lymphocytes did not reduce in 
frequency, in direct contrast to non-IBD control PBMC T lymphocyte responses. 
A proliferation assay showed CD patient PBMC Tconvs had a higher capacity for 
proliferation upon stimulation with anti-CD3/28 beads, compared to non-IBD 
control PBMC Tconvs. 
 
3.4.2 Methodology 
In this study, immune cells were isolated from patient peripheral blood to 
examine functional differences between non-IBD and CD patient immune 
responses to various types of stimulation. As colonic biopsies are difficult to 
obtain and colonic immune cells survive poorly in vitro, PBMCs are routinely 
used to observe CD patient immune profiles and responses. In this study, colonic 
biopsies were reserved for intestinal organoid experiments (Chapter 5), whereas 





3.4.3 PBMC T lymphocyte profiles and nomenclature 
A flow cytometry panel was designed to identify three T lymphocyte cell types 
of interest associated with CD - Tregs (CD3+CD25HIFOXP3+), IFNγ+ T 
lymphocytes (CD3+CD4/8+IFNγ+), and IL-17A+ T lymphocytes (CD3+CD4/8+IL-
17A+)[147]. This approach allowed the collection of data representing a ‘snapshot 
in time’ of peripheral blood T lymphocyte populations. As such, we could 
compare the immune cell profiles of non-IBD and CD patient PBMCs and use 
these data to infer information about intestinal immune cell populations and 
responses to various stimuli.  
Tregs are a suppressive T lymphocyte phenotype. Tregs regulate immune 
responses of other T lymphocyte populations via expression of IL-10, TGF-β, and 
immune checkpoint surface proteins, such as CTLA4 and LAG3[148]. In contrast 
to other T lymphocyte subsets, the activation of Tregs engages a suppressive 
response to stimulation. Activated Tregs upregulate expression of CD25 and 
FOXP3[149]. CD25 is the IL-2-receptor and is critical for Treg suppressive 
function. It is believed that high expression of CD25 by Tregs sequesters IL-2 
from the environment, starving other T lymphocyte subsets of IL-2[150]. FOXP3 
generally functions as a master regulator of suppression[149]. Expression of 
FOXP3 is required for IL-10 and TGF-β expression in Tregs. Dysfunctional 
immune responses by Tregs can cause susceptibility to inflammatory disease. 
Immunodysregulation polyendocrinopathy enteropathy X-linked syndrome 
(IPEX) is caused by mutations in the FOXP3 locus[151]. IPEX causes dysfunction 
in Tregs, resulting in the inability to resolve inflammatory responses, leading to 
autoimmunity. Indeed, mice depleted of Tregs using anti-CD25 antibodies were 
susceptible to the development of spontaneous colitis-like disease[152]. Models 
of IBD have implicated dysfunctional Treg function in IBD-like disease, however, 
Treg dysfunction in human CD remains largely unknown. A recent study 
showed patients with CD had higher numbers of circulating CD4+IL-17+FOXP3+ 
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double-expressing cells, than non-IBD controls, suggesting an imbalance in 
Th17/Treg plasticity in patients with CD[153]. 
IFNγ+ T lymphocytes are often referred to as ‘Type-1 helper T lymphocytes’ (Th1) 
and are identified by their expression of CD3, either CD4 or CD8, IFNγ+, and their 
expression of the transcription factor, T-bet[154]. In this thesis, these cells are 
referred to as ‘IFNγ+ T lymphocytes’, these cells directly respond to pathogenic 
stimuli, as opposed to only serving a ‘helper’ role. IFNγ+ T lymphocytes 
propagate inflammatory responses by ‘helping’ other immune cells via the 
production of IFNγ+, upon exposure to cognate antigen displayed on MHC by 
APCs[155]. IFNγ is an inflammatory cytokine that promotes activation and 
recruitment of other inflammatory immune cell subsets to the site of 
inflammation[156]. IFNγ+ T lymphocytes can also express and secrete TNF and 
IL-2, cytokines both involved in immune cell activation and survival. IFNγ+ T 
lymphocytes kill intracellular viruses, bacteria, and tumour cells. IFNγ+ T 
lymphocytes can induce cytolysis in infected or cancerous cells via secretion of 
TNF, granzyme, and perforin[157, 158]. Historically, IFNγ+ T lymphocytes were 
thought to be the major mediators of inflammation in CD, as patients with CD 
often have higher abundances of these cells and higher serum concentrations of 
IFNγ and TNF, compared to non-IBD controls[159]. However, treatments using 
anti-IFNγ Abs have limited efficacy in patients with IBD[160]. Interestingly, the 
subcutaneous injection of recombinant IFNγ protein reduced C-reactive protein 
levels in patients[161]. These data suggest that although IFNγ-signalling 
pathways may play a role in CD pathology, direct targeting of this subset does 
not induce remission. 
IL-17A+ T lymphocytes are typically referred to as ‘T helper 17 cells’ (Th17) and 
are identified by their expression of CD3, either CD4 or CD8, IL-17A, and the 
transcription factor, RORγT[162]. IL-17A+ T lymphocytes propagate 
inflammation via direct response and helper roles. IL-17A+ T lymphocytes protect 
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against extracellular pathogens and fungi. The main effector cytokines of IL-17A+ 
T lymphocytes are IL-17A, IL-17F, IL-17A/F, IL-21, and IL-22[163]. IL-17A+ T 
lymphocytes, upon exposure to cognate antigen, promote induction of 
inflammatory Granulocyte-colony stimulating factor (G-CSF), macrophage 
inflammatory protein (MIP)-2, and promote activation and recruitment of 
neutrophils to sites of inflammation[164]. The IL-17 family consists of IL-17A, IL-
17B, IL-17C, IL-17D, IL-17E, IL-17F, and the heterodimer IL-17A/F. IL-17A, IL-
17F, and IL-17A/F induced joint inflammation in murine models of collagen-
induced arthritis[165] and are implicated as drivers of inflammation in human 
autoimmune diseases, as well as IBD[166, 167].   
Non-IBD and CD patient PBMC T lymphocyte immune profile data were more 
similar than expected. Both CD4+ and CD8+ Tregs and IFNγ+ T lymphocyte 
frequencies were similar between groups when analysed as a total of CD3+ T 
lymphocytes, and as a total of CD4+ or CD8+ T lymphocytes. However, CD patient 
PBMCs had higher frequencies of CD4+IL-17A+ T lymphocytes. This was an 
important validation for this technique as IL-17A+ T lymphocytes are currently 
implicated as a major contributor to disease pathology in the literature. 
Furthermore, IL-17A+ T lymphocytes are more abundant in CD patient PBMCs 
and intestinal mucosa, compared to non-IBD controls[168, 169]. 
Overall, non-IBD and CD patient PBMC T lymphocyte profiles were similar. Data 
in this thesis agrees with the literature, which suggests that patients with CD 
have higher frequencies of IL-17A+ T lymphocytes, than non-IBD controls[97]. 
However, CD patients did not have higher frequencies of IFNγ+ T lymphocytes 
or lower frequencies Tregs, than non-IBD controls. It is important to note that 
these data are from peripheral blood, not the intestinal mucosa. Furthermore, it 
has been suggested that the onset of disease likely coincides with a retraction of 
the circulating pool of Tregs as they migrate to the intestinal site of 
inflammation[71]. As such, varied disease states within this human cohorts can 
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result in a wide range of patient T lymphocyte frequencies. Ideally, PBMCs 
would be taken at multiple time intervals from the same patients; however, this 
was not within our ethics and disease state at the time of colonoscopy was not 
well-documented. 
Data within this thesis suggest that patients with CD in this study had a larger 
pool of circulating IL-17A+ T lymphocytes, which could migrate to the intestine 
upon the induction of inflammation. To investigate this population further, α4β7-
integrin and L-selectin could be observed to suggest the direction in which these 
cells are migrating[170, 171]. α4β7-integrin interacts with the addressin, mucosal 
vascular addressin cell adhesion molecule (MAdCAM)-1, which facilitates T 
lymphocyte migration into the intestinal mucosa. L-selectin is a homing receptor 
which facilitates migration towards lymph nodes. Vedolizumab, an α4β7-
integrin neutralising mAb, induced remission in patients with UC and CD by 
inhibiting trafficking of gut-tropic immune cells[172, 173]. It would be interesting 
to observe the expression of these markers on CD patient PBMCs, to elucidate 
the trafficking dynamics of their IL-17A+ T lymphocytes.  
 
3.4.4 T lymphocyte responses to commensal bacteria 
CD has been associated with a loss of tolerance to commensal intestinal microbes, 
evidenced by the low abundance of certain commensal species in CD patient 
intestines[174], as well as the presence of commensal-specific lymphocytes in CD 
patient peripheral blood and intestinal mucosa[108]. In this study, two heat-
killed candidate commensal species, F. prausnitzii and B. fragilis, were co-cultured 
with non-IBD or CD patient PBMCs to identify differences in lymphocyte 
response, in vitro. F. prausnitzii is an obligate anaerobe, whereas B. fragilis is a 
facultative anaerobe. To maintain uniformity of bacteria numbers and condition, 
bacteria were heat-killed before freezing, then thawed for experimentation. 
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F. prausnitzii is a common commensal microbe, often comprising up to 5% of the 
faecal microbiota of adults[175]. Thus, the observation of low abundances of F. 
prausnitzii in patients with IBD made F. prausnitzii a good candidate for 
experimentation. F. prausnitzii produces butyrate and MAM[74]. Butyrate is a 
fuel source for enterocytes, which contributes to intestinal epithelial barrier 
function and integrity. MAM activates Tregs, increasing Treg survival and 
function. Thus, F. prausnitzii is typically abundant in healthy intestinal 
microbiomes and is an inducer of intestinal tolerance and homeostasis. 
B. fragilis, similar to F. prausnitzii, is a common intestinal commensal. B. fragilis 
contributes to intestinal tolerance through the production of butyrate, as well as 
PSA, a capsular protein that activates Tregs[142].  
Interestingly, it was found that non-IBD and CD patient PBMC T lymphocytes 
had different responses to the presence of F. prausnitzii and B. fragilis, which may 
contribute to a failure to maintain intestinal tolerance. 
 
3.4.4.1 Tregs 
There were differences in CD Treg responses in both F. prausnitzii and B. fragilis 
co-culture conditions, compared to non-IBD controls. In the presence of F. 
prausnitzii, at a 1:1 PBMC:bacteria ratio, CD patient CD4+ Tregs significantly 
increased in frequency with a subsequent decrease at a 1:10 ratio, whereas non-
IBD CD4+ Tregs did not display any increase in frequency. Interestingly, this 
increase in frequency was consistent across all tested individual CD patient 
PBMCs. There was no difference in CD8+ Treg frequency between groups; 
however, these cells were a rare cell subset and are not considered to be major 
contributors to suppression.  
In contrast, both non-IBD and CD patient PBMC Tregs increased in frequency in 
the presence of 1:1 B. fragilis ratio. However, non-IBD control Tregs decreased at 
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1:10 B. fragilis ratio, whereas CD patient Tregs maintained their initial increase. 
Furthermore, CD patient CD8+ Tregs increased in frequency at a 1:10 B. fragilis 
ratio, whereas non-IBD Tregs increased by a lesser magnitude. 
These data suggest that CD patient PBMC Tregs may be more susceptible to 
activation by certain intestinal microbes, than non-IBD control PBMC Tregs. 
However, it is difficult to be sure of these results as it was hypothesised that non-
IBD Tregs would also increase in frequency upon exposure to F. prausnitzii, due 
to the presence of anti-inflammatory MAM protein[74]. It is possible this effect 
may have not occurred due to the use of heat-killed bacteria. Future experiments 
could add bacterial-derived PSA and MAM to media instead of heat-killed 
bacteria. This would provide a more uniform measurement of response and may 
help to elucidate mechanisms that caused the observed differences between non-
IBD and CD patient Tregs. Nonetheless, within this model, there is evidence of 
abnormal responses to commensal bacteria in CD patient Tregs. 
These data suggest a possible new way to think about how inflammation initially 
occurs in CD patients. As these data suggest hyperresponsiveness by CD patient 
PBMC Tregs to commensal bacteria, it is possible that CD patients could contain 
regions of LP with high levels of suppression. As Tregs comprise a large fraction 
of intestinal immune cells, abnormal responses by Tregs could have a large 
impact on the balance of intestinal tolerance and maintenance of homeostasis. It 
is known that the intestinal immune profiles are highly diverse along the 
gastrointestinal tract, theorised to be caused by responses to highly regional 
microbial diversity and epithelial barrier cell composition[176]. Functional 
intestinal Treg populations are critical for the maintenance of intestinal tolerance. 
IL-10-/- murine models of CD develop spontaneous colitis-like pathology, caused 
by a lack of Treg-induced suppression[177]. However, studies have shown 
patients with UC have higher expression of IL-10 in macroscopically inflamed 
and uninflamed colonic tissues, compared to non-IBD control tissues[178]. It is 
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also known that the expansion of Tregs can cause immune suppression in 
cancer[179, 180]. Thus, it may be fair to speculate that patients with CD may be 
more susceptible to initial microbial assault, due to a lack of immune response in 
local regions of intestinal tissue, caused by hyperresponsive Treg activity. 
This theory also accounts for the sporadic, patchy manifestation of CD pathology, 
and the frequent remission/relapse nature of the disease. It is also possible, that 
if the intestine fails in this way, that chronic exposure to luminal contents may 
lead to the development of commensal-specific immune cells. 
However, it is impossible to validate these ideas in this simple co-culture model, 
as we cannot ascertain which effect is a cause or consequence of another.  Thus, 
to further probe these questions, an intestinal organoid model was generated, as 
discussed in Chapter 5. 
 
3.4.4.2 IFNγ+ T lymphocytes 
Non-IBD control PBMC CD4+IFNγ+ T lymphocytes reduced in frequency in the 
presence of F. prausnitzii, whereas CD patient CD4+IFNγ+ T lymphocytes did not. 
Interestingly, non-IBD control CD4+IFNγ+ T lymphocytes were consistent among 
all tested patients in their decrease in frequency, whereas 4/7 CD patient IFNγ+ T 
lymphocyte frequencies decreased and 3/7 increased. It is possible that these CD 
patient responses could be stratified into responders and non-responders to F. 
prausnitzii co-culture. Indeed, in the 2016 study by Calderón-Gómez et al., 75% of 
PBMCs from CD patients responded to at least one of five commensal-derived 
proteins[108]. These data indicated that CD patient responsiveness to commensal 
bacteria was heterogeneous; and therefore, patients may not share the same 
response to F. prausnitzii. It has been shown that colonic Tregs utilise a different 
TCR repertoire than Tregs and inflammatory T lymphocytes of other tissues[73]. 
Furthermore, it was found that CT2/CT6 TCR sequences, typically found in 
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murine colonic Tregs, were expressed in colonic inflammatory T lymphocyte 
subsets in mice susceptible to the development of spontaneous colitis. Thus, it is 
possible that, in some CD patients, IFNγ+ T lymphocytes produce an 
inflammatory response to the presence of certain commensal species. 
These data show that non-IBD CD4+IFNγ+ T lymphocyte frequencies were 
reduced in the presence of F. prausnitzii and B. fragilis, whereas this effect appears 
to be compromised in some CD patients. Thus, it is possible that patients with 
CD may be less able to maintain a tolerogenic intestinal environment as, in some 
patients, CD4+IFNγ+ T lymphocytes may increase in the presence of commensal 
bacteria. However, confirmation of the presence of commensal-specific 
lymphocytes was not pursued in this thesis. Interestingly, CD patient Treg 
frequencies increased in these conditions, suggesting that although CD patient 
Tregs may increase in frequency in response to commensals, their ability to 
suppress inflammatory T lymphocytes may be compromised. TCR clonotyping 
and comparison of CD patient Tregs to non-IBD control Tregs, and to both non-
IBD and CD patient IFNγ+ and IL-17A+ T lymphocyte subsets, may elucidate 
commensal specificity. Indeed, inflammatory T lymphocytes in mice susceptible 
to spontaneous colitis express commensal microbe-specific TCR sequences 
usually reserved for expression by colonic Tregs, implicating a loss of tolerance 
to commensal microbes[73]. Together, these data suggest that inherent 
differences in CD patient IFNγ+ T lymphocyte responses to commensal bacteria 








3.4.4.3 IL-17A+ T lymphocytes 
Non-IBD control CD4+IL-17A+ T lymphocytes decreased when co-cultured with 
both 1:1 and 1:10 ratios of F. prausnitzii, whereas CD patient CD4+IL-17A+ T 
lymphocytes only significantly decreased in frequency at 1:10 F. prausnitzii. 
However, overall, responses to F. prausnitzii were similar between non-IBD and 
CD patient PBMC IL-17A+ T lymphocytes. Non-IBD CD4+IL-17A+ T lymphocytes 
decreased in frequency when co-cultured with B. fragilis, whereas CD CD4+IL-
17A+ T lymphocytes had a lesser reduction in frequency. 
Together, these data suggest that non-IBD control CD4+IL-17A+ T lymphocytes 
reduce in frequency in the presence of commensal bacteria, whereas this effect 
may be compromised in CD CD4+IL-17A+ T lymphocytes. These abnormal 
responses to commensal bacteria may contribute to an inflamed intestinal 
environment, as IL-17A+ T lymphocytes are often associated with IBD pathology. 
 
3.4.4.4 Overall immune response to commensal bacteria  
Together, these data suggest inherent abnormalities in CD patient PBMC 
responses to commensal bacteria, F. prausnitzii and B. fragilis. These data appear 
to contradict current thoughts on the pathogenesis of CD. Firstly, it is possible 
that ‘cold-spots’ (areas of immune suppression) may manifest in highly local 
regions of intestinal tissue, as CD patient Tregs may be hyperresponsive to 
certain commensal bacteria. Likewise, in other regions of tissue where Tregs may 
be less abundant, it is possible that CD patient IFNγ+ and IL-17A+ T lymphocytes 
do not reduce in frequency in the presence of commensal bacteria, which may 
lead to inflammation, compromising the intestinal barrier. It is also possible that 
although CD patient Tregs increased in response to commensal bacteria, they 
cannot compensate for the abnormal IFNγ+ and IL-17A+ T lymphocyte responses. 
It is interesting to note that non-IBD control T lymphocyte responses were mostly 
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consistent, in contrast to CD patient immune responses, which suggests that CD 
patient data may require stratification based on their responses. 
 
3.4.5 T lymphocyte responses to stimulation 
One hypothesis for the cause of inflammation in CD, is that immune cells in CD 
have a lower threshold of activation and a higher upper limit for inflammatory 
potential, compared to non-IBD immune cells. To test this theory, non-IBD and 
IBD patient PBMCs were stimulated with anti-CD3/28 beads, a T lymphocyte-
specific stimulation.   
 
3.4.5.1 T lymphocyte population responses to stimulation 
Stimulation with anti-CD3/28 beads increased the frequencies of both non-IBD 
and CD patient PBMC Tregs, IFNγ+ T lymphocytes, and IL-17A+ T lymphocytes, 
as expected. Interestingly, CD patient PBMC IFNγ+ T lymphocytes and IL-17A+ T 
lymphocytes increased by a greater magnitude under stimulation conditions, 
compared to non-IBD T lymphocytes, whereas Treg responses to stimulation 
were similar between groups.  
These data suggest that CD patient T lymphocytes may be more susceptible to 
differentiation than non-IBD cells, in response to stimuli.  Furthermore, this 
differentiation was apparent in inflammatory immune cell subsets; whereas CD 
patient PBMC Treg differentiation had a similar increase in frequency fold-
change to non-IBD control Tregs. This could suggest that CD patient PBMCs 
were more able to differentiate into an inflammatory profile than non-IBD control 
PBMCs, and that CD patient Tregs did not amplify to compensate. It is important 
to note that this experiment observed T lymphocyte population dynamics within 
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a set population and did not account for cells that would be recruited to the site 
of stimulus. 
One possible explanation for the differences in differentiation is a difference in T 
lymphocyte plasticity capacity. T lymphocyte plasticity is the intrinsic ability for 
T lymphocytes to transition between lymphocyte subsets, in response to different 
environmental stimuli. It has been well-described in the literature that each of the 
cells of interest in this study had the ability to transition into the other cell 
types[181, 182]. A 2013 study showed specific pathogen-free IL-10-/- mice, in a 
model of Helicobacter hepaticus-induced typhlocolitis, had elevated frequencies 
and numbers of CD4+IFNγ+IL-17A+ double-expressing cells, compared to 
uninfected mice[183]. Chromatin immunoprecipitation (ChIP) analysis of histone 
modifications inferred a predisposition for IL-17A+ T lymphocytes to upregulate 
an IFNγ+ T lymphocyte program, suggesting the enhanced capacity for a 
directional plasticity bias. Another 2013 study showed that CD patient PBMCs 
had higher frequencies of inflammatory-like Tregs (CD4+IL-17A+FOXP3+), 
compared to non-IBD control PBMCs[153]. Authors speculated that defective 
suppressive function in CD patient peripheral Tregs supported plasticity 
between IL-17A+ and Treg populations.  
It is possible that CD patient PBMC Tregs in this study differentiated into IFNγ+ 
and IL-17A+ T lymphocytes; it is also possible that defective CD patient Tregs 
were less able to regulate differentiation of naïve T lymphocytes into 
inflammatory subtypes than non-IBD control Tregs.  Unfortunately, tracking of 
these cells was beyond the scope of this study. These data only show total 
population composition after stimulation, which was compared between groups. 
However, it is still possible that CD patient PBMCs were more plastic than non-
IBD control PBMCs. Considering the inflammatory environment of the CD 
intestine, and subsequent exposure to luminal stimuli, increased potential for 
differentiation into inflammatory phenotypes could have a high potential for 
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further pathology, especially if Treg populations do not compensate for this 
abnormality.  
 
3.4.5.2 T lymphocyte proliferation 
Data indicated that CD patient PBMC Tregs were hyperresponsive to commensal 
bacteria, however, the increase in Treg frequency did not result in the reduction 
of IFNγ+ or IL-17A+ T lymphocyte populations. Thus, it was evident that CD 
patient Tregs may be inherently defective. To test this hypothesis, a Treg 
suppression assay was conducted to observe and compare the Treg suppression 
capacity of non-IBD and CD patient PBMC Tregs. 
The Treg suppression assay did not successfully result in suppression of Tconv 
populations. Within non-IBD and CD patient groups, the proliferation index and 
precursor frequencies remained consistent in all Treg:Tconv ratios, suggesting 
suppression did not occur at detectable levels. This could be due to sorting cells 
that were not ‘true’ Tregs. Tregs were gated and sorted as 
CD3+CD4+CD25HICD127- cells, which is a phenotype of Tregs; however, activated 
T lymphocytes can upregulate FOXP3, upregulate CD25, and downregulate 
CD127, which could have reduced the accuracy of the sort[184]. However, during 
optimisation of the protocol, sorted Tregs were stained intracellularly and were 
confirmed CD3+CD4+CD25HIFOXP3+, confirming their phenotype as Tregs, but 
this was not conducted routinely (Supplementary Figure 10). It is also possible 
that the 1:10 cells:anti-CD3/28 beads ratio was too strong of a stimulus. Assays 
were also conducted at 1:1, 1:2, and 1:5 ratios; however, only the 1:10 ratio 
produced discernible proliferation peaks. 
Interestingly, the Treg suppression assay identified differences in the 
proliferation index and precursor frequency of non-IBD and CD patient PBMC 
Tconvs. The proliferation index of each Treg:Tconv co-culture ratio was 
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calculated to determine the capacity for the average Tconv cell to undergo 
division in the presence of Tregs. The proliferation index is a calculation that 
accounts for the number of cells that are present in a proliferation peak and 
normalises back to initial population numbers (ie. If 10 cells of a total initial 
population of 100 divided twice, then the second peak would contain 40 cells). 
In contrast, the precursor frequency represents the average number of divisions 
a cell from the initial pool of cells that proliferated underwent. Simply, precursor 
frequency represents total cell division capacity, whereas proliferation index 
represents the average number of divisions responder cells underwent. This 
distinction is important as these readouts represent different ways Tregs can 
influence the ability for a Tconv to respond to a stimulus. For example, Tregs 
could reduce the number of divisions the average cell undergoes (reducing 
proliferation index) but a higher frequency of total cells may have still 
proliferated at least once (higher precursor frequency). 
CD patient PBMC Tconvs had a higher proliferation index and precursor 
frequency than non-IBD control Tconvs. This is interesting, as these data suggest 
that CD patient PBMC Tconvs were more likely to proliferate and the average 
cell proliferated more, on average, than non-IBD Tconvs. Thus, it is possible that 
CD patient T lymphocytes may more aggressively proliferate in response to 
intestinal stimuli; however, this effect was only tested using a T lymphocyte-
specific anti-CD3/28 bead stimulation.  
 
3.4.5.3 Cytokine production 
CD patient PBMCs secreted significantly higher concentrations of IL-17A, TNF, 
and IL-6 proteins than non-IBD control PBMCs, in response to anti-CD3/28 bead 
stimulation. Interestingly, IFNγ secretion by CD patient PBMCs was not 
significantly different to non-IBD but did stratify into high-IFNγ- and low-IFNγ-
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secreting groups. Indeed, upon stimulation with anti-CD3 antibodies, PBMCs 
from patients with CD, who had an rs1861494 polymorphism, secreted more 
IFNγ than PBMCs from CD patients lacking the polymorphism[185]. Genetic 
phenotyping was not conducted on patients in this study; however, mutations of 
this nature may explain the presence of high-IFNγ- and low-IFNγ-secreting 
groups. IL-17A is highly expressed by IL-17A+ T lymphocyte subsets upon 
stimulation, whereas TNF and IFNγ are highly secreted by IFNγ+ T lymphocytes; 
however, both cell types have the capacity to produce any of these cytokines[186, 
187]. IL-6 is mainly produced by monocytes, which were not studied here[188]. 
These data agree with stimulation data in this thesis which showed a larger fold-
increase in CD patient IFNγ+ T lymphocyte and IL-17A+ T lymphocyte 
frequencies, compared to non-IBD control PBMCs. IL-12p70 and IL-4 were 
similar between non-IBD and CD responses, in agreement with literature that 
suggests this cell type is more associated with UC, than CD[189]. The suppressive 
cytokine, IL-10, was not different between non-IBD and CD, suggesting that 
Tregs in IBD patients may not compensate for the increased inflammatory 
capacity of IBD patient PBMCs. 
 
3.4.5.4 Future experiments 
If intestinal T lymphocytes display the same characteristics as PBMCs in this 
model, it would suggest that, upon stimulation, intestinal T lymphocytes could 
be hyperproliferative in response to intestinal stimuli. Hyperproliferation could 
result in excessive inflammation in the intestine upon exposure to luminal 
microbes and damaged epithelial tissues. In patients with CTLA-4 deficiency, not 
only did Tregs have reduced suppressive capacity, but also resulted in a 
hyperproliferative phenotype in T and B lymphocytes, compared to healthy 
controls[190, 191]. Although patients with CTLA-4 deficiency had lymphopenia, 
hyperproliferative T and B lymphocytes caused pathology in non-lymphoid 
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organs and autoimmune cytopenias. Thus, Treg regulation of T lymphocyte 
proliferation is important for the maintenance of homeostasis, and this balance 
may be dysfunctional in CD.  
Future research should seek to use intestinal cells from patients with CD. It 
would be of interest to investigate which immune cells, at intestinal mucosal sites 
of CD inflammation, were recruited and which were due to excessive 
proliferation. Further, experiments should identify whether these cells display 
different capacities or affinities for inflammation. Future experiments should 
observe the proliferative capacity of non-IBD and CD patient intestinal Tconvs, 
as well as their proliferative capacity in co-culture with commensal bacteria. 
These experiments should also include subset-defining markers to observe if 
there is a bias in T lymphocyte population expansion, in response to stimulation. 
To further investigate heightened plasticity as a potential factor in CD 
pathogenesis, in combination with cytokine expression, transcription factors 
would need to be added to the flow cytometry panel, in which their co-expression 
would suggest a transition between two T lymphocyte phenotypes. T-bet, 
RORγT, and FOXP3, are canonical transcription factors for IFNγ+ T lymphocytes, 
IL-17A+ T lymphocytes, and Treg populations, respectively. However, it would 
be difficult to discern which direction cells are transitioning, as lymphocyte 
plasticity is a normal function to maintain homeostasis. The combination of 
cytokine expression and transcription factors has been used to monitor plasticity. 
Mathematical models have been built to investigate the process of plasticity 
between IFNγ+ T lymphocytes and Type-2 T lymphocytes[192]. This model 
considered fluorescent signal intensities of polarising signals from differentiating 





3.4.6 Heterogeneous T lymphocyte profiles 
viSNE and SPADE analyses highlighted the natural heterogeneity of cytokine 
expression in human PBMCs. A major difficultly in the treatment of CD is the 
accurate identification of the mechanism of disease in individual patients. 
Interestingly, cluster analyses did not suggest differences between non-IBD and 
CD patient data, in contrast to traditional analysis using defined gating. These 
data suggest that although CD patient PBMCs contained higher frequencies of 
IL-17A+ T lymphocytes than non-IBD controls, these IL-17A+ T lymphocytes had 
diverse expression profiles. Diversity within expression profiles of these cells 
suggests they may influence pathology differently, thus, treating T lymphocytes 
as uniform populations of interest may be short-sighted.  
 
3.4.7 Limitations of the co-culture model 
The commensal co-culture model was useful for the comparison of non-IBD and 
CD patient immune responses to commensal bacteria and generated some 
interesting hypotheses. However, this model lacked the complexity to further 
validate these ideas. 
The use of PBMCs, while standard practice in CD research, is not ideal as 
intestinal T lymphocytes are phenotypically different to PBMCs. The intestinal 
milieu is a tolerogenic environment, and cells which exist there are more 
tolerogenic than in the peripheral blood. Research has indicated that CD patient 
PBMCs and serum display similarities to the intestinal mucosa. It has been shown 
that both the intestinal mucosa and peripheral blood share high frequencies of 
IL-17A+ T lymphocytes and high concentrations of serum TNF and IL-17A, 
compared to non-IBD controls [86, 97]. However, it remains that we can only infer 
that data in this thesis were representative of intestinal T lymphocyte responses. 
Intestinal biopsy immune cells were used in initial experiments, but they are low 
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in abundance and difficult to culture. Therefore, it was decided that PBMCs 
would be a proxy for intestinal cell responses. 
It is also true that these immune responses may artefacts of in vitro 
experimentation. This model could not account for the subtleties that may control 
immune responses in the intestinal milieu. As the intestinal mucosa is a 
tolerogenic environment, the increases in IFNγ+ and IL-17A+ T lymphocyte 
responses to commensal bacteria may indeed be controlled and compensated for 
in the LP. The intestine contains a higher abundance of Tregs than the peripheral 
blood. In addition,  intestinal monocytes produce retinoic acid, a driver of Treg 
differentiation[193]. Thus, observations in this model may be artefacts of in vitro 
experimentation; however, commensal co-culture experiments conducted in 
Chapter 5 using monolayers derived from intestinal organoids suggest that these 
data are likely to be true. 
 
3.4.8 The use of peripheral blood mononuclear cells 
Gene expression analyses and immune cell profiling of colon tissues have 
contributed much to the current understanding of CD. In contrast to colonic 
tissues, peripheral blood is a more accessible source of patient cells; however, 
studies based on PBMC responses may not fully represent intestinal immune cell 
responses.  
Intestinal immune cells are initially recruited from the circulating pool of 
peripheral blood immune cells[194]. Expression of homing molecules, such as the 
α4β7-integrin, bind to MadCAM-1 protein. Circulating lymphocytes and DCs 
express α4β7-integrin after signals are received from the intestine[194]. α4β7-
integrin binds to MadCAM-1 expressed on intestinal high endothelial venules, 




Once in intestinal tissues, circulating immune cells are exposed to intestinal 
environmental cues, produced by various external cues from the intestinal lumen 
and immune cell cross-talk[196]. Intestinal DCs facilitate the conversion of food-
derived retinol into retinoic acid[197]; thus, retinoic acid is highly concentrated 
in the intestinal mucosal barrier. Retinoic acid upregulates intestine-homing 
receptors α4β7 and CCR9, and reduce expression of skin-homing E-selectin 
ligands[197].  
Once in the intestinal mucosa, T lymphocytes are exposed to environmental cues 
which induce a tolerogenic phenotype[196]. Tissue-resident T lymphocytes are 
memory-like effector cells[198]. These memory-like cells have low rates of 
proliferation and require high levels of stimulation for complete in vitro 
activation, compared to circulating T lymphocytes. Intestinal memory-like T 
lymphocytes produce effector cytokines, such as IFNγ, IL-2, IL-4, and IL-17A, in 
response to activation[198, 199]. Together, these studies suggest intestinal 
resident T lymphocytes maintain a memory-like phenotype, with the capability 
for rapid effector responses; however, these cells have reduced proliferative 
capacity. Thus, while tissue-resident cells are critical for homeostasis at the 
intestinal border, immune cells are pulled from the periphery for large-scale 
immune responses. 
GWAS studies have used human PBMCs to identify genetic polymorphisms in 
IBD patients[106, 200]. Studies have shown that IBD patient PBMCs have 
different functional responses to activation, compared to non-IBD controls. For 
example, PBMCs from non-active disease CD patients produce more IFNγ and 
IL-17 against candida, than non-IBD control PBMCs, in vitro[201]. Further, CD 
patient PBMC CD4+ T lymphocytes have more frequent specificity to commensal 
microbe antigens than non-IBD control CD4+ T lymphocytes[108]. Thus, PBMCs 
are a viable sample material due to their ease of access and relevance to 
mechanisms of CD pathology. 
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In this thesis, CD patient PBMC responses to commensal bacteria were unique to 
non-IBD responses. CD patient PBMC Tregs displayed hyperresponsiveness to 
F. prausnitzii (Figure 3.14a), and CD patient PBMC IFNγ+ T lymphocytes did not 
reduce in frequency in response to F. prausnitzii (Figure 3.15a), in contrast to non-
IBD responses. It could be argued that these responses may have been reduced 
in the CD intestine due to intestinal tolerogenic programming. However, CD is a 
disease in which this tolerogenic programming has failed; thus, PBMCs still offer 
valuable information into the mechanisms of disease. 
 
3.4.9 Conclusions 
In this study, CD patient PBMCs displayed a higher capacity for secretion and 
expression of cytokines associated with IBD pathology. Furthermore, CD patient 
PBMCs had abnormal responses to commensal bacteria. CD patient PBMC Tregs 
expanded in co-culture with F. prausnitzii, whereas non-IBD PBMC Tregs were 
not influenced by co-culture. IFNγ+ and IL-17A+ T lymphocyte populations did 
not reduce in frequency in co-culture with F. prausnitzii, in contrast to the 
frequency reduction in non-IBD T lymphocytes. Although the Treg suppression 
assay was not able to discern differences in suppression capacity, it was evident 
that CD patient PBMC Tconvs had a higher capacity for proliferation and the 
average cell proliferated more than non-IBD PBMC Tconvs. 
Together, these data support a new possible theory of initial CD pathology 
manifestation. It is possible that CD patients have intestinal ‘cold spots’, areas of 
excessive suppression due to Treg abundance, caused by hyperresponsiveness to 
commensal bacteria. It is known that intestinal microbe abundances vary along 
the gastrointestinal tract [202]. Further, it has been shown that the immune 
repertoire also varies along the gastrointestinal tract [203]. It has been speculated 
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that this immune locality is largely organised pre-birth, but also that bacterial 
species of the microbiota influence these regional immune profiles.  
Data in this thesis showed that CD, but not non-IBD, PBMC Tregs increased in 
frequency in the presence of F. prausnitzii. It is possible that regional success of 
certain bacterial species may induce pro- or anti-inflammatory effects to regions 
of the gastrointestinal tract. If true, it is possible that certain commensal species 
could induce excessive tolerance via Treg suppression, allowing other bacterial 
species to evade immune detection. Thus, it is possible that regional 
inflammation, due to intestinal immune cold spots, could provide a reason for 
the patchy manifestation of CD ‘cobblestone’ lesions.  
It is also possible that frequent exposure of intestinal immune cells to commensal 
species may result in the development of commensal-specific immunity, which 
could explain the reduction of commensal species seen in CD patients after the 
establishment of chronic inflammation[204]. However, as these are PBMC data, 
the same response cannot be inferred for intestinal immune cells. 
These ‘cold spots’ could allow for bacterial success and translocation into the 
lamina propria due to the suppression of immune responses. Bacterial success 
could eventually lead to large-scale immune responses due to bacterial load, 
leading to epithelial damage. Upon damage of the intestinal epithelium, 
hyperproliferative T lymphocytes could proliferate uncontrollably, causing 
further inflammation and epithelial damage. As these cold spots could 
theoretically manifest anywhere along the intestinal tract, it is possible that 
frequent epithelial breakdown could lead to chronic exposure to commensal 






Stratification and analysis of individual patient data 
4.1 Introduction 
Due to the heterogeneous nature of CD, it is important to analyse patient data at an 
individual level.  Transformation of multi-parameter data can obscure individual 
patient responses. A common question regarding CD research is whether patients are 
or are not on active treatment, and what impact this had on the results. When 
presenting immune cell profiling data, it can be difficult to display data in a 
translational way, as well as portray individual patient responses to experimental 
conditions. 
In this chapter, patient PBMC data from Chapter Three was reanalysed using different 
strata to observe individual patient immune profile patterns. Data were stratified on 
age, active treatment status, and cytokine secretion profiles of activated PBMCs. 
EarlyBird, a data visualisation tool created by Cytoanalytics, was used to observe 
individual patient PBMC responses over different analytes. 
Stratification of patient data is an important tool to help elucidate mechanisms of 
favourable immune responses. Ideally, stratification would be performed on a large 
cohort. Large numbers per group increase accuracy and confidence in results. In this 
thesis, due to low patient numbers in stratified groups, conclusions were largely 
speculative in an attempt to make sense of patient data.  
Strata were selected based on relevant recorded cohort information. Progressed age is 
commonly associated with immunosenescence, reduced generation of B cells, thymic 
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involution, and defective memory responses; further, latent viral infections skew 
elderly human immune profiles to a terminally differentiated CD8+ T cell bias[206]. 
Active treatment status was chosen as the activity of immunosuppressants might have 
impaired or altered T lymphocyte profiles and PBMC cytokine secretion responses to 
stimulation[207]. Cytokine secretion from stimulated PBMCs provided information 
about immune cell responses to stimulation within individual patients. These data 
were also used to speculate on immune cell associations and potential immune cell 
interactions and pathways biases.  
 
4.2 Aims  
This chapter was designed to further analyse patient data from Chapter Three. 
Analyses in this chapter were designed to pull apart individual patient PBMC data to 
elucidate pathways of immune response to stimulation. CD patient immune profiles 
and cytokine secretion responses to stimulation were heterogeneous. As such, patient 
data in this chapter were stratified on strata known to have a profound influence on 
general immune responses and profiles.  
The specific aims of this chapter were to determine whether: 
• Visualisation of individual patient data would elucidate differences in CD 
patient immune profiles and response, potentially suggesting different 
mechanisms of disease in individuals 
 
• Stratification of patient data by age or active treatment status were viable strata 
to explain heterogeneous immune profiles and PBMC responses to stimulation 
 
• Associations between secreted concentrations of effector cytokines by 
stimulated PBMCs could suggest mechanisms of disease in individual patients 
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4.3 Results  
4.3.1 Stratification of patient data 
CD patient T lymphocyte and cytokine secretion profiles had high degrees of 
variability in Chapter Three. In general, human PBMCs display high degrees of 
heterogeneity, and this heterogeneity is due to a combination of heritable and 
environmental factors[208]. To better understand the heterogeneity displayed in 
Chapter Three, patient data were stratified by age (Figures 4.2, 4.5, & 4.9), active 
treatment status (Figures 4.1, 4.4, & 4.10-4.12), and expression levels of effector 
cytokines (Figures 4.6-4.8). Patient PBMC data were visualised using EarlyBird, a data 
visualisation tool developed by Cytoanalytics (Figure 4.3). EarlyBird displays 
individual patient data as a curved line across multiple analytes or immune cell 
profiling data. This made it possible to easily observe the immune responses of 
individual patients across multiple parameters. EarlyBird graphs can be manipulated, 
and data are displayed based on the selection of groups within parameters. For 
instance, Figure 4.6 highlighted data based on the disease status of the patients - non-
IBD (Figure 4.6a) and CD (Figure 4.6b-c) – as well as the secretion of high or low 
concentrations of secreted IFNγ from PBMCs within those groups (Figure 4.6b-c). 
Data which did not fall within selected parameters were transparent, which improved 
visualisation of relevant data. 
Stratification by active treatment at the time of appointment did not account for T 
lymphocyte profile heterogeneity. Non-IBD, CD patients on medication, and CD 
patients not on medication had a wide range of Treg, IFNγ+, and IL-17A+ T lymphocyte 
subsets (Figure 4.1). Stratification by age showed CD patients over 50 years old had 
lower CD4+ Treg and CD4+IFNγ+ T lymphocyte frequencies than other CD patients 
(Figure 4.2); however, once stratified, groups were too small for conclusive data to be 
obtained.  These data highlight the heterogeneity within all human PBMC data 













Figure 4.1: Stratification of CD patient data on medication status did not separate groups. Peripheral blood mononuclear cells were isolated 
from non-inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples were processed as described in the 
Materials and Methods, then analysed by flow cytometry. a-b) Frequencies of CD4+ (a - top row) and CD8+ (b - bottom row) regulatory T 
lymphocytes (CD25HIFOXP3+), IFNγ+ T lymphocytes, and IL-17A+ T lymphocytes, as a percentage of total CD3+ cells.  Data shown are individual 
patients and labelled as non-IBD controls(blue) or CD patients with (red) or without (green) active treatment at the time of appointment. The bar 
represents the median frequency. Non-IBD (n=17-21), no mediation CD (n=3-4), CD on medication (5-8). Some patient data missing due to a lack 














Figure 4.2: Low CD4+IFNγ+ T lymphocyte frequencies are associated with increased age. Peripheral blood mononuclear cells were isolated 
from non-inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples were processed as described in the 
Materials and Methods, then analysed by flow cytometry. a-b) Frequencies of CD4+ (a - top row) and CD8+ (b - bottom row) regulatory T 
lymphocytes (CD25HIFOXP3+), IFNγ+ T lymphocytes, and IL-17A+ T lymphocytes, as a percentage of total CD3+ cells.  Data shown are individual 
patients and labelled as non-IBD controls (blue) or CD patients <40 years old (green), CD patients 41-49 years old (red), or CD patients >50 years 
old (black). The bar represents the median frequency. Non-IBD (n=17-21 [all <40 years old]), CD <40 years old (n=3-6), CD 41-50 years old (n=3-
4), and CD >50 years old (n=2). Some patient data missing due to a lack of confidence in staining quality. Statistical analyses were calculated 





Figure 4.3: T lymphocyte profiles of non-IBD and CD patient PBMCs. a-b) Peripheral blood mononuclear cells were isolated from non-
inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples were processed as described in the Materials and 
Methods, then 80,000 PBMCs were cultured with anti-CD3/CD28 beads at a 1:1 ratio for 48 hours. Immune cells were then analysed by flow 
cytometry and visualised using the EarlyBird graphing tool (earlybird.cytoanalytics.com). Blue (non-IBD) and orange (CD) lines represent 
individual patient T lymphocyte data across different parameters. Numbers represent the frequency of indicated lymphocytes as a percentage 
of total CD3+ cells. The red boxes indicate selected, relevant information for display. The doughnut (top right) indicates the number of patients 
within the selected criteria, out of the total number of patients. Non-IBD (n=11), CD (n=8).  
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Stratification of effector cytokines by active treatment at the time of appointment did not 
account for PBMC cytokine secretion heterogeneity (Figure 4.4). Cytokine analysis 
was performed  
In contrast, stratification of PBMC cytokine secretion by age showed differences 
between CD patients under 50 years old and those over 50-years old. CD patients 
under 50 years old had higher concentrations of secreted IFNγ, compared to CD 
patients over 50 years old. Non-IBD patient PBMCs also secreted high concentrations 
of IFNγ. Moreover, all non-IBD control participants were under 30 years old, 
suggesting high IFNγ secretion by PBMCs was associated with age (Figure 4.5). IL-1β, 
IL-2, IL-4, IL-6, IL-17A, IL-12p70, and IL-23 were also elevated in CD patients under 








Figure 4.4: Stratification of CD patient data on treatment status did not separate groups. Peripheral blood mononuclear cells were isolated 
from non-inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples were processed as described in the 
Materials and Methods, then 80,000 PBMCs were cultured with anti-CD3/CD28 beads at a 1:1 ratio for 48 hours. Cytokine supernatants were 
then analysed by flow cytometry. Data shown are individual patients and labelled as non-IBD controls (blue) or CD patients with (red) or without 
(green) active treatment at the time of appointment. The bar represents the median concentration (pg/mL). Non-IBD (n=6), CD (n=10). Non-IBD 
(n=6), no medication CD (n=6), CD on medication (n=4). Statistical analyses were calculated using the Mann-Whitney U test.
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Figure 4.5: Low secretion of effector cytokines is associated with increased age. Peripheral blood mononuclear cells were isolated from non-
inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples were processed as described in the Materials and 
Methods, then 80,000 PBMCs were cultured with anti-CD3/CD28 beads at a 1:1 ratio for 48 hours. Cytokine supernatants were then analysed by 
flow cytometry. Data shown are individual patients and labelled as non-IBD controls (blue) or patients <50 years old (green), or CD patients >50 
years old (red). The bar represents the median concentration (pg/mL). Non-IBD (n=6), CD <50 years old (n=7), CD >50 years old (n=3). Statistical 
analyses were calculated using the Mann-Whitney U test. 
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4.3.2 Patient stratification by cytokine expression 
Cytokines secreted by immune cells are potentiators of T lymphocyte differentiation 
and cytokine expression. As such, cytokine expression profiles were analysed to 
identify possible differences in CD patient PBMC responses to T lymphocyte 
stimulation with anti-CD3/28 beads. Patient data were stratified by high and low 
secretion of IFNγ, TNF, IL-6, and IL-1β. 
2/10 CD patient PBMCs secreted low concentrations of TNF, whereas 2/10 secreted 
high concentrations of TNF, and 6/10 secreted TNF above the limit of detection (Figure 
4.4). In contrast, 9/10 non-IBD controls secreted low concentrations of TNF, compared 
to CD. High secretion of TNF was associated with high secretion of IL-2 in CD patient 
PBMCs, however, 1/8 PBMCs, which were high-secretors of TNF, secreted the lowest 
IL-2 of all CD patient PBMCs (Figure 4.7c). All non-IBD control PBMCs secreted high 
concentrations of IFNγ and IL-2, and 5/6 secreted low-intermediate concentrations of 
TNF (Figure 4.7a). Non-IBD control PBMCs secreted low concentrations of IL-1β, 
however, PBMCs from one non-IBD control secreted high concentrations of TNF and 
IL-1β. Furthermore, IL-1β secretion appeared to be associated with secretion of IFNγ 
in CD patient PBMCs, as 4/5 high-IL-1β secreting CD patient PBMCs had IFNγ 
concentrations >2500 pg/mL, in contrast, there was no association in non-IBD control 
PBMCs (Figure 4.8). High secretion of IL-6 was associated with high secretion of IL-
1β in both non-IBD and CD (Figure 4.8). Stratification of cytokine expression did not 
resolve the high- and low-secreting IFNγ groups identified in Figure 3.13. 
Together, these data show that CD patient PBMCs, which secreted high 
concentrations of IFNγ and TNF, also secreted high concentrations of IL-2. 
Furthermore, high concentrations of IL-6 secretion were associated with high 
concentrations of IL-1β. Non-IBD control PBMCs secreted high concentrations of IFNγ 
and IL-2 but not TNF, as previously shown in Figure 3.13. 1/6 non-IBD control PBMCs 
secreted IL-1β and IL-6, suggesting that the associations found between these 
cytokines were not limited to CD patient PBMCs
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Figure 4.6: High IFNγ-secreting CD patient PBMCs associated with high secretion of TNF, IL-2, and IL-1β. Peripheral blood mononuclear 
cells were isolated from non-inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples were processed as 
described in the Materials and Methods, then 80,000 PBMCs were cultured with anti-CD3/CD28 beads at a 1:1 ratio for 48 hours. Cytokine 
supernatants were then analysed by flow cytometry and visualised using the EarlyBird graphing tool (earlybird.cytoanalytics.com). Blue (non-
IBD) and orange (CD) lines represent individual patient data and cytokine secretion. Data are stratified as non-IBD (a) or CD (b-c) and high (b) 
or low (c) secretion of IFNγ.  The red boxes indicate selected, relevant information for display. The doughnut (top right) indicates the number of 
patients within the selected criteria, out of the total number of patients. Numbers represent the concentration of the indicated cytokine (pg/mL). 






Figure 4.7: Non-IBD PBMC secreted cytokines have a distinct effector T lymphocyte profile. Peripheral blood mononuclear cells were isolated 
from non-inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples were processed as described in the 
Materials and Methods, then 80,000 PBMCs were cultured with anti-CD3/CD28 beads at a 1:1 ratio for 48 hours. Cytokine supernatants were 
then analysed by flow cytometry and visualised using the EarlyBird graphing tool (earlybird.cytoanalytics.com). Blue (non-IBD) and orange 
(CD) lines represent individual patient data and cytokine secretion. Data are stratified as non-IBD (a) or CD (b-c) and high (b) or low (c) secretion 
of TNF. The red boxes indicate selected, relevant information for display. The doughnut (top right) indicates the number of patients within the 







4.3.3 Patient stratification by age 
Human immune responses can wane with progressed age[209]. As such, 
discrepancies in T lymphocyte profiles could have been due to differences in the age 
of patients within the cohort. CD patient T lymphocyte profiles were stratified into 
patients under 40, patients between 41-50, and patients over 50 years old, whereas all 
non-IBD control were under 50 years old. CD patients over 50-years old had the lowest 
frequencies of CD4+ Tregs and CD4+IFNγ+ T lymphocytes of CD patient PBMCs 
(Figure 4.2). However, it was difficult to discern patterns in T lymphocyte frequencies 
with the low number of patients within these groups. Therefore, age was inadequate 
for stratification of T lymphocyte profiles in this cohort. 
High- and low-IFNγ and -IL-1β-secreting CD PBMCs were observed in Figures 4.6b-
c and 4.8. Interestingly, high-IFNγ secretion was associated with CD patients under 
40 years old (Figure 4.9c), whereas patients older than 40 years old had low-
intermediate IFNγ secretion (Figure 4.9b). CD patients under 40 years old also 
consistently secreted high concentrations of TNF and IL-2, suggesting an IFNγ+ T 
lymphocyte cytokine profile (Figure 4.9b). 2/6 CD patients over 40 years old secreted 
low concentrations of TNF, and IL-2 secretion was scattered in this age group (Figure 
4.9c). In contrast, all non-IBD control PBMCs secreted high concentrations of IFNγ 
(Figure 4.9a), however, high IFNγ secretion was not associated with high IL-1β 
secretion in non-IBD control PBMCs (Figure 4.6a).  
From these data, it can be inferred that patients under 40 years old had an IFNγ+ T 
lymphocyte-biased cytokine response to stimulation. This result was true in both non-
IBD and CD patient PBMCs, however, CD IFNγ+ T lymphocyte cytokine profile may 
have been associated with elevated secretion of IL-1β. CD patients over 40 years old 
had lower secretion of IFNγ than other groups and mixed ranges of IL-2 secretion, 









Figure 4.8: High secretion of IL-1β is associated with IL-6 secretion. Peripheral blood mononuclear cells were isolated from non-inflammatory 
bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples were processed as described in the Materials and Methods, then 
80,000 PBMCs were cultured with anti-CD3/CD28 beads at a 1:1 ratio for 48 hours. Cytokine supernatants were then analysed by flow cytometry 
and visualised using the EarlyBird graphing tool (earlybird.cytoanalytics.com). Blue (non-IBD) and orange (CD) lines represent individual 
patient data and cytokine secretion. Data are stratified by PBMCs which secreted high concentrations of IL-1β. The red boxes indicate selected, 
relevant information for display. The doughnut (top right) indicates the number of patients within the selected criteria, out of the total number 




Figure 4.9: Low secretion of IFNγ and IL-2 is associated with increased age. Peripheral blood mononuclear cells were isolated from non-
inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples were processed as described in the Materials and 
Methods, then 80,000 PBMCs were cultured with anti-CD3/CD28 beads at a 1:1 ratio for 48 hours. Cytokine supernatants were then analysed by 
flow cytometry and visualised using the EarlyBird graphing tool (earlybird.cytoanalytics.com). Blue (non-IBD) and orange (CD) lines represent 
individual patient data and cytokine secretion. Data are stratified as non-IBD (a) or CD (b-c) and <40 (b) or >40 years old (c). The red boxes 
indicate selected, relevant information for display. The doughnut (top right) indicates the number of patients within the selected criteria, out of 






4.3.4 Patient stratification by active treatment status 
CD patient treatments in this cohort were diverse. As a result, conclusive results could 
not be obtained due to low patient numbers per group. However, individual immune 
responses of patients were still observed and analysed. Patients were considered as 
on ‘active treatment’ if they were on a treatment regimen at the time of appointment. 
Interestingly, PBMCs from patients on active treatment had similar T lymphocyte 
profiles (Figure 4.1) and cytokine secretion profiles (Figure 4.10b) to PBMCs from 
patients not on any treatment (Figure 4.10a).  
Individual patients in the active treatment group were being treated by a diverse 
range of therapeutic drugs, each with differing mechanisms of action. 2/6 CD patients 
on active treatment were on a regimen of Humira, an anti-TNF biologic mAb (Figure 
4.11a). Anti-TNF biologics are second-line treatments for CD and function by 
inhibiting TNF-signalling, thereby reducing inflammation via the TNF pathway. 
Interestingly, activated PBMC T lymphocytes from patients on Humira secreted TNF 
above the limit of detection, indicating that anti-TNF treatment may only affect TNF-
signalling, but not directly influence immune cell capacity for TNF secretion.  
Azathioprine dampens immune proliferation via inhibition of purine synthesis, and 
subsequently reducing immune cell proliferation[210]. 1/6 CD patients on active 
treatment were prescribed azathioprine alone, and 1/6 was prescribed Azathioprine + 
Humira (Figure 4.11b). PBMCs from patients treated with Azathioprine had high 
secretion of TNF but low secretion of IFNγ and low-intermediate secretion of IL-2. It 
is possible azathioprine’s inhibition of immune cell proliferation prevented IFNγ+ T 
lymphocyte proliferation and subsequently reduced secretion of IL-2 and IFNγ. 
However, as both of these patients were over 60-years old, impaired secretion of IFNγ 
and IL-2 may have been due to differences in age-related immune response. 
Mesalazine, also known as 5-ASA, is orally ingested and induces localised anti-
inflammatory effects in the gastrointestinal tract. 5-ASA inhibits prostaglandins in the 
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intestine and has been shown to inhibit TNF-stimulated NF-κB activation[211]. NF-κB 
activation induces expression of proinflammatory molecules and adhesion 
molecules[212]. Thus, 5-ASA is believed to inhibit immune cell proliferation and 
inflammatory capacity locally, in the intestine[213]. 2/6 CD patients on active 
treatment were treated with 5-ASA (Figure 4.12a). PBMCs from one patient secreted 
high concentrations of IFNγ, TNF, and IL-2, whereas the second patient secreted low 
IFNγ and TNF, but high IL-2. As 5-ASA is believed to act locally in the intestine, it is 
possible that PBMC cytokine secretion was not affected by active treatment with 5-
ASA. 
Prednisone is a glucocorticoid, which induces reduced expression of inflammatory 
cytokines and increased expression of anti-inflammatory cytokines through binding 
with the glucocorticoid receptor on immune cells[214]. 1/6 patients on active treatment 
were on a regimen of Prednisone (Figure 4.12b). This patient had high PBMC secretion 
of TNF, IL-2, and IL-1β, but had intermediate secretion of IFNγ. These data were 
similar to other CD patient cytokine secretion data; however, Prednisone may have 
impaired IFNγ secretion by PBMCs from this patient. 
Overall, conclusive data could not be obtained due to low patient numbers per group. 
However, individual treatment regimen may explain some heterogeneity identified 




Figure 4.10: Treatment status is not associated with cytokine profile. Peripheral blood mononuclear cells were isolated from non-inflammatory 
bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples were processed as described in the Materials and Methods, then 
80,000 PBMCs were cultured with anti-CD3/CD28 beads at a 1:1 ratio for 48 hours. Cytokine supernatants were then analysed by flow cytometry 
and visualised using the EarlyBird graphing tool (earlybird.cytoanalytics.com). Orange lines represent individual CD patient data and cytokine 
secretion. Data are stratified as inactive (a) or active (b) treatment at the time of appointment. The red boxes indicate selected, relevant information 
for display. The doughnut (top right) indicates the number of patients within the selected criteria, out of the total number of patients. Numbers 






Figure 4.11: Cytokine secretion profiles of patients stratified by treatment with Humira or Azathioprine. Peripheral blood mononuclear cells 
were isolated from non-inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples were processed as described 
in the Materials and Methods, then 80,000 PBMCs were cultured with anti-CD3/CD28 beads at a 1:1 ratio for 48 hours. Cytokine supernatants 
were then analysed by flow cytometry and visualised using the EarlyBird graphing tool (earlybird.cytoanalytics.com). Orange lines represent 
individual CD patient data and cytokine secretion. Data are stratified based on treatment with Humira (a) or Humira and/or Azathioprine (b) at 
the time of appointment. The red boxes indicate selected, relevant information for display. The doughnut (top right) indicates the number of 







Figure 4.12: Cytokine secretion profiles of patients stratified by treatment with Mesalamine or Prednisone. Peripheral blood mononuclear 
cells were isolated from non-inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples were processed as 
described in the Materials and Methods, then 80,000 PBMCs were cultured with anti-CD3/CD28 beads at a 1:1 ratio for 48 hours. Cytokine 
supernatants were then analysed by flow cytometry and visualised using the EarlyBird graphing tool (earlybird.cytoanalytics.com). Orange lines 
represent individual CD patient data and cytokine secretion. Data are stratified based on treatment with Mesalamine (a) or Prednisone (b) at the 
time of appointment. The red boxes indicate selected, relevant information for display. The doughnut (top right) indicates the number of patients 






4.4 Discussion  
Human patient data are heterogeneous. Genetic, non-genetic, and environmental 
factors contribute to variations in peripheral blood immune cell composition and 
presence of soluble mediators involved in immune response[215]. As such, it is 
important to observe patient immune profiles over multiple parameters to 
identify potential patterns of response. In this thesis, patient data was stratified 
by age, active treatment status, and expression of effector cytokines. Due to low 
numbers of patients within each group, associations between patient PBMC 
attributes were speculative based on observed trends. 
Flow cytometry can generate vast amounts of data from individual experiments. 
With increasing panel size and the advent of mass cytometry, big data is rapidly 
becoming a mainstream method of experimental design. Cluster analyses are 
useful for the analysis of big data; however, the resolution of individual patient 
responses can be lost. Flow cytometry experiments using smaller, well-defined 
antibody panels are still considered a gold-standard of immune profile 
observation and individual patient data are easier to analyse and manipulate. 
However, as flow cytometry is a multi-dimensional analysis, patient immune 
profile trends can often be overlooked upon the transformation of data into 2D 
visualisation tools. EarlyBird is a data visualisation tool designed by 
Cytoanalytics (http://earlybird.cytoanalytics.com/). EarlyBird allows for the 
stratification of data by cohort attributes. In this way, individual patient response 
parameters were observed in a single graph and visualisation of data were 
manipulated by the selection of data of interest. This allowed for a deeper, more 
easily accessible analysis of individual patient responses to various conditions. 
Furthermore, tracking of individual patient responses allowed for the 
identification of patient response patterns based on specific stratum criteria, and 




4.4.1 Stratification by age 
Many factors that can influence immune profiles across different groups of 
patients. For instance, an analysis of healthy individuals showed increased age 
had an inverse relationship with proportions of CD4+ and CD8+ recent-thymic 
emigrant T lymphocytes and transitional B cells but had a positive relationship 
with IFNγ+ T lymphocytes, CD4+ and CD8+IL-2+ T lymphocytes, and invariant 
natural killer cells[216]. One study showed that different immune cell subsets 
have altered gene expression with age, notably, researchers identified a reduction 
in gene expression of ribosomal protein synthesis machinery with increased age, 
suggesting an impaired capacity for immune response. T lymphocytes are known 
to exhibit functional impairment with age progression[209]. Progressed age has 
been associated with a reduction in CD4/CD8 ratio and expansion of CD8+ T 
lymphocytes[217]. Furthermore, the prevalence of Cytomegalovirus (CMV) 
seropositivity is increased with age, which is speculated to contribute to general 
immune profile shifts in aged patient immune systems[206]. CMV seropositivity 
has been linked to reduced abundances of naïve T lymphocytes and increased 
memory T lymphocytes, compared to CMV-negative PBMCs[218]. These data 
suggest that older patients, who may have been CMV positive, might have 
responded to stimuli via different immune pathways, compared to younger 
patients. Thus, age-based immune profile differences could account for some 
heterogeneity in CD patient immune profiles in this thesis. However, CMV 
seropositivity data was not collected in this cohort, so this could not be validated. 
In Figure 3.13, CD patient PBMCs stimulated with anti-CD3/28 beads were 
separated into high- and low-IFNγ-secreting groups. CD has been associated 
with high serum and intestinal IFNγ and high expression of IFNγ by IFNγ+ T 
lymphocytes, caused by a polymorphism in the IFNG rs1861484 T allele[185]. It 
is possible that other mutations also lead to similar overexpression of IFNγ in T 
lymphocytes, among other immune cell subsets. Genetic analysis of study 
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participants was beyond the scope of this study; however, it was evident that 
4/10 CD patient PBMCs did have a high PBMC secretion of IFNγ. Interestingly, 
IFNγ secretion in CD PBMCs had an inverse association with increased age. All 
under 45-year old CD patient PBMCs secreted high concentrations of IFNγ. Non-
IBD control PBMCs also secreted high concentrations of IFNγ. All non-IBD 
peripheral blood samples came from donors under 30 years old; thus, high IFNγ 
secretion by PBMCs in this cohort was associated with young donors, and IFNγ 
secretion was impaired in older participants. Furthermore, IL-2 secretion was 
high in all young CD and non-IBD control PBMCs but had a varied range of 
secretion from PBMCs from older CD patients. IL-2 and IFNγ are closely related 
to T lymphocyte effector function. Older CD patients also had the lowest 
frequencies of CD4+IFNγ+ T lymphocytes. It is possible that the effector function 
of CD4+IFNγ+ T lymphocytes was impaired in older CD patients in this thesis. As 
a high proportion of patients with CD are considered elderly, this could explain 
why subcutaneous injection of IFNγ[161], and anti-IFNγ biologic treatments[160] 
have had mixed results in patients with CD. 
Together, these data suggest that age is a viable attribute for immune profile 
stratification. Increased cohort numbers and age-matching of groups would 
further increase the power of this stratification for observation of group-based 
analyses. 
 
4.4.2 Stratification by cytokine expression 
The effector function of immune cells is potentiated by signalling molecules 
within their immediate environment. As such, stimulation of immune cells in 
vitro with anti-CD3/28 beads provided an isolated environment to observe 
immune responses to T lymphocyte stimulation, in the absence of other immune-
modulating factors present in the peripheral blood. CD has been associated with 
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IFNγ and IFNγ+ T lymphocyte responses[48], as well as elevated levels of serum 
and intestinal mucosal TNF[53]. As such, it was important to observe cytokine 
secretion profiles from individual patient PBMCs to elucidate PBMC cytokine 
secretion capacity, as well as the associations these cytokines had with other 
cytokines. 
In this cohort, non-IBD control PBMCs, stimulated with anti-CD3/28 beads, 
consistently secreted high concentrations of IFNγ and IL-2, and 5/6 secreted low 
concentrations of TNF. 8/10 CD patient PBMCs secreted high concentrations of 
TNF, suggesting that high TNF concentrations observed in CD literature could 
result from elevated T lymphocyte-mediated induction of TNF secretion. High 
secretion of IFNγ by CD patient PBMCs was consistently associated with high 
concentrations of TNF and IL-2, suggesting that these patients may have an IFNγ+ 
T lymphocyte-biased response to stimulation. CD patient PBMCs with low-
intermediate IFNγ had high TNF secretion but a mixed range of IL-2 secretion, 
suggesting that IFNγ+ T lymphocytes in these patients may not have biased 
responses to stimulation. 
5/6 patient PBMCs which secreted high concentrations of IL-1β also secreted high 
concentrations of TNF and IL-6. Macrophages are major producers of IL-1β, IL-
6, and TNF[219], however, TNF can also be produced by CD4+ T 
lymphocytes[220]. It is possible that PBMCs from these CD patients have a bias 
for T lymphocyte/macrophage interactions. These interactions could potentiate 
activation of macrophages upon T lymphocyte stimulation and lead to increased 
secretion of TNF, IL-6, and IL-1β. Indeed, inflammatory intestinal macrophages 
have been associated with pathology in CD pathogenesis[221, 222]. CD patients 
typically have low abundances of macrophages in the peripheral blood, 
compared to non-IBD controls, speculated to be due to macrophage migration to 
the intestine[223]. Elevated CD PBMC macrophage migration into the intestine 
was further validated via injection of radiolabelled PBMCs, which found 
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monocytes preferentially migrated into the intestine in CD patients compared to 
other cell types[224].  Thus, it is possible that within this subset of CD patients, a 
T lymphocyte/macrophage interaction bias may play a role in pathogenesis. 
 
4.4.3 Stratification by active treatment status 
CD is a heterogeneous disease which can affect patients of all backgrounds. As 
such, many patients are administered different treatments for their symptoms. In 
this cohort, stratification by treatment type did not provide conclusive results as 
patients were on different types of treatments at the time of appointment, or not 
on current treatment. To determine if active treatment could have caused 
heterogeneity in immune profiles in these experiments, CD patients were also 
stratified by whether they were on a treatment regimen at the time of 
appointment, or not. 
Interestingly, active treatment status did not suggest immune suppression in this 
cohort. Patients who were on active treatment had similar T lymphocyte profiles 
and expressed high concentrations of TNF, IFNγ, and IL-2. It is possible that data 
from these patients could have been higher had the patient not been on current 
treatment, however, active treatment patient PBMCs were in line with those not 
on current treatment. 
The majority of CD patient mediations were broad-acting immunosuppressants. 
It was expected that these patients would have had lower T lymphocyte 
frequencies and cytokine secretion, compared to those not on treatment. 
However, the diverse range of treatments resulted in the inability to obtain 
conclusive results. It is possible that these treatments did alter immune responses 
in these patients; however, it is not possible to know the extent of immune 
modulation without PBMC data taken prior to treatment.  
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Stratification on active treatment status could provide valuable information in a 
larger cohort. This would allow for observation of immune responses across a 
wide range of patient treatments. However, it would be much more useful to 
stratify patient data on specific treatments as pathology mechanisms could be 
investigated. Furthermore, it would be optimal to observe patient data before, 
during, and after treatment to more accurately determine treatment influence on 
the immune response. 
 
4.4.4 Personalised analysis 
Due to the heterogeneous nature of CD, analysis of immune profiles and cytokine 
secretion should be observed at an individual level. Treatment of CD is often 
ineffective, and patients either lack response or lose response over time. CD is 
currently associated with elevated IL-17A+ T lymphocyte profiles and elevated 
intestinal IL-17 protein. However, treatment with Infliximab, a frontline anti-TNF 
biologic mAb, did not induce remission in 10-40% of patients[225], and 23-46% 
of responders lost response over time[5]. Biologic treatments targeting other 
immune response pathways have been effective in patients who do not response 
to anti-TNF therapy[226, 227]. Clinical use of biologic treatments has made it 
clear that patients with CD have unique, personal mechanisms of pathogenesis. 
As such, observation of immune responses should be conducted with 
individuality in mind. 
Tools, such as EarlyBird, provide a convenient way to observe patient data and 
stratify data. Although patient data are inherently heterogeneous, attempts 
should still be made to identify possible patterns. It is important to emphasise 
that, due to a low number of patient samples, these associations are mostly 
speculative. However, these data still contributed to the understanding of 






Development of an in vitro intestinal monolayer model for 
the analysis of Crohn’s disease intestinal interactions 
5.1 Introduction 
A core debate surrounding IBD pathology is whether the breakdown of the intestinal 
epithelial barrier is a cause or consequence of disease[228]. CD is a chronic, relapsing 
inflammation of the intestinal tract. However, it is unclear what the initial cause of 
inflammation is, nor what makes CD patients susceptible to the establishment of 
chronic inflammation. CD patients typically have elevated intestinal epithelial barrier 
permeability compared to healthy people[101]. Indeed, increased permeability can 
increase translocation of luminal antigens and microbes into the LP. The presence of 
any microbe in the LP, commensal or pathogenic, will elicit an inflammatory immune 
response. Observation of CD patient intestinal tract provides information after the 
establishment of chronic inflammation. As such, the study of human patient samples 
provides insight into the consequences of the disease, not the cause. Thus, in vitro 
models are required to elucidate the mechanisms of intestinal inflammation before the 
establishment of chronic inflammation. 
Intestinal organoids are derived from colonic biopsies taken from patients during 
colonoscopy. Intestinal organoids can be cultured indefinitely and expand in 
culture[123]. Thus, intestinal organoids provide a powerful tool to investigate 
intestinal disease in individual human tissues. Intestinal organoids have been used to 
145 
 
investigate intestinal cell interactions with microbes and immune cells[134, 135]. 
However, they have not been used to study these interactions in the context of CD. 
Furthermore, groups have shown it is possible to mechanically disrupt intestinal 
organoids and seed them as 2D monolayers, emulating intestinal epithelial barrier 
organisation[133]. Moreover, immune cell cocktails can be added to observe the 
resulting influence on monolayer cells and the immune response.   
Data from Chapter 3 and Chapter 4 showed CD patient PBMCs responded differently 
than non-IBD control PBMCs to co-culture with commensal bacteria. Furthermore, CD 
patient PBMCs had higher proliferative capacity and inflammatory potential than 
non-IBD controls. Therefore, it is possible that these CD PBMC T lymphocytes play an 
influential role in CD pathogenesis. Thus, in this chapter, a 2D intestinal monolayer 
was developed to allow for the comparison of non-IBD and CD patient tissue and 
immune responses to co-culture with or without commensal bacteria. In this way, it 
was possible to investigate epithelial interactions with commensal bacteria, in the 
absence of an immune response. Furthermore, PBMCs were added to co-culture 
conditions; thus, providing an immune-regulated environment for comparison. 
CD is a heterogeneous disease with varied mechanisms of pathology. Thus, 
personalised, human in vitro tools are the gold standard for CD research. Intestinal 
organoid technology is still in its infancy. However, organoid tools are rapidly 
developing and becoming more accessible. Intestinal organoids provide a unique tool 





The aims of this chapter were to develop an organoid model capable of emulating the 
intestinal epithelial barrier. Furthermore, this model was to facilitate the addition of 
commensal bacteria and matched-patient PBMCs.  
The specific aims of this chapter were to: 
• Culture intestinal organoids from non-IBD and CD patient biopsies 
 
• Develop a 2D intestinal monolayer model 
 
• Identify differences in non-IBD and CD monolayer and immune cell 




5.3 Results  
5.3.1 Rationale 
A fundamental difficulty in CD research is ascertaining whether pathologies or 
patient immune profiles are a cause or consequence of chronic inflammation. Thus, 
we strategised methods to observe immune responses to intestinal cells and bacteria, 
in vitro, using intestinal organoids. 
Intestinal organoids are derived from crypt-based stem cells isolated from patient 
colonic tissue biopsies. Once isolated, colonic crypts are cultured in Matrigel® and 
specialised medium for 4-6 days, and routinely passaged via mechanical disruption. 
Colonic crypts mature in Matrigel® cultures and develop over time. Overnight from 
initial isolation, intestinal crypts close at their apical tips and begin to swell into 
rounded shapes, known as spheroids. The cells that comprise spheroids continue to 
differentiate into gut specialist cells, developing into mature colonoids. Each passage 
breaks organoids into fragments, allowing new organoids to form, expanding the 
organoid culture. Thus, we can take intestinal biopsies from individual patients and 
culture them in long-term, in vitro cultures. 
From these 3D organoid cultures, I designed a protocol that generated a model capable 
of emulating intestinal epithelial barrier organisation. Furthermore, this model had 
the capacity to include matched immune cells from the tissue donor, as well as a 
bacterial component. To achieve this, intestinal organoids were cultured, passaged 
several times, then mechanically disrupted and seeded onto 0.4 μM Transwell® 
membranes. These organoids achieved confluence on the Transwell® membranes, 
forming a monolayer. As such, matched donor immune cells could be added basally 
and bacteria, apically, loosely resembling the organisation of the intestinal epithelial 
barrier. Furthermore, this model allowed for the generation of control monolayers, 




5.3.2 Generation of intestinal organoids 
To culture intestinal monolayers from patient tissues, I first needed to consistently 
establish successful organoid cultures from both non-IBD and CD patient biopsies. 
Patient tissues were collected as small biopsies from the transverse colon, taken from 
visually non-inflamed tissue. These biopsies were washed in dithiothreitol (DTT), a 
mucolytic compound which breaks the disulphide bonds in the mucin which coats the 
luminal side of the biopsies. Then, biopsies were incubated with EDTA, a Ca2+ chelator 
that breaks cadherin proteins which form cell-cell junctions. Thus, upon light 
mechanical agitation, colonic crypts are liberated from intestinal biopsies (Figure 5.1). 
Colonic crypts contain stem cells at the base of the crypt structure. These stem cells 
are potent proliferating cells, responsible for the generation of the cells that comprise 
the intestinal epithelial barrier. Thus, when cultured in vitro, colonic crypts are 
supplemented with factors that induce stemness, such as Wnt3a and R-spondin. In 
this environment, crypt stem cells proliferate in culture conditions, allowing 
organoids to grow and develop (Figure 5.2). Within days, colonic crypts transition into 
spheroids; highly proliferative cysts but which contain few differentiated cells (Figure 
5.3a). Further culture sees the differentiation of spheroids into convoluted structures 
known as colonoids, which contain higher frequencies of differentiated enterocytes, 
among other gut specialist cells (Figure 5.3b-c). 
To track the health of these organoid cultures, pictures were taken using a dissection 
microscope at days 4, 7, and 12 of culture, post-passage (Figure 5.4). Spheroids and 
colonoids were measured by taking the average of two cross-section lines across each 
organoid in a culture. Cultures began with high frequencies of spheroids and low 
frequencies of colonoids but transitioned to a more balanced population after 7 and 
12 days of culture, however, changes in the ratio were not significant over time (Figure 
5.4c). Both spheroids and colonoids continued to increase in size over time. 
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Passage every 5-7 days was optimal for the successful expansion of organoid cultures. 
If organoid cultures lacked spheroids, the subsequent passage yielded fewer 
organoids, with low proliferation potential; thus, slowing expansion of the culture. As 
humans are highly heterogeneous, this process was donor-specific, meaning that 
cultures were not always equal in their ability to proliferate and thrive after passage. 
Therefore, it was important to monitor each culture daily, ensuring cultures did not 





Figure 5.1: Successful intestinal crypt isolation from non-IBD and CD patient transverse 
colonic biopsies. (a) Non-inflammatory bowel disease (IBD) (top) and Crohn’s disease (CD) 
(bottom) patient intestinal crypts isolated from transverse colonic biopsies and suspended in 
Matrigel®. b) Isolated image of a single intestinal crypt isolated from a non-IBD control 
colonic biopsy. Images were taken using a dissection microscope with a x20 objective. These 









Figure 5.2: Successful establishment and growth of intestinal organoids Matrigel® culture. 
Non-inflammatory bowel disease (IBD) colonic organoids at day 4 (left) and day 7 (right). 
Organoids were derived from the culture of transverse colonic crypts in Matrigel®, as 
described in Materials and Methods. Images were taken using a dissection microscope with a 



























Figure 5.3: Microscopy images of transverse colonic spheroids and colonoids. Images of a 
spheroid (a) and mature-colonoid (b) derived from transverse colonic biopsies and cultured 
in Matrigel® for 7 days. c) An image of a colonoid (left) and spheroid (right), cultured as in a-
b. Images were taken at a 40x magnification using a light microscope. These images are 





Figure 5.4: Organoid culture and growth over time. a-b) Frequency of distribution of non-
inflammatory bowel disease (IBD) spheroid (a) and colonoid (b) diameters (μm) for cultured 
organoids at day 4 (broken line), day 7 (dotted line) and day 12 (solid line). c) 
Spheroid:colonoid ratios of data in a-b at indicated time points. Individual organoid size was 
determined by two cross-section measurements using FIJI: ImageJ software. These data 
represent pooled data of single wells from n = 5 non-IBD control samples. Statistical analyses 




5.3.3 Generation of intestinal monolayers 
Protocols for 3D intestinal organoid cultures have been developed since their initial 
establishment using murine intestinal biopsies in 2009, by the Sato laboratory[229]. 
Since then, well-established human 3D organoid protocols have been designed, 
improving the accessibility of this new technology[123]. However, 3D organoid 
models are difficult to analyse, as organoids are highly heterogeneous and generate a 
self-contained lumen. From an immunological perspective, 3D organoid structures are 
too complex as a starting point for CD investigation.  Thus, I designed an intestinal 
monolayer system to provide a more simplistic, 2D representation of the intestinal 
epithelium. The generation of organoid monolayers was a stepwise process. Organoid 
cultures must be passaged at least three times before being viable for seeding on 
Transwell® membranes. Firstly, upon initial isolation, organoid cultures are not pure 
populations of colonic crypts. Mesenchymal cells, as well as organisms from the 
intestinal lumen, are present in initial cultures. Multiple passages allow time for 
antibiotics within the culture medium to mitigate the risk of microbial contamination. 
Furthermore, mesenchymal cells aggressively proliferate in organoid culture 
conditions, quickly outcompeting organoids for space and nutrients. Upon passage, 
mesenchymal cells can be removed after centrifugation, as they loosely sit above 
organoids, which form a dense pellet. Secondly, intestinal monolayers require many 
organoids to ensure confluence is achieved on the Transwell® membrane. As such, 
multiple passages ensure organoid cultures have expanded enough to achieve viable 
numbers for monolayer seeding. Together, from initial isolation of intestinal crypts, 






Figure 5.5: Model concept for generation of intestinal monolayers. Intestinal crypts were 
isolated from patients as described in Materials and Methods. Organoids were routinely 
passaged until at least passage 3, cultured for a further 6-8 days, then mechanically disrupted 
and seeded on 0.4 μm Transwell® membranes. Monolayers were cultured until they reached 
confluence, observed by a Transepithelial electrical resistance (TEER) readout of >800 Ω on an 
EVOM 2 TEER reader. To emulate the intestinal environment, paired patient PBMCs were 
added basally and F. prausnitzii was added apically. An in-depth protocol is described in 






5.3.4 Seeding intestinal monolayers 
To seed intestinal monolayers, 3D organoids were mechanically disrupted, otherwise 
intact organoids would line the membrane, preventing establishment of a monolayer. 
I first attempted to disrupt cells using the passage method of mechanical disruption 
using a 23G syringe, as described in Materials and Methods. These disrupted 
organoids were seeded onto a 24-well Transwell® membrane, pre-coated with 
Matrigel® diluted in DMEM/F12 media. However, no monolayers formed through 
this technique. Upon visual inspection, the disrupted organoids were present, but 
were largely intact or split into two or three pieces. The media did not change colour 
after 2-3 days of culture, suggesting little metabolic activity, which is a sign of a dead 
culture. I hypothesised that mechanical disruption was too destructive, thus, a 
chemical dissociation was required to liberate viable, proliferating cells from 
established 3D organoid cultures.  
Initially, cells were incubated in EDTA on ice for 30 minutes, followed by 10 minutes 
in a water bath at 37oC, to reduce the subsequent mechanical stress. I then used a p1000 
pipette, rather than a syringe, and mechanically disrupted the organoids 40-50 times, 
after incubation. This process successfully liberated cells from 3D organoids, 
generating a seeding population of small aggregates of cells; although, some intact 
organoids were still present. Regardless, this process generated viable monolayers on 
the Transwell® membranes. 
To further improve the dissociation of 3D organoids, organoids were incubated 
organoids in Gibco TrypLE-Express + EDTA (0.5 mM), a trypsin(like)-EDTA 
formulation, used for gentle tissue dissociation. This product was commercially 
standardised and was advertised as being less harsh on cells than EDTA or trypsin 
alone. To ensure inactivation of the trypsin-like enzyme, equal parts FCS was added 
to the organoids after incubation in the ice. TrypLE-Express offered a similar result to 
EDTA alone; however, its standardised formula made TrypLE-Express the optimal 
choice. The addition of ROCK-inhibitor in the initial seeding media (as in the passage 
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protocol) helped organoids achieve confluence sooner, reducing culture time. ROCK-


























Figure 5.6: Variation in monolayer formation displayed in both non-IBD and CD patient-
derived monolayers. a-b) H&E light microscopy images of non-inflammatory bowel disease 
(IBD) and Crohn’s disease (CD) patient intestinal monolayers on a 0.4 μM Transwell® 
membrane after 7 days of culture in NDM (non-differentiation media; containing Wnt3a or R-
spondin), and a further 3 days culture in DFM (differentiation media; not containing Wnt3a 
or R-spondin). a) Non-IBD and CD patient-derived monolayers formed polarised monolayers. 
(b) Multi-layered epithelial monolayers resulted from seeding monolayers with too many 
organoids. c) H&E images showing the presence of goblet cells in monolayers (examples 
indicated by black arrows). Images were taken using a light microscope at 40x magnification.  
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5.3.5 Differentiation of intestinal monolayers 
The human intestinal epithelial barrier is comprised mostly of differentiated 
enterocytes. Enterocytes are apically exposed to luminal contents. Thus, it was 
important to ensure that the monolayers were forming well-organised, matured 
epithelial cells. Thus far, monolayers were seeded and cultured using non-
differentiation media (NDM - containing Wnt3a and R-spondin), which suggested 
that the cells forming the monolayers may have a stem-like phenotype, representing 
the base of colonic crypts, as opposed to luminally exposed epithelia. For this study, 
the cells which directly interact with luminal contents and microbes were more 
relevant to immune:epithelia:bacterial interactions, than the stem cell niche. 
It is important to note that monolayer structure was highly specific to individual 
patients (Supplementary Figures 12-19).  In some cases, monolayers formed highly 
polarised, differentiated columnar cells, with large populations of goblet cells (Figure 
5.6c). In some cases, a uniform monolayer was generated, but neither polarised cells 
nor goblet cells were present. In other cases, the seeded organoids did not form 
uniform monolayers, but instead generated multi-layered epithelia (Figure 5.6b). The 
latter was typically the result of seeding with too many organoids, or the use of day 
3-4 cultures which contained too many spheroids.  
The first successful attempts at generating monolayers produced thin layers of 
compacted epithelial cells (Figure 5.7c - top). It was hypothesised that removal of 
drivers of stemness, such as Wnt3a and R-spondin, would drive differentiation in the 
monolayers. As such, organoid monolayers were cultured for 5-6 days in NDM, then 
a further 3 days in differentiation media (DFM – not containing Wnt3a and R-
spondin). Culture in DFM for 3 days significantly increased transepithelial resistance 
(TEER) (p = 0.078), whereas culture in NDM maintained TEER over the culture period 
at about 400 – 500Ω.cm2 TEER (Figure 5.7a). A permeability assay using 4 kDa FITC-
Dextran showed that after 3 days of DFM culture, monolayers prevented the 
translocation of 4 KDa FITC-Dextran through the monolayer (Figure 5.7b). 
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The goal of this model was to achieve consistent organoid monolayers across 
monolayers derived from a single patient, not uniform monolayers across different 
patients. Simply, monolayers were considered successful if a (mostly) single layer of 
cells formed on the Transwell® membrane, regardless of cellular differentiation, and 
that repeat monolayers derived from the same donor looked similar. 
Interestingly, the data showed that monolayers derived from CD patients had lower 
TEER than non-IBD controls, suggesting a potential inherent permeability defect 
(Figure 5.7d). At day 9, non-IBD control monolayers were, on average, 637 Ω higher 
in TEER than IBD monolayers (p = < 0.0001) (Figure 5.7d). At day 12, three days after 
induced differentiation using DFM, non-IBD control monolayers were, on average, 
920 Ω higher in TEER than CD patient monolayers (p = < 0.0001) (Figure 5.7d). 
 
5.3.6 Guidelines for optimal culture 
As organoid growth rates were donor-specific, a set of rules were established to ensure 
a level of uniformity between monolayers derived from different donor tissues.  
1) Organoids must be counted before seeding, using a haemocytometer. 
Monolayers should contain between 50-75 organoids per 24-well Transwell® plate 
membrane 
If too many organoids were seeded onto a membrane, confluence was achieved but 
not maintained. I do not know the mechanism of this deterioration, but 
observationally, the organoids would quickly achieve confluence (a sharp increase in 
TEER), followed by complete loss of TEER within 1-2 days.  





2) Seeded monolayers must achieve >800 Ω TEER (EVOM2) before experimental 
conditions are initiated 
This provided for a threshold for what I considered to be confluence, ensuring 
monolayers used in these experiments were to a baseline standard, before culture 
conditions were changed. However, some monolayers quickly exceeded this 
threshold, often non-IBD controls exceeding the EVOM2 detection limit of >2000 Ω. 
3) Monolayers from the same patient origin should develop similarly  
Under observation from a light microscope, monolayers can form smooth confluent 
sheets, or develop a ‘maze-like’ pattern, after differentiation. To ensure results are 
consistent with a set of organoids, monolayers should look macroscopically similar 





Figure 5.7: CD patient-derived monolayers have lower TEER than non-IBD controls. a-d) 
Intestinal organoids were dissociated and seeded on 0.4 μM Transwell® and cultured in non-
differentiation media (NDM) for 6-8 days until a confluent monolayer was obtained, as 
determined by a transepithelial electrical resistance (TEER) readout of >800 Ω on an EVOM 2, 
then for 3 days in differentiation media (DFM), or maintained in NDM. a) TEER (Ω.cm2) at 
day 0 (blue) and day 3 (red) after 72 hours culture in DFM. The dotted line represents the 
detection limit of the EVOM 2. n = 5 non-inflammatory bowel disease (IBD) control samples. 
b) Absolute fluorescence intensity readings after monolayer permeability assay using 4 kDa 
FITC-Dextran which was added to the apical compartment and subsequently detected in the 
basal compartment. N.D = not detected in the basal chamber. n = 5 non-IBD control samples. 
c) H&E stained monolayers after 6-8 days culture, then a further 72 hours culture in NDM 
(top) or DFM (bottom). d) Non-IBD (blue) and Crohn’s disease (CD) (red) patient intestinal 
monolayers were cultured for 9 days in NDM, then for 3 days in DFM. TEER readings were 
taken at indicated intervals. The vertical dotted line represents the change from NDM to DFM. 
a-d) n = (non-IBD = 5), (CD = 4). Statistical analyses were calculated using the Two-Way 
ANOVA with Sidak’s multiple comparisons test. (* = p < 0.05, ** = p < 0.01, **** = p < 0.0001). 
a-b) Error bars represent the range. 
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5.3.7 Integration of immune cell and bacterial components to the monolayer model 
It is understood that CD patients can have abnormal immune responses to luminal 
commensal bacteria. However, the mechanisms of these abnormal responses are 
poorly understood. The question of cause or consequences is always debated: Do 
patients with CD have inherent intolerance to commensal bacteria, leading to the 
establishment of inflammation; or do patients with CD develop intolerance to 
commensal microbes due to frequent inappropriate immune exposure to commensals. 
Thus, for the latter argument, the epithelial barrier and its interaction with commensal 
microbes may also be implicated in the generation of abnormal immune responses to 
commensals. 
The intestinal monolayer model was developed to help elucidate answers to the cause 
or consequence of CD pathology. The monolayer model is a single layer of colonic 
epithelial cells, resembling the single layer of cells that form the intestinal epithelial 
barrier. The monolayer is derived from organoids which have been passaged to 
remove other passenger cells, and thus, is not under influence of any underlying 
inflammation or immune interactions. Antibiotics in the organoid media mitigate the 
presence of intestinal microbes, allowing for the controlled addition of heat-killed 
bacteria and their components. Thus, we are able to address these questions from the 
observation of a baseline epithelium, then, in a stepwise manner, increase the 
complexity of the interactions. 
For these experiments, dissociated organoids were initially seeded on 24-well 
Transwell® plates for 6-9 days in NDM. Monolayer differentiation was then induced 
by culturing monolayers in DFM for a further 3 days. TEER was recorded after 3 days 
of DFM culture (day 0), then monolayers were cultured with either 106 PBMCs only, 
MOI 10 or 50 F. prausnitzii only, both 106 PBMCs and MOI 10 or 50 F. prausnitzii, 106 
PBMCs and antiCD3/28 beads (1:1 cell:bead ratio), or alone, for 72 hours in DFM (day 
3) (Figure 5.8). To emulate in vivo organisation, bacteria were added into the apical 
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chamber, whereas PBMCs and anti-CD3/28 beads were added into the basal chamber 
(Figure 5.5). 
In monolayer only conditions, CD patient monolayers had lower average TEER 
readings than non-IBD controls (Figure 5.8b). However, both non-IBD and CD patient 
monolayers maintained TEER between day 0 and day 3 (Figure 5.8a-b). The addition 
of 106 PBMCs did not influence TEER in non-IBD or CD patient monolayers (Figure 
5.8a-b). Immune cells isolated after culture were viable and expressed effector 
cytokines (Figures 5.11-14).  
Non-IBD control monolayer TEERs did not change in the presence of MOI 10 or 50 F. 
prausnitzii (Figure 5.8a-b). Interestingly, CD patient monolayers had a non-significant 
dose dependent TEER reduction in the presence of MOI 10 and 50 F. prausnitzii. 
Furthermore, the presence of both PBMCs and MOI 10 (p = 0.0230) or MOI 50 (p = 
0.0008) F. prausnitzii, in CD patient monolayers, exacerbated TEER reduction, whereas 
non-IBD controls remained unaffected (Figure 5.8a-b). Interestingly, H&E staining of 
CD patient monolayers, exposed to PBMCs and MOI 10 F. prausnitzii, or even MOI 10 
or 50 alone, remained intact; however, monolayer cells were small, and areas of the 
monolayer were extremely thin and appeared unhealthy, possibly contributing to the 
reduction in TEER (Supplementary Figures 12-19). In contrast, H&E staining of CD 
patient monolayers, exposed to both PBMCs and MOI 50 F. prausnitzii were highly 
damaged, and in many cases large gaps in the monolayer were present, or the 
monolayer was missing entirely (Figure 5.10). 
PBMCs were stimulated with anti-CD3/28 beads to determine if T lymphocytes had 
the capacity to induce monolayer degradation. In both non-IBD and CD patient 
monolayers, stimulation of PBMCs with anti-CD3/28 beads reduced TEER completely 
(Figure 5.8a-b). H&E examination of these monolayers, in most cases, showed 
complete monolayer degradation (Supplementary Figures 12-19). In one case, 
monolayer cells were present, but the monolayer cells were highly damaged and large 
sections of the monolayer was missing (Supplementary Figure 15). Strikingly, these 
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H&E images resembled IBD patient monolayers cultured with both MOI 50 F. 
prausnitzii and PBMCs. 
Statistical analyses were conducted on Figures 5.11-5.13; however, statistical 
significance was not achieved due to the low numbers of CD patient monolayers. 
Regardless, consistent degradation of CD patient monolayers suggest that these 
results are biologically relevant. 
Together, these data suggest that, within this monolayer model, stimulated T 
lymphocytes have the capacity to induce monolayer degradation. In non-IBD 
monolayer conditions, the presence of PBMCs and F. prausnitzii did not induce TEER 
reduction and H&E staining showed healthy, intact monolayers in all conditions, 
excluding anti-CD3/28 bead conditions. CD patient monolayers displayed a reduction 
in TEER in the presence of F. prausnitzii alone, suggesting that the epithelium itself 
may have abnormal interactions and responses to the presence of commensal bacteria. 
The addition of immune cells alone did not induce a reduction in TEER, suggesting 
that in the steady-state, CD patient PBMCs may not be deleterious to epithelial 
integrity. However, in the presence of F. prausnitzii, the presence of PBMCs 
exacerbated monolayer degradation, in most cases destroying the monolayer 
completely, an observation similar to direct stimulation of PBMC T lymphocytes with 
anti-CD3/28 beads. Thus, epithelial damage caused by the presence of F. prausnitzii 
may induce immune responses that further contribute to epithelial degradation, as 




Figure 5.8: Co-culture of CD intestinal monolayers with PBMCs and F. prausnitzii reduced 
epithelial integrity.  a-b) Differentiated intestinal monolayers were cultured alone, cultured 
with 106 peripheral blood mononuclear cells added to the basal compartment, or cultured with 
MOI 10 or 50 F. prausnitzii:immune cell added to the apical compartment, or cultured with 
both immune cells and MOI 10 or 50 F. prausnitzii, or cultured with anti-CD3/28 beads, for 72 
hours. a) Data are shown as the percentage of transepithelial electrical resistance (TEER) at 72 
hours of each indicated condition, compared to hour 0 (before condition change). Colours 
represent monolayers derived from a single patient. b) Data are shown as the TEER reading 
(Ω) taken at day 3. n = (non-IBD = 5), (Crohn’s disease; CD = 4). Statistical analyses were 
calculated using the Friedman test with Dunn’s multiple comparisons, comparing monolayer 
only (control) to each condition within non-IBD and CD groups (* = p < 0.05, *** = p < 0.001). 





Figure 5.9 Examples of non-IBD control intestinal monolayers. Peripheral blood 
mononuclear cells (PBMC) were isolated from non-inflammatory bowel disease (IBD) 
controls. Samples were processed as described in the Materials and Methods. 106 PBMCs were 
added to the basal compartment of confluent intestinal monolayers, cultured with apical MOI 
10 or 50 F. prausnitzii, basal anti-CD3/28 beads (1:1 cell:bead ratio), or alone, for 72 hours, then 
processed for H&E staining. H&E image shows intestinal cells lining a 0.4 μm Transwell® 
membrane. All conditions maintained TEER over the 72 hours [except with the addition of 
anti-CD3/28 beads]. Gaps between monolayer cells in this image were likely due to post-
processing events. This monolayer was derived from patient C158 but representative of four 




Figure 5.10 Co-culture with F. prausnitzii and PBMCs was deleterious to patient intestinal 
monolayers. Peripheral blood mononuclear cells (PBMC) were isolated from Crohn’s disease 
(CD) patients Samples were processed as described in the Materials and Methods. 106 PBMCs 
were added to the basal compartment of confluent intestinal monolayers, cultured with apical 
MOI 10 or 50 F. prausnitzii, basal anti-CD3/28 (1:1 bead:cell ratio), or alone, for 72 hours, then 
processed for H&E staining. H&E image shows intestinal cells lining a 0.4 μm Transwell® 




3.3.8 Immune cell responses to monolayer conditions 
Immune cells were recovered after the monolayer experiments in Figure 5.8 and Tregs, 
IFNγ+ T lymphocytes, and IL-17A+ T lymphocyte populations were identified. These 
experiments were conducted for two purposes: 1) To identify if non-IBD and CD 
patient PBMCs have inherent differences in their responses to the presence of 
matched-epithelia and the influence commensal bacteria may have on the system; 2) 
To identify if T lymphocyte populations could provide insight into the differences 
between non-IBD and CD patient monolayer responses to F. prausnitzii. 
 
5.3.8.1 IFNγ+ T lymphocytes 
CD4+IFNγ+ T lymphocytes did not display large frequency changes in response to 
changing conditions (Figure 5.11a). Non-IBD CD4+IFNγ+ T lymphocytes had a 
consistent reduction in frequency in the presence of a monolayer and MOI 10 F. 
prausnitzii. However, when exposed to MOI 50 F. prausnitzii, 3/5 patient samples 
decreased further, whereas 2/5 increased, compared to MOI 10. In contrast, CD 
CD4+IFNγ+ T lymphocytes did not show a consistent reduction in any condition. 
Interestingly, in the presence of anti-CD3/28 beads, non-IBD control CD4+IFNγ+ T 
lymphocytes consistently increased, whereas only 1/3 CD patient CD4+IFNγ+ T 
lymphocytes increased. Non-IBD and CD patient CD8+IFNγ+ T lymphocytes did not 
consistently change in any condition (Figure 5.11b). 
These data indicate that non-IBD and CD patient CD4+IFNγ+ and CD8+IFNγ+ T 
lymphocytes have similar population responses to monolayers and to the addition of 
F. prausnitzii. Furthermore, non-IBD and CD patient IFNγ+ T lymphocyte profiles are 
similar between non-IBD and CD patient groups. Together, these data do not suggest 
that epithelial degradation in IBD patient monolayer conditions were due to abnormal 




Figure 5.11: Non-IBD and CD IFNγ+ lymphocyte responses to bacteria were similar in 
intestinal monolayer model. Peripheral blood mononuclear cells (PBMC) were isolated from 
non-inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). 
Samples were processed as described in the Materials and Methods. 106 PBMCs were added 
to the basal compartment of confluent intestinal monolayers, cultured with apical MOI 10 or 
50 F. prausnitzii, basal anti-CD3/28 beads (1:1 cell:bead ratio), or alone, for 72 hours, then 
analysed via flow cytometry. a-b) Frequency of T lymphocytes (a) CD4+IFNγ+ (b) CD8+IFNγ+ 
as a percentage of total CD3+ cells at indicated co-culture ratios. Data shown are individual 
patient PBMCs in each culture condition. Non-IBD (n=5), CD (n=4). Colours represent PBMCs 
derived from a single patient. Statistical analyses were calculated using the Wilcoxon 
matched-pairs signed-rank test, comparing monolayer only (control) to each condition within 
non-IBD and CD groups. The black line represents the median value.  
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5.3.8.2 IL-17A+ T lymphocytes 
IL-17A+ T lymphocyte responses to monolayer conditions between non-IBD and CD 
patient PBMCs were similar (Figure 5.12a-b). 2/5 non-IBD and 2/4 CD patients 
displayed abnormally high frequencies of CD4+IL-17A+ T lymphocytes in no-
monolayer control conditions (Figure 5.12a). In each of these cases, the presence of a 
monolayer and F. prausnitzii reduced the frequency of these cells. Similarly, CD8+IL-
17A+ T lymphocytes were reduced in both non-IBD and CD patient PBMCs when co-
cultured with monolayers and F. prausnitzii (Figure 5.12b). 
Together, these data show that in the presence of a monolayer, the addition of F. 
prausnitzii either reduces the frequency of IL-17A+ T lymphocytes or does not influence 
this population in non-IBD and CD patient conditions. Thus, the epithelial 
degradation in CD patient monolayers cannot be explained by abnormal CD patient 





Figure 5.12: Non-IBD and CD IL-17A+ lymphocyte responses to bacteria in intestinal 
monolayer model are similar. Peripheral blood mononuclear cells (PBMC) were isolated from 
non-inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). 
Samples were processed as described in the Materials and Methods. 106 PBMCs were added 
to the basal compartment of confluent intestinal monolayers, cultured with apical MOI 10 or 
50 F. prausnitzii, basal anti-CD3/28 beads (1:1 cell:bead ratio), or alone, for 72 hours, then 
analysed via flow cytometry. a-b) Frequency of T lymphocytes (a) CD4+IFNγ+ (b) CD8+IFNγ+ 
as a percentage of total CD3+ cells at indicated co-culture ratios. Data shown are individual 
patient PBMCs in each culture condition. Non-IBD (n=5), CD (n=4). Colours represent PBMCs 
derived from a single patient. Statistical analyses were calculated using the Wilcoxon 
matched-pairs signed-rank test, comparing monolayer only (control) to each condition within 





CD4+ Treg population frequencies were similar between non-IBD and CD patients 
(Figure 5.13a). Both non-IBD and CD patient PBMCs did not change in frequency in 
the presence of a monolayer, nor the addition of F. prausnitzii. In the presence of anti-
CD3/28 beads, both non-IBD and CD patient Treg populations increase, with the 
exception of 1/3 CD patients. CD8+ Tregs were almost undetectable in most conditions 
(Figure 5.13b). 
Together, these data did not suggest that CD patients have abnormal Treg populations 
in monolayer co-culture conditions. Interestingly, in CD patient experimental 
conditions in which the monolayer degraded, Treg frequencies did not increase, as 
they did when cultured with F. prausnitzii alone (Figure 3.14). This suggests that full 
contact with heat-killed bacteria may be required for the increase in Treg frequency, 
whereas bacterial products translocating the 0.4 μM Transwell® membrane, through 
a degraded monolayer, may not elicit the same effect; or, the degradation of the 




Figure 5.13: Non-IBD and CD Treg responses to bacteria in intestinal monolayer model are 
similar. Peripheral blood mononuclear cells (PBMC) were isolated from non-inflammatory 
bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples were processed 
as described in the Materials and Methods. 106 PBMCs were added to the basal compartment 
of confluent intestinal monolayers, cultured with apical MOI 10 or 50 F. prausnitzii, basal anti-
CD3/28 beads (1:1 cell:bead ratio), or alone, for 72 hours, then analysed via flow cytometry. a-
b) Frequency of T lymphocytes (a) CD4+IFNγ+ (b) CD8+IFNγ+ as a percentage of total CD3+ 
cells at indicated co-culture ratios. Data shown are individual patient PBMCs in each culture 
condition. Non-IBD (n=5), CD (n=4). Colours represent PBMCs derived from a single patient. 
Statistical analyses were calculated using the Wilcoxon matched-pairs signed-rank test, 
comparing monolayer only (control) to each condition within non-IBD and IBD groups. The 
black line represents the median value. 
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5.3.8.4 Cytokine response 
Effector cytokines were analysed for the supernatants of apical and basal 
compartments of all monolayer co-culture conditions in Figure 5.8. The T lymphocyte 
effector cytokines: IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17A, IL-17F, IL-21, IL-22, 
TNF, and IFNγ, were labelled by LegendPlex assay and analysed via flow cytometry. 
Although IFNγ+ and IL-17A+ T lymphocyte populations were present in most 
monolayer conditions, IFNγ and IL-17A were not detected in basal or apical 
supernatants (Figure 5.14). IL-5, IL-6, IL-9, IL-10, IL-21, and TNF were present in most 
monolayer conditions, but due to a low number of samples, no consistent differences 
were identified between non-IBD and CD patient cytokine secretions (Supplementary 
Figures 20-24). IL-2, IL-4, IL-12, and IL-17F were not present in any monolayer 
condition. Stimulation of T lymphocytes with anti-CD3/28 beads in monolayer 
conditions induced secretion of all cytokines in both non-IBD and CD patient apical 
and basal supernatants; proving that T lymphocytes can produce cytokine responses 
in the monolayer system. 
Overall, T lymphocyte responses to each monolayer condition, both CD4+ and CD8+, 
were similar to matched PBMCs in control (no monolayer) conditions, suggesting that 
the presence of a monolayer did not alter T lymphocyte profiles in a meaningful way. 
Together, T lymphocyte population dynamics did not implicate any subset of interest 
that may be responsible for the degradation of CD patient monolayers. Furthermore, 
non-IBD and CD PBMCs had similar responses to each condition, suggesting that, 
within this model, IBD patient PBMCs do not abnormally respond to the presence of 






Figure 5.14: No difference between non-IBD and CD cytokines produced in response to co-
culture conditions in intestinal monolayer model. Supernatants were collected from apical 
(left) and basal (right) compartments of experiments conducted in Figures 8-11. Cytokines 
from supernatants were labelled using a LegendPlex cytokine analysis kit, then analysed by 
flow cytometry. Data are shown as individual patients, and the bar represents the mean 
concentration (pg/mL). Non-inflammatory bowel disease (IBD) (n=3), Crohn’s disease (CD) 
(n=3). Statistical analyses were calculated using the Wilcoxon matched-pairs signed-rank test, 
comparing monolayer only (control) to each condition within non-IBD and CD groups. The 








2D intestinal monolayers were generated from 3D large intestinal organoids to 
observe interactions between non-IBD and CD patient epithelial cells, PBMCs, and 
commensal bacteria. CD patient monolayers had lower TEER than non-IBD 
monolayers. Co-culture of patient monolayers with F. prausnitzii induced a reduction 
in TEER in CD patient monolayers, but not non-IBD control monolayers. The addition 
of PBMCs to monolayers, in the presence of F. prausnitzii, exacerbated TEER reduction 
in CD patient monolayers and resulted in complete monolayer degradation. These 
data did not implicate T lymphocytes as the mediators of degradation in this model; 
however, stimulation via CD3 and CD28 induced similar degradation in both non-
IBD and CD patient monolayers. Together, these data suggest that IBD patient 
intestinal epithelial barriers may respond abnormally to commensal bacteria and that 
deleterious monolayer responses can occur regardless of the presence of an immune 
response. 
 
5.4.2 Rationale for the use of intestinal organoids 
An inherent difficulty for CD investigation is the location of the cells of interest. 
Obtaining cells from the intestinal region requires biopsy collection during an invasive 
colonoscopy. Few immune cells are obtained from colonic biopsies, compared to 
peripheral blood; furthermore, once biopsies are removed from the intestinal milieu, 
immune cells do not survive well in in vitro culture conditions. It is also possible that 
immune profiles vary along the gastrointestinal tract due to regional abundances of 
bacterial species, offering information relevant to a local region[231-233]. To 
compensate, biopsies are collected from multiple visually non-inflamed regions; 
however, the use of intestinal immune cells is still difficult and relative to the tissues 
selected by the clinician obtaining the biopsies. 
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To make the best use of colonic biopsies, intestinal organoids were cultured from stem 
cells isolated from colonic biopsies. As a consequence, intestinal immune cell data was 
not obtained; instead, matched-peripheral blood and intestinal organoids were 
cultured to allow investigation of immune cell:intestinal cell interactions and 
responses to various stimuli. Intestinal organoids provide a self-renewing culture of 
patient tissues with robust potential for experimental manipulation[123]. 
A fundamental unanswered question in CD pathology is whether chronic 
inflammation is a cause or consequence of epithelial dysfunction. Is inflammation in 
CD due to microbial migration through a dysfunctional epithelium, leading to 
inflammation; or are inappropriate immune responses responsible for inflammation 
that induces epithelial dysfunction? Intestinal organoids, in theory, provide the 
opportunity to observe intestinal cell interactions, without the presence of a functional 
immune system. In this way, intestinal organoids allow investigation into questions 
regarding the cause or consequence of disease pathology. 
 
5.4.3 Rationale for the development of intestinal monolayers 
3D intestinal organoids are complex structures, containing multiple types of intestinal 
specialist cells, as well as a self-contained lumen. While 3D intestinal organoids are a 
useful tool for the in vitro generation of patient intestinal tissues, their complex design 
makes immunological investigation difficult. First, 3D intestinal organoids were 
cultured and passaged to expand the number of organoids. Then, to allow for a more 
uniform method of tissue culture, intestinal monolayers were generated from 3D 
intestinal organoids. Intestinal monolayers have recently been developed by other 
laboratories to investigate intestinal epithelial interactions with bacteria and immune 
cells[133, 234]. 
Here, we generated our method of monolayer culture, as well as optimised the 
inclusion of bacteria and PBMCs from matched patient donors. As far as I am aware, 
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we are the first group to combine all three of these components to study immune 
cell:epithelial cell:bacterial interactions in CD. 
In this study, monolayers were generated from non-IBD and CD patient tissues, 
allowing the comparison of responses to the addition of PBMCs and commensal 
bacteria. Previous data in this study suggested that CD patient PBMCs have abnormal 
responses to commensal bacteria; however, previous co-culture models were unable 
to account for the compensatory affects the intestinal milieu may provide. Although 
this model did not completely represent intestinal organisation, and lacked 
representation of the lamina propria, the monolayer model still provided a 
biologically relevant organisation of intestinal cells to test our hypotheses. 
 
5.4.4 Development of intestinal monolayers 
Defining what an intestinal monolayer biologically represents is conjecture. The 
organoid model is a single layer of intestinal cells, derived from 3D intestinal 
organoids. This model allows the observation of interactions relevant to intestinally 
derived cells, not a true representation of the intestinal epithelial barrier and LP. 
Monolayers generated from an individual patient shared similar TEER increases over 
time. Monolayers were phenotypically heterogeneous between patients; however, this 
was expected, as intestinal organoids derived from individual patients were observed 
to have high levels of heterogeneity in their growth rates. 
Monolayer cells, once seeded, were cultured in standard organoid media, containing 
Wnt3a and R-spondin. Wnt3a is a driver of stemness in intestinal crypts and was 
supplemented into media to compensate for the lack of a Wnt3a-producing 
mesenchyme in organoid cultures derived from the large intestine[8]. R-spondin is a 
potentiator of the Wnt3a pathway. R-spondin binds to the surface receptor 
RNF43/ZNRF3, preventing RNF43/ZNRF3-mediated ubiquitination and eventual 
degradation of the Wnt3a receptor, Frizzled[8]. It was hypothesised that the removal 
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of Wnt3a and R-spondin would induce differentiation of intestinal monolayer cells. 
To this end, monolayers were cultured in regular organoid media for 6-8 days, then 
Wnt3a and R-spondin were removed for the remainder of culture. Within 72 hours of 
removal of Wnt3a and R-spondin, non-IBD control monolayers increased in TEER 
above detectible levels by the EVOM2 (>2000 Ω), suggesting the development of more 
robust monolayer. Indeed, when H&E slides of monolayers were observed, 
monolayers cultured without Wnt3a and R-spondin contained larger, more polarised 
cells than those cultured with Wnt3a and R-spondin. Interestingly, some intestinal 
monolayers displayed large, developed goblet cells, although, this was not a 
consistent finding. 
Both non-IBD and CD patient organoids generated confluent intestinal monolayers. 
Interestingly, CD patient monolayer TEERs plateaued at day 9 (day of media change 
to DFM), whereas non-IBD monolayers continued to increase in TEER. These data 
suggest that monolayers derived from CD patient organoids may have inherent 
defects in their ability to form a robust monolayer. This is in line with the literature, 
which suggests that CD patient intestinal barriers are more permeable than non-IBD 
control intestinal barriers[235]. CD patient monolayers had lower TEER than non-IBD 
monolayers in the absence of immune cells. These data imply that CD patient 
intestinal barriers may be more permeable than non-IBD control intestinal barriers, 
regardless of immune cell influence. H&E images of CD patient monolayers did not 
provide definitive evidence of increased permeability. Some CD patient monolayers 
had small, unpolarised cells; however, non-IBD control monolayers with high TEERs 
had similar cell organisation.  
 
5.4.5 Intestinal monolayer response to commensal bacteria 
CD has been associated with intestinal dysbiosis. In a 2007 analysis by Frank et al., UC 
and CD patients had lower abundances of commensal bacteria, lower microbial 
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diversity, and lower abundances of Firmicutes and Bacteroidetes than non-IBD 
controls[138]. It is not known if the lack of commensal bacteria is an initiating factor 
in IBD pathology, or if CD patients lack these commensal species due to inappropriate 
immune cell responses. It has been shown that both non-IBD and CD patients can 
produce commensal-specific T lymphocytes[108]. 12/16 tested CD patient PBMCs 
proliferated in responses to commensal antigen, and of these 10/12 responded to more 
than one type of commensal antigen. Of note, CD patient PBMC responders to 
commensal antigens had a bias for CD4+IL-17A+ and CD4+IL-17A+IFNγ+ T 
lymphocytes, whereas non-IBD responder cells were CD4+IFNγ+IL-17A-. Further, it 
was found that CD4+ commensal antigen-specific T lymphocytes had elevated Th17 
signature gene expression compared to non-IBD control equivalents, whereas Th1-
related genes were similar between groups. These data suggest that although both CD 
and non-IBD PBMCs can proliferate in response to commensal antigens, only CD CD4+ 
T lymphocytes respond with a Th17 bias. Thus, it is likely that abnormal naïve T 
lymphocyte responses to commensal antigens may drive inflammatory T lymphocyte 
differentiation and pathology in CD. 
Studies have shown that dysfunctional immune responses can contribute to dysbiosis 
and intestinal pathology[236, 237]. NLRP-/- mice, which lack a functional 
inflammasome, had dysbiosis and an abundance of pathology-inducing Prevotella 
species. NLRP-/- mice were susceptible to colitis; furthermore, transfer of NLRP-/- 
microbiota to wild-type mice also induced colitis[237]. These data suggest IBD 
patients may have colitis-inducing microbiota, which may be the consequence of 
aberrant immune responses to commensals. Indeed, patients with CD can benefit from 
the use of broad-acting antibiotics[238]. Data also suggest that CD patient intestinal 
epithelial barriers are more permeable than those of non-IBD controls, allowing 
luminal contents to diffuse through and induce immune responses in the LP[235].  
Studies often focus on immune-mediated damage of the intestinal epithelial barrier in 
CD; however, it is possible that the intestinal epithelial barrier is also defective. The 
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intestinal monolayer model allowed for the observation of epithelial cell:bacteria 
interactions, in the absence of an immune system. In this way, we were able to 
investigate whether CD patient epithelial cells were susceptible to commensal-
induced pathology. Previous studies using 2D small intestinal monolayers derived 
from healthy, human donors, showed that co-culture with enterohemorrhagic 
Escherichia coli induced monolayer permeability[234].  
The addition of MOI 10 or MOI 50 F. prausnitzii to non-IBD control monolayer 
conditions caused no change in TEER after 72 hours of culture. Strikingly, CD patient 
monolayers had a reduction in TEER with the addition of MOI 10 and MOI 50 F. 
prausnitzii, in a dose-dependent manner. H&E images of the monolayers did not show 
abnormalities of monolayer organisation that would be responsible for a major 
reduction of TEER, beyond typical heterogeneity. The H&E stains were performed on 
small slices of monolayer membranes, it is possible that abnormal regions of the 
monolayer were present in other regions of the monolayer. 
These data suggest that CD patient monolayer cells may have abnormal responses to 
the presence of F. prausnitzii. F. prausnitzii is commonly labelled as a commensal 
bacterium; as such, research has not been conducted to investigate potential 
deleterious interactions F. prausnitzii may have with intestinal cells. These data 
suggest that CD patient intestinal cells may abnormally respond to F. prausnitzii, 
which may lead to an increase in permeability, a hallmark of CD intestinal pathology. 
As previously mentioned, CD patient organoids may have an inflammation-
influenced phenotype, even when isolated from non-inflamed tissues[239]. Data from 
a 2003 study suggested that following exposure to the chemical stressor dinitrophenol, 
T84 human colonic tissue cell monolayers abnormally responded to commensal E. coli 
HB101 as a pathogen, resulting in a reduction of TEER and production of IL-8[205]. 
Therefore, it is possible that CD epithelial cells are conditioned to incorrectly respond 
to commensal bacteria. Furthermore, if CD organoids possess a stressed phenotype, 
in vitro culture may further contribute to CD patient organoid stress.  
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A mechanism for this effect was beyond the scope of this project, particularly because 
little is known about the interactions between the intestinal epithelium and luminal 
bacteria. It is possible that as IBD patient monolayers have a lower TEER than non-
IBD control monolayers before the addition of bacteria, bacterial components are able 
to diffuse through CD patient monolayers into the basal compartment. TLRs, such as 
TLR9, can induce an inflammatory response in epithelial cells when bound to a ligand 
on the basal surface, whereas apical binding would not trigger a response[111]. 
Translocation of bacterial products could be identified through a combination of size 
exclusion chromatography and Matrix-Assisted Laser Desorption/Ionisation-Time of 
Flight mass spectrometry of apical and basal compartment supernatants. Further, a 
Transwell® membrane pore size large enough for bacterial translocation could be 
used to allow bacteria to translocate through the membrane if barrier conditions allow. 
This could be tracked using fluorescent anti-F. prausnitzii antibodies[240]. Epithelial 
cell inflammatory responses triggered by bacterial antigens can lead to cell shedding 
and renewal[241], which may cause a loss of monolayer integrity in this model. To test 
this theory, F. prausnitzii could be added to the basal compartment of non-IBD control 
monolayers to determine its effects on permeability, and whether the subsequent basal 
presence of bacterial components causes TEER reduction, as observed in CD patient 
monolayers. 
Mucin is an important part of the epithelial barrier and helps to maintain bacterial 
control. Mucin provides a protective layer, separating bacteria from the apical surface 
of epithelial cells. In this study, the process of fixation for H&E staining prevented the 
possibility of detecting an intact mucin layer. Therefore, it is possible that the presence, 
absence, or abnormality of mucin layers in the monolayer system could account for 
the differences seen in non-IBD and CD patient monolayer responses to F. prausnitzii. 
Indeed, aberrant mucin layers in mice can lead to spontaneous development of colitis-
like inflammation[242]. Most monolayers did not contain detectible goblet cells, 
suggesting that a complete mucin layer was unlikely in either group of patient 
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monolayers. Future experiments should aim to detect mucin layers, to further 
elucidate potential mechanisms of abnormal responses to F. prausnitzii. In future 
experiments, mucin layers can be detected by Alcian blue staining or immunostaining 
of mucin proteins using anti-mucin antibodies[243]. 
Together, these data suggest CD patient intestinal cells may have inherent integrity 
dysfunction and have abnormal interactions with F. prausnitzii. Interestingly, these 
abnormalities were apparent in the absence of a functional immune system, 
suggesting that abnormalities in epithelial cells alone, may have significance in the 
onset of intestinal pathology in CD. 
 
5.4.6 Intestinal monolayer response to PBMCs 
The intestinal microbiota is essential for the digestion of nutrients as well as the correct 
development of the gastrointestinal tract. Germ-free mice have been extensively 
studied and much of the understanding of human intestinal development is based on 
murine experiments. Germ-free animals have a range of major health and immune 
defects, including stunted intestinal development[244], impaired development of 
GALT[245], as well as impaired ability to generate tertiary lymphoid follicles[246]. 
Germ-free mice are more susceptible to DSS-induced colitis than conventionally 
raised mice[247]. Germ-free mice lack development of T lymphocyte subsets[248]. As 
a result, Germ-free mice are more susceptible to pathogenic infection than wild-type 
and specific-pathogen-free mice[248, 249]. Due to a lack of immune development, 
germ-free rodents are resistant to various spontaneous inflammatory diseases[250, 
251].  
Exposure to luminal microbes is critical for immune development. Ex-germ-free mice, 
which have gradually become tolerant to the transfer of a microbiome or microbial 
products, show improved development of GALT and immune populations[246]. 
Thus, exposure to luminal microbes is critical for the development of intestinal 
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tolerance and maintenance of homeostasis; a failure to maintain homeostasis can 
result in dysbiosis and deleterious immune responses. Improper regulation of 
commensal bacteria can result in an inflammatory immune response. GWAS of IBD 
patient genomes identified ATG16L1 as a risk factor in IBD[252]. Mutations in 
ATG16L1 can result in improper autophagic degradation of intracellular bacteria and 
expendable cellular machinery and debris[115]. Dysfunctional autophagy can reduce 
bacterial clearance and reduce cellular survival due to accumulation of expired 
cellular components[253]. Lysosomal storage disorders are a group of 
neurodegenerative disorders caused by a failure to recycle cytosolic products due to 
defective autophagy[254]. Thus, the accumulation of bacterial and cytosolic 
components within cells may be highly immunogenic upon cellular death. 
CD is often referred to as an auto-immune disease in which the immune system can 
inappropriately target host cells and commensal bacteria. In a 1999 study, 3/12 tested 
UC patients had peripheral blood cytotoxic lymphocytes that had increased 
cytotoxicity to matched colonic epithelial cells via the production of antibody-
dependent cell-mediated cytotoxicity, compared to non-IBD controls[255]. However, 
in most cases, the culture of immune cells with monolayers did not significantly alter 
T lymphocyte frequencies. In this thesis, compared to PBMC culture alone, 1/5 non-
IBD control PBMCs had a lower frequency of CD4+IFNγ+ T lymphocytes and 2/5 had 
a reduction in the frequency of IL-17A+ T lymphocytes. 1/4 IBD patient PBMCs had a 
higher frequency of CD4+IFNγ+ T lymphocytes and both CD4+IL-17A+ and CD8+IL-
17A+ T lymphocytes, whereas 1/4 CD patient PBMCs had a lower frequency of CD4+ 
and CD8+IL-17A+ T lymphocytes. However, the general response, in both non-IBD and 
CD patient PBMCs was no change in any T lymphocyte population in response to the 
presence of a monolayer. These data do not suggest that CD patient PBMCs have an 
autoimmune response to matched intestinal monolayers. Observation of H&E images 
did not suggest a difference between control and immune cell co-cultured monolayers 
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in either group. These conditions provided validation that PBMCs could be co-
cultured with intestinal monolayers, without adverse effects. 
 
5.4.7 Intestinal monolayer response to commensal bacteria and PBMCs 
Abnormal T lymphocyte responses to commensal bacteria (as seen in Chapter 3) may 
have significance to CD pathology. CD has been associated with a loss of tolerance to 
commensal microbes, but it is not known if the loss of tolerance is a cause or 
consequence of epithelial barrier pathology. Therefore, PBMCs and F. prausnitzii were 
co-cultured with monolayers to observe if abnormal CD patient PBMC responses to 
commensal bacteria could be an initiating factor in epithelial barrier degradation. 
The addition of both PBMCs and F. prausnitzii did not reduce TEER in non-IBD control 
monolayers. 1/5 non-IBD monolayers had a TEER reduction at MOI 10 F. prausnitzii, 
and 2/5 at MOI 50 F. prausnitzii; however, reduced TEERs were still considered 
confluent (>800 Ω). In contrast, all CD patient monolayers had a reduction in TEER at 
both MOI 10 and MOI 50 F. prausnitzii, in the presence of PBMCs. The addition of 
PBMCs caused a greater reduction in TEER than the addition of bacteria alone. Indeed, 
H&E images displayed a complete breakdown of CD patient monolayers, whereas 
non-IBD control monolayers appeared healthy in all bacterial co-culture conditions.  
To determine if non-IBD control T lymphocytes had the capacity to induce epithelial 
degradation, anti-CD3/28 beads were added to monolayers co-cultured with 106 
PBMCs to induce non-specific TCR activation of T lymphocytes. As seen in Figure 
3.12, stimulation of either non-IBD or CD patient PBMCs resulted in an increase of 
differentiated IFNγ+ T lymphocytes, IL-17A+ T lymphocytes, and Tregs, as well as 
induced the secretion of T lymphocyte effector cytokines (Supplementary Figures 20-
24). The stimulation of T lymphocytes with anti-CD3/28 beads caused a reduction in 
TEER in both non-IBD and CD patient monolayers. Strikingly, H&E images showed 
epithelial degradation was similar between anti-CD3/28 bead-stimulated conditions 
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and CD patient monolayers co-cultured with PBMCs and F. prausnitzii. It is possible 
that the production of effector cytokines by activated T lymphocytes induced pro-
apoptotic pathways in monolayer cells or impaired paracellular adhesion between 
cells, leading to monolayer degradation. Both TNF and IFNγ were induced by anti-
CD3/28 stimulation of PBMCs (Supplementary Figure 20). TNF regulates both anti- 
and pro-apoptotic pathways in intestinal epithelial cells and is thought to contribute 
to the increased apoptosis of intestinal barrier enterocytes seen in IBD patients[256, 
257]. Thus, it is possible that TNF secretion by T lymphocytes induced pro-apoptotic 
pathways in intestinal monolayer cells.  IFNγ impairs expression of tight junction-
related proteins, such as ZO-1, which could result in the degradation of paracellular 
connections between monolayer cells[49]. Recombinant proteins could be added to 
monolayer media, without the presence of matched-PBMCs, to determine if immune 
cell interactions were required for monolayer degradation. Further, cytokine-
neutralising antibodies could be added to all monolayer conditions to elucidate the 
role of each cytokine in immune cell:monolayer cell interactions. 
Together, these data suggest that not only do CD patient intestinal cells have abnormal 
responses to F. prausnitzii, but the addition of matched PBMCs induced complete 
epithelial degradation. Monolayers from non-IBD controls remained confluent in all 
bacterial conditions; however, T lymphocyte stimulation with anti-CD3/28 beads 
induced similar degradation to CD patient monolayers. Thus, these data suggest that 
CD patient PBMCs may have abnormal responses to F. prausnitzii. However, it is 
possible that CD patient PBMCs responded to inflammatory signals provided by 
abnormal epithelial responses to F. prausnitzii, as opposed to direct immune 
stimulation by bacterial components. 
The addition of Enteropathogenic Escherichia coli (EPEC) to small intestinal 
monolayers induced deleterious effects on monolayer integrity[133]; however, this is 
the first-time commensal F. prausnitzii has been observed to have deleterious effects 
on intestinal monolayers. Furthermore, the degradation of the CD patient monolayers 
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in response to co-culture produced a more severe degradation than EPEC co-cultured 
with non-IBD control monolayers. 
PBMC immune profiles of each monolayer condition were observed for Treg, IFNγ+ T 
lymphocyte, and IL-17A+ T lymphocyte responses to co-culture. Interestingly, in 
almost all cases, non-IBD and CD patient immune responses to each condition were 
similar. With the exception of outliers, Treg populations did not change between 
conditions. Both non-IBD and CD patient CD4+IFNγ+ T lymphocytes and CD4+IL-17A+ 
T lymphocytes reduced in frequency with the addition of F. prausnitzii, in a dose-
dependent manner. Therefore, T lymphocyte phenotype data were not able to provide 
an explanation for CD patient monolayer degradation. 
The addition of anti-CD3/28 beads and PBMCs caused epithelial degradation in both 
non-IBD and CD patient monolayers. In these conditions, both non-IBD and CD 
patient Tregs, IFNγ+ T lymphocytes, and IL-17A+ T lymphocytes increased in 
frequency. Thus, the stimulation of T lymphocytes is able to induce epithelial 
degradation in this model but may not be the cause of epithelial degradation in other 
monolayer conditions. It is possible that other immune cell subsets were responsible 
for epithelial degradation in CD patient monolayers; it is also possible that other 
immune cell:epithelial cell interactions that we did not account for were responsible 
for the degradation. 
Inflammatory cytokines were analysed in apical and basal compartments of all 
monolayer conditions. A variety of inflammatory cytokines were analysed to cover 
multiple immune cell types. Cytokines produced by IFNγ+ T lymphocytes, IL-17A+ T 
lymphocytes, Type 2 lymphocytes, monocytes, and Tregs were detected using a 
LegendPlex assay. There were no clear differences between non-IBD and IBD patient 
cytokine secretion in any condition.  In fact, in most conditions, cytokines were not 
present at detectible concentrations.  
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2D small intestinal organoid monolayers have been previously used to elucidate 
response coordination between macrophages and epithelial cells to bacterial 
stimuli[133]. Macrophages were seen reaching dendrites through the paracellular 
spaces between monolayer cells to interact with apical-enterotoxigenic E. coli (ETEC). 
The presence of macrophages improved monolayer protection against ETEC-induced 
TEER reduction; however, there was no change in the macrophage cytokine secretion. 
Therefore, it is possible PBMCs in our model were able to influence monolayers in a 
T lymphocyte cytokine-independent manner. 
The absence of T lymphocyte effector cytokines suggested that epithelial degradation 
in CD patient monolayers was T lymphocyte-independent. In this model, F. prausnitzii 
did not induce cytokine production in T lymphocytes. Furthermore, there was no 
consistent T lymphocyte frequency change in any monolayer condition, even in 
conditions resulting in CD patient monolayer degradation (excluding anti-CD3/28 
stimulation). In previous experiments, co-culture of F. prausnitzii and PBMCs 
influenced T lymphocyte differentiation. Therefore, it is possible that PBMC 
stimulation required direct contact with bacterial components, and thereby did not 
respond due to the 0.4 μM Transwell® membrane barrier which separated the apical 
and basal compartments. Future experiments should identify the cytokine response 
of PBMC co-culture with F. prausnitzii, separated by a Transwell® membrane. If direct 
contact does induce cytokine responses, monolayers could be seeded on Transwell® 
membranes with a larger pore size to determine if the response was due to large 
microbial products. 
Direct stimulation of T lymphocytes with anti-CD3/28 beads induced secretion of most 
analysed cytokines in both non-IBD and IBD conditions, proving that PBMCs in these 
cultures were capable of cytokine secretion. Future experiments could optimise the 
addition of anti-CD3/28 beads, recombinant proteins, neutralising antibodies, or other 
stimulation factors, to induce different levels of inflammation or stimulate cells of 
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interest. In this way, the model could allow for the observation of any immune cell 
type and their interactions with intestinal cells and their responses to bacteria.  
 
5.4.8 Conclusions 
Together, these data suggest that although the addition of PBMCs exacerbated 
epithelial degradation in CD patient monolayers co-cultured with F. prausnitzii, our 
analysis did not implicate T lymphocytes as mediators of this degradation. However, 
T lymphocytes had the capacity to induce epithelial degradation under stimulatory 
conditions.  
These data provide interesting contributions to the cause or consequence debate 
regarding CD. In this monolayer model, CD patient epithelial cells had lower TEER 
and had abnormal responses to F. prausnitzii, compared to non-IBD control 
monolayers. This suggested that CD patient loss of intestinal tolerance may be due to 
inappropriate responses to luminal commensals, resulting in dysregulation of the 
monolayer and subsequent reduction in TEER. The intestinal epithelial barrier of CD 
patients may become more permeable when exposed to luminal commensals, 
allowing migration of luminal microbes into the lamina propria and subsequent 
exposure to immune cells. It is also possible that signals produced by these abnormal 
responses, or abnormal responses from immune cells exacerbate epithelial 
degradation, leading to the establishment of chronic inflammation. Thus, these data 
suggest inherent defects in the epithelial barrier of IBD patients and their responses to 











In recent years, clinical treatment of the symptoms of CD has greatly improved. Better 
identification of disease by medical professionals and diversification of frontline 
treatments have reduced the burden of CD. However, the aetiology of CD remains 
largely unknown. Due to the heterogeneous nature of CD, it is difficult to accurately 
identify the mechanism of disease in individual patients. There is no single test to 
diagnose CD; rather, the disease is diagnosed using data from a culmination of blood 
tests, colonoscopies, and process of elimination. Consequently, diagnosis and 
treatment for CD symptoms is time-consuming and further exacerbates patient stress 
and increases time to remission. There is no cure for CD. Furthermore, the heterogony 
of disease means that patients may or may not respond to treatment or may lose 
response to treatment over time. To improve time to remission in patients with CD, it 
is imperative that the mechanisms of disease are elucidated and rapidly identified in 
patients. 
The immune mechanisms of CD remain largely unknown. Peripheral blood and 
intestinal biopsies from patients with CD have associated disease pathology with 
higher abundances of IL-17A+ T lymphocytes, IFNγ+ T lymphocytes, and their effector 
cytokines: TNF, the IL-17 superfamily, and IFNγ, compared to non-IBD control 
profiles. GWAS have implicated over 163 SNPs associated with IBD[112]. These SNPs 
have been broadly categorised into biological functions, such as autophagy, IL-10 
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signalling, adaptive immunity, innate immunity, and defective epithelial barrier 
integrity. There is a clear genetic component to the establishment of chronic 
inflammation; however, genetic studies can only infer broad potential complications 
of cellular interactions. Microbiome analysis and TCR repertoire studies have also 
implicated abnormal immune responses to commensal bacteria may be an initiating 
factor in IBD pathology[108, 174]. CD has also been associated with auto-immune 
responses targeting intestinal cells[255]. A constant debate regarding the pathology of 
CD is whether immune responses in the intestine are a cause or consequence of 
disease. Thus, interrogation of immune cell responses to commensal bacteria and 
further development of biologically relevant in vitro assays are required for the 
accurate and rapid identification of mechanisms of disease in individual patients, and 
subsequent prescription of optimal treatments. 
In this thesis, phenotypic analysis of CD patient PBMC responses yielded interesting 
results pertaining to responses to commensal bacteria and T lymphocyte stimulation. 
CD patient PBMC IFNγ+ T lymphocyte and IL-17A+ T lymphocyte frequencies 
increased by a greater magnitude than non-IBD control lymphocytes, in response to 
stimulation with anti-CD3/28 beads. Furthermore, CD patient PBMCs had a higher 
proliferative index and precursor frequency than non-IBD control PBMCs. These data 
suggest that CD patient PBMCs were more prone to proliferation and differentiation 
in response to stimuli. Furthermore, CD patient PBMCs secreted higher 
concentrations of the inflammatory cytokines TNF, IL-6, and IL-17A, compared to 
non-IBD control PBMCs. CD patient PBMCs also had abnormal T lymphocyte 
phenotypic responses to the presence of commensal bacteria. In contrast to non-IBD 
control PBMCs, co-culture with commensal bacteria increased the frequency of IBD 
patient Tregs but did not reduce frequencies of IFNγ+ T lymphocytes or IL-17A+ T 
lymphocytes, as was seen in non-IBD control PBMC responses. Together, these data 
suggest that CD patient PBMCs have a higher potential for inflammatory response 
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than non-IBD control PBMCs and may have perturbed ability to maintain intestinal 
tolerance to commensal bacteria. 
Intestinal organoids were employed to ascertain whether these abnormal CD patient 
PBMC responses were deleterious to intestinal cells. To achieve this, a 2D monolayer 
organoid model was developed to combine epithelial cells, an immune response, and 
a microbiota, into a functional assay. In this model, CD patient monolayers had lower 
average TEER than non-IBD monolayers, indicating a similarity to observed 
heightened permeability in CD patient intestinal epithelial barriers[101]. Co-culture of 
IBD patient PBMCs with F. prausnitzii reduced TEER in CD patient monolayers in a 
dose-dependent manner but did not reduce TEER in non-IBD control monolayers. 
Interestingly, the co-culture of F. prausnitzii with patient monolayers reduced TEER in 
CD patient monolayers but not non-IBD control monolayers, in a dose-dependent 
manner. Within this model, when F. prausnitzii was present, CD patient PBMCs 
exacerbated epithelial degradation. F. prausnitzii co-culture, without immune cell 
presence, induced a reduction in CD patient monolayer TEER, suggesting an 
abnormal epithelial response to commensal bacteria. Furthermore, CD patient PBMCs 
did not have deleterious effects on CD patient monolayers without the addition of a 
stimulus, suggesting that CD patient PBMCs did not display auto-immunity in this 
model. 
Together, using a variety of in vitro assays, data in this thesis show distinct 
abnormalities in CD patient PBMC responses to stimulation and commensal bacteria. 
The intestinal monolayer model showed deleterious epithelial responses to F. 
prausnitzii, which were exacerbated by the presence of immune cells. These data 
suggest that abnormal CD patient PBMC responses to commensal bacteria may be a 
driver of intestinal inflammation and may be responsible for the associated loss of 
tolerance to commensal microbes. Furthermore, inherent lower monolayer TEER and 
deleterious interactions with commensal bacteria may implicate specific commensal 
bacteria as initiators of pathology.  
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6.2 Regulatory T lymphocytes in Crohn’s disease 
Tregs have been implicated in pathology in CD; however, their involvement largely 
remains unknown. Due to the inflammatory nature of CD, it is commonly assumed 
CD patient Tregs must have an inherent defect which limits their suppressive 
capacity. Indeed, Tregs and suppressive DCs are responsible for the maintenance of 
intestinal tolerance to luminal microbes and foreign antigens. As such, depletion of 
Tregs in mice induces spontaneous development of colitis-like disease[258]. Loss-of-
function mutations in IL-10 signalling in humans leads to early-onset enterocolitis, 
among a range of other inflammatory diseases[259]. GWAS have identified IL-10 and 
IL-10R polymorphisms associated with IBD[260].  
The mechanisms in which Tregs may contribute to CD pathology are varied. Indeed, 
complete loss of suppressive IL-10 results in almost complete inability to resolve 
inflammatory responses. However, inflammation in CD is usually localised to the 
intestinal tract, suggesting that patients with CD are not systemically susceptible to 
chronic inflammatory responses. Thus, it is likely that more subtle abnormalities in 
localised immune responses to the intestinal environment are responsible for the 
disease. Germ-free mice have fewer intestinal Tregs, which express less Foxp3 than 
wild-type mouse Tregs, suggesting a role for commensal interactions and intestinal 
Treg development[261]. Studies have shown that colonic Tregs utilise TCR repertoires 
different from IFNγ+ T lymphocytes, IL-17A+ T lymphocytes, and Tregs of other 
tissues[73]. Intestinal Tregs have specificity to commensal microbes, which promotes 
intestinal tolerance to the microbiome.  It is possible that IBD patient Tregs display an 
abnormal TCR repertoire, but this has not been extensively researched in humans. 
An interesting theory in the breakdown of intestinal tolerance is an imbalance in the 
IL-17A+ T lymphocyte/Treg axis. T lymphocyte plasticity is a multi-dimensional 
spectrum which controls the phenotype of individual cells. Transcription factors 
regulate expression of large blocks of genes associated with subset phenotypes and 
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functions. IL-17A+ T lymphocytes are associated with expression of RORγt, whereas 
Tregs express FOXP3. This dichotomy of phenotype is controlled by the exposure to a 
combination of cytokines. Naïve T lymphocytes differentiate into Tregs upon 
exposure to TGFβ and IL-2, whereas the presence of additional cytokines IL-6 and IL-
23, drive IL-17A+ T lymphocyte differentiation. Thus, control of this axis is heavily 
influenced by neighbouring intestinal cytokine-producing APCs and the intestinal 
milieu. Interestingly, inflamed and non-inflamed intestinal tissues from CD patients 
had more FOXP3+IL-17A+ dual-expressing T lymphocytes, than non-IBD 
controls[262]. Furthermore, these cells were found to have retained their TCR 
repertoire and had higher suppressive capacity than traditional Tregs. It was found 
that LP T lymphocytes from UC and CD patients expressed FOXP3+IL-17A+ upon 
exposure to TGFβ, however, differentiation of these cells was not induced in non-IBD 
controls. It is possible that inflammation in CD patient intestinal mucosa drives Treg 
differentiation into a FOXP3+IL-17A+ dual-expression phenotype. Although 
FOXP3+IL-17A+ T lymphocytes have a higher capacity for suppression than traditional 
Tregs, these cells may continue to transition towards a FOXP3-IL-17A+ inflammatory 
T lymphocyte phenotype. Microenvironmental cues of CD patient intestinal milieu 
may contribute to this transition through the presence of inflammatory cytokines. CD 
patient intestinal mucosal tissues had higher concentrations of the T lymphocyte 
differentiation-driving cytokines, TGFβ and IL-6[263, 264]. In this thesis, stimulated 
CD patient PBMCs secreted higher concentrations of IL-6 than non-IBD controls, 
TGFβ was not analysed. 
Patients with CD, compared to non-IBD controls, have been shown to have lower 
frequencies of PBMC Tregs[265] and higher concentrations of serum and intestinal 
mucosa TNF[53]. After 14 days of treatment with anti-TNF antibodies, CD patient 
circulating Treg frequencies increased two-fold, which positively correlated with 
improved disease score[266]. After treatment, CD patient Tregs had three-fold higher 
expression of FOXP3 and improved suppressive capacity. Thus, inhibition of 
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inflammatory pathways may rescue CD patient Treg polarisation into other cell types, 
promoting immune suppression. 
In this thesis, CD patient PBMC Tregs increased in frequency upon exposure to F. 
prausnitzii, whereas non-IBD controls had no response. Interestingly, both non-IBD 
and CD patient Tregs increased in frequency upon exposure to B. fragilis. These data 
suggest CD patients may respond abnormally to certain commensal species, which 
may disrupt intestinal homeostasis. Non-IBD control IFNγ+ T lymphocytes decreased 
in frequency upon exposure to F. prausnitzii, whereas CD PBMCs maintained their 
frequency. A mechanism for this response was not identified. It is possible that CD 
patient PBMCs increased to compensate for the non-reduction of IFNγ+ T 
lymphocytes. This lack of response could have been due to IFNγ+ T lymphocytes 
avoiding suppression, or Treg inability to induce suppression. Upon stimulation of 
PBMCs with anti-CD3/28 beads, CD patient PBMCs had a higher proliferation index 
and precursor frequency than non-IBD control PBMCs. Therefore, it is possible that 
CD patient PBMC Treg suppression did not compensate for the elevated rate of T 
lymphocyte proliferation. However, neither non-IBD nor CD patient PBMC Tregs 
induced Tconv suppression in the Treg suppression assay. It is possible that CD 
patient Tregs have dysfunctional suppressive capacity, but this was not verified in this 
thesis.  
It was not investigated whether these Treg responses to F. prausnitzii were mediated 
through thymic-Treg or peripheral Treg populations. It is possible that non-IBD and 
CD patient PBMC Tregs develop specificity to different commensal bacteria during 
development in the thymus. In contrast, it is also possible that Treg differentiation was 
induced on naïve T lymphocytes in the intestinal mucosa. Studies have shown that 
patients with CD had less butyrate-producing colonic bacteria compared to non-IBD 
controls[138]. Butyrate promotes DC-mediated Treg differentiation, which would 
suggest CD patients would have reduced capacity for colonic Treg 
differentiation[143]. It would be interesting to investigate Treg TCR repertoire and 
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cross-reference these with IFNγ+ and IL-17A+ T lymphocyte repertoire to elucidate 
potential inconsistencies between non-IBD and CD patient Treg responses to colonic 
bacteria. 
Non-IBD and CD patient Tregs did not change in intestinal monolayer conditions with 
F. prausnitzii. Interestingly, in CD monolayers conditions in which co-culture induced 
epithelial degradation, CD patient Tregs still did not have a change in frequency. 
However, upon anti-CD3/28 bead-induced epithelial degradation of monolayers, both 
non-IBD and CD patient Tregs increased in response. This was expected as 
stimulation of naïve T lymphocytes with anti-CD3/28 drives Treg differentiation[267]. 
Importantly, Tregs were not able to prevent degradation in any condition where 
epithelial degradation occurred. This could be due to CD patient Tregs lacking the 
suppressive capacity to prevent inflammation in this model, whereas non-IBD control 
monolayer conditions remained healthy. However, as non-IBD control Treg 
populations did not change in any monolayer condition, Treg frequencies did not 
elucidate a mechanism of pathology in this model. 
Together, these data suggest abnormal increases in CD patient Treg frequencies in 
response to the presence of F. prausnitzii may contribute to disease. Over-expansion of 
Tregs due to commensal species inhabiting local regions of intestinal tissues may lead 
to the generation of immunosuppressed ‘cold spots’. This could provide an 
explanation for the patchy manifestation of CD intestinal lesions. 
 
6.3 IFNγ+ T lymphocytes in Crohn’s disease 
Historically, CD has been associated with IFNγ+ T lymphocyte responses. IFNγ+ T 
lymphocytes express IFNγ, TNF, and IL-2, which are potent inducers of inflammation. 
IFNγ can recruit and activate macrophages, among other inflammatory immune cells, 
and increases expression of MHC on APCs. Patients with CD have been reported to 
have higher frequencies of IFNγ+ T lymphocytes and higher concentrations of IFNγ 
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and TNF in serum and the intestinal mucosa, compared to non-IBD controls[268, 269]. 
Thus, it is plausible that intestinal pathology in CD could be due to excessive IFNγ-
mediated activation of macrophages. Expression of IFNγ enhances macrophage 
antigen presentation capacity, thereby increasing interactions with T lymphocytes and 
subsequently increasing macrophage activation and expression of TNF. Furthermore, 
APCs isolated from CD patient LP produce higher concentrations of IL-12, an inducer 
of IFNγ+ T lymphocyte differentiation, than non-IBD control APCs[270]. Interestingly, 
subcutaneous injection of IFNγ protein in patients with CD did not exacerbate 
disease[271]; in contrast, a study found 3/4 tested CD patients who completed the 
course had their C-reactive protein levels return to non-IBD control 
concentrations[161]. C-reactive protein activates the complement system and its 
presence is associated with an inflammatory response. Phase II trials of Fontolizumab, 
an anti-IFNγ biologic, did not induce clinical response in CD patients with high IFNγ 
concentrations in the intestinal mucosa; however, Fontolizumab did induce a 
reduction in C-reactive protein[160]. These data suggest that although IFNγ+ T 
lymphocytes and IFNγ signalling may play a role in CD pathogenesis, targeting IFNγ 
signalling alone remains ineffective in most patients. 
Neutralising TNF has seen success in the treatment of CD. Interestingly, anti-TNF 
biologics have also been effective in treating patients with UC[272]. UC has 
historically been categorised as a ‘Type 2 T lymphocyte disease’, driven by IL-4 and 
IL-13[273]; however, the effectiveness of anti-TNF biologics in these patients suggests 
CD aetiology is more complex than a single cell type association. 
A recent study implicated more direct mechanisms of IFNγ+ T lymphocyte 
involvement in CD pathology. In a murine study of colitis, CT2/CT6 TCR sequences, 
typically expressed by wild-type mouse colonic Tregs, were instead expressed by 
IFNγ+ T lymphocytes in mice susceptible to the development of spontaneous 
colitis[73]. Authors of this study speculated that naïve T lymphocytes, in mice 
susceptible to colitis, failed to develop into Tregs, as they did in wild-type mice. Thus, 
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it is possible that commensal specificity of IFNγ+ T lymphocytes and IL-17A+ T 
lymphocytes in patients with CD is due to dysfunctional plasticity and failed 
development of Tregs. CD patient intestinal mucosa IFNγ+ T lymphocytes secreted 
higher concentrations of IFNγ and TNF than non-IBD control T lymphocytes[48].  
Together, these data suggest IFNγ+ T lymphocytes can contribute to pathology in mice 
with colitis-like disease; however, their overall contribution to CD pathology in 
humans remains to be elucidated. 
In this thesis, CD IFNγ+ T lymphocytes stimulated with anti-CD3/28 beads had a larger 
fold-increase in frequency than non-IBD control IFNγ+ T lymphocytes. CD patient 
PBMCs expressed higher concentrations of TNF than non-IBD control PBMCs. Thus, 
these data suggest CD patient PBMC IFNγ+ T lymphocytes have a greater capacity for 
inflammation than non-IBD control PBMCs. Interestingly, non-IBD control IFNγ+ T 
lymphocytes decreased in frequency in the presence of F. prausnitzii; in contrast, 3/7 
CD patient IFNγ+ T lymphocytes increased in frequency and 4/7 decreased. These data 
suggest potential differences in mechanisms of disease within individual CD patients. 
A study analysing PBMC responses to commensal antigens found that 75% of tested 
CD patients had PBMC responses to at least one of five commensal antigens, 83% of 
responders, do so to more than one antigen[108]. It is possible that individual patients 
with CD in this cohort have different susceptibilities to commensal microbes, and 
therefore, potentially have different mechanisms of disease. 
Non-IBD control CD4+IFNγ+ T lymphocytes decreased in co-culture monolayer 
conditions with F. prausnitzii, in a dose-dependent manner, whereas CD patient IFNγ+ 
T lymphocytes maintained their frequency. These data reaffirm co-culture data 
obtained in Chapter Three, in which CD patient IFNγ+ T lymphocytes did not respond 
to the presence of F. prausnitzii. Interestingly, CD patient IFNγ+ T lymphocyte 
frequencies did not change in monolayer conditions of epithelial degradation. There 
was also no increase in non-IBD or CD patient IFNγ+ T lymphocyte-associated 
cytokines in apical or basal monolayer compartments in any condition. These data do 
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not implicate IFNγ+ T lymphocytes as mediators of epithelial degradation in this 
model. Interestingly, stimulation with anti-CD3/28 beads -which induced epithelial 
degradation in both non-IBD and CD patient monolayers – increased IFNγ+ T 
lymphocyte frequencies and associated cytokines. Therefore, T lymphocytes have the 
potential to induce epithelial degradation in this model but were most likely not the 
cause of degradation in co-culture conditions. 
 
6.4 IL-17A+ T lymphocytes in Crohn’s disease 
Current thoughts on CD pathogenesis implicate IL-17A+ T lymphocytes as the main T 
lymphocyte subset associated with CD pathology. Studies have shown patients with 
CD had higher frequencies of IL-17A+ T lymphocytes and higher concentrations of IL-
17A and IL-17F, than non-IBD controls[274]. Furthermore, successful treatment of CD 
symptoms in patients with various biologics is typically associated with a reduction 
in IL-17A+ T lymphocytes and their effector cytokines, IL-17 and IL-23[275, 276]. 
However, trials investigating cell subtypes in disease only describe associations, not 
mechanisms of disease. For instance, although high concentrations of IL-17A are 
associated with IBD, anti-IL-17A biologic treatments reduce disease in rheumatoid 
arthritis, but exacerbate disease in patients with CD[89]. Thus, functional IL-17A 
signalling by IL-17A+ T lymphocytes may be critical for maintenance of intestinal 
homeostasis. 
Currently, it is unknown how anti-TNF treatment reduces inflammatory T 
lymphocyte-driven pathology in patients with CD. TNF is a broad inflammatory 
protein. Studies have shown TNF-primed monocytes can polarise naïve T 
lymphocytes into both IFNγ+ T lymphocytes and IL-17A+ T lymphocytes[277]. 
Furthermore, TNF-inhibitor drugs induced IL-10 expression in CD4+IL-17A+ T 
lymphocytes[278]. These data suggest that beneficial treatment of CD may require the 
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transitioning of IL-17A+ T lymphocytes into a regulatory-inflammatory T lymphocyte 
phenotype, rather than directly targeting IL-17A+ T lymphocyte responses. 
In this thesis, CD patient PBMCs had higher frequencies of IL-17A+ T lymphocytes 
than non-IBD controls, reaffirming their association with disease in the literature. 
Interestingly, 7/12 CD patients had higher frequencies of IL-17A+ T lymphocytes, 
compared to non-IBD controls, whereas 5/12 CD patients had frequencies similar to 
non-IBD controls. These data further highlighted the heterogeneity of immune 
profiles in CD. CD patient PBMC CD4+ and CD8+IL-17A+ T lymphocytes, stimulated 
by anti-CD3/28 beads, had a larger increase in fold-change than non-IBD controls. 
Furthermore, CD patient PBMCs secreted higher concentrations of IL-17A than non-
IBD controls. Non-IBD and CD patient PBMC IL-17A+ T lymphocytes had similar 
responses to co-culture with F. prausnitzii and B. fragilis. However, 3/8 CD patient 
PBMCs secreted IL-21 upon exposure to F. prausnitzii at a 1:1 cell:bacteria ratio. IL-21 
is produced by IL-17A+ T lymphocytes and promotes differentiation and activation of 
IL-17A+ T lymphocytes. It is possible that abnormal PBMC responses to commensal 
bacteria could drive an IL-17A+ T lymphocyte response in CD patients; however, IL-
17A+ T lymphocyte population profiles did not reflect this theory in this co-culture 
model. 
Non-IBD and CD patient PBMC responses to monolayer co-culture with F. prausnitzii 
were similar. Both non-IBD and CD patient frequencies of IL-17A+ T lymphocytes 
reduced upon exposure to F. prausnitzii, compared to culture with monolayers alone. 
Co-culture with CD patient PBMCs and F. prausnitzii induced complete monolayer 
degradation. Considering CD patient IL-17A+ T lymphocyte frequencies reduced in 
these conditions, these data did not implicate IL-17A+ T lymphocytes as responsible 
for the degradation. Furthermore, IL-17A+ T lymphocyte cytokines IL-17A, IL-17F, IL-
21, and IL-22 were not different between groups or monolayer conditions. However, 
stimulation with anti-CD3/28 beads induced expression of each of these cytokines, 
indicating that IL-17A+ T lymphocytes have inflammatory potential in this model.  
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Together, data in this thesis provided evidence that CD patient IL-17A+ T lymphocytes 
have a higher inflammatory response potential to stimulation than non-IBD controls. 
However, these findings were only identified in a subset of CD patients, suggesting 
heterogeneity in the immune response to stimulation and commensal interaction. 
Analysis of IL-17A+ T lymphocyte populations and cytokines did not implicate this 
subset in monolayer degradation in this model. It is possible that these cells played a 
role in monolayer degradation, however, assays in this thesis did not detect this. 
 
6.5 Intestinal organoids as a tool for Crohn’s disease investigation 
6.5.1 Personalised treatments 
CD treatment is usually selected by a process of elimination of frontline drugs. CD is 
a heterogeneous disease with varying mechanisms of disease in individuals. 
Consequently, patients often do not respond to primary treatments, and many lose 
response over time. Currently, diagnosis of disease does not implicate a mechanism 
of disease in individuals, just that IBD-like inflammation and pathology is present. 
Medical expertise can help to identify appropriate medications to use but it is evident 
that personalised assays are required to improve the accuracy of diagnosis and reduce 
time to remission. 
Intestinal organoid technology has become widespread in the past decade and 
continues to become more accessible to laboratories around the world. Researchers 
have learnt much about cellular interactions using various organoids derived from 
different human and murine tissues. Intestinal organoids could provide personalised 
assays for the elucidation of disease mechanisms in individual patients and potential 
responses to treatment. Indeed, intestinal organoids have successfully been used to 
verify the appropriateness of the administration of a cystic fibrosis drug to patients. 
In vitro analysis of intestinal organoids from these patients found that the treatment 
increased organoid size in response to forskolin, validating the opening of a 
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previously closed ion channel, caused by a mutation in CFTR[279]. This test improved 
the quality of life for the patients, but also reduced the costs involved in trial and error 
treatment. Data in this thesis showed it is possible for small laboratory groups to 
successfully culture and expand patient intestinal organoids from intestinal biopsies. 
Thus, intestinal organoids provide a promising future for the development of 
personalised treatments. 
 
6.5.2 Intestinal dysregulation – A cause or consequence of disease? 
The intestinal epithelial barrier separates luminal antigens from immune cells in the 
LP. Epithelial integrity of the barrier is vital to the maintenance of homeostasis and 
selective permeability of nutrients and water. Intestinal epithelial barriers from 
patients with CD are more permeable than non-IBD controls. Furthermore, the 
development of intestinal lesions in patients with CD further exacerbates epithelial 
dysregulation and subsequent migration of luminal contents into the LP. Altered 
tight-junction structures have been associated with increased permeability in patients 
with CD[101]. IFNγ, a cytokine elevated in the intestinal mucosa of CD patients[280], 
downregulates expression of tight junction proteins. Elevated rates of intestinal 
epithelial crypt apoptosis has been described in patients with CD[281, 282]. It is 
possible that intestinal epithelial dysregulation in patients with CD is an initiating 
factor in CD pathology; however, CD pathology is more commonly associated with 
immune-mediated inflammation. A study using small intestine monolayers showed 
the co-culture of macrophages protected the monolayer cells from pathogenic E. coli-
induced damage[133]. Thus, immune cell and epithelial cell crosstalk is important for 
the maintenance of epithelial integrity. As intestinal organoid monolayers could be 
cultured in a variety of culture conditions, monolayers were an optimal model to 
investigate initiators of pathology in patient tissues. 
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A 2014 study using organoids derived from murine small intestine crypts, found that 
LGR5+ stem cells within the base of crypts highly expressed NOD2[283]. Upon 
stimulation with the NOD2 ligand, the bacterial peptidoglycan derivative, MDP, 
LGR5+ stem cells were protected from apoptosis. NOD2 knockout mice had a smaller 
average crypt size and a lower frequency of regenerative crypts, thus, suggesting a 
potential role for luminal bacteria in the induction of regenerative responses, and 
maintenance in small intestine crypt stem cells. CD has been associated with abnormal 
immune responses to commensal bacteria, but it is unknown if pathology is initially 
caused by an immune response to commensal bacteria or dysregulation of the 
intestinal epithelial barrier. 
In this thesis, CD patient monolayers had a lower TEER than non-IBD control 
monolayers. CD patient monolayer TEER plateaued after culture in DFM, whereas 
non-IBD control monolayer TEER continued to increase to above the detection limit. 
Both non-IBD and CD patient monolayers maintained TEER in the presence of 
PBMCs, suggesting CD patient PBMCs were not inherently deleterious to monolayer 
cells. CD patient monolayer TEER reduced in the presence of F. prausnitzii; 
furthermore, the reduction in TEER was exacerbated in the presence of CD patient 
PBMCs, resulting in complete TEER reduction and epithelial degradation. Non-IBD 
control monolayers maintained TEER and confluence in all co-culture conditions. 
These data suggest abnormal interactions between CD patient monolayer cells and F. 
prausnitzii may induce epithelial dysregulation. It is possible that the low TEER 
observed in CD patient monolayers represents heightened permeability, a finding that 
would be consistent with in vivo CD patient permeability[101]. Heightened 
permeability could have allowed the migration of F. prausnitzii molecular components 
into the basal compartment, allowing interaction with basolateral PRRs. A study 
showed that interaction of commensal molecular components with basal TLR9 
induces an inflammatory response in enterocytes, whereas apical binding does 
not[111]. It is also possible that deleterious interactions between CD patient epithelial 
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cells and commensal bacteria could induce intestinal epithelial barrier permeability, 
leading to luminal migration of antigens into the lamina propria, and subsequent 
initiation of an immune response.  Data in this model supported the theory that 
immune response to commensals is a consequence of epithelial dysregulation, not an 
initial cause. 
A 2017 study examined the effects of chronic in vitro inflammation on murine colonic 
organoids[239]. Murine colonic organoids were stimulated with a cocktail of 
inflammatory cytokines for over 60 weeks. Stimulation induced expression of NF-κB-
target genes in the organoids, which amplified over time. Chronically stimulated 
organoids had reduced size and cell differentiation, compared to organoids cultured 
without cytokines. Enhanced expression of NF-κB-target genes was present 11 weeks 
after removal of the inflammatory cytokines. Therefore, chronic exposure to 
inflammatory cytokines may imprint a long-term response in epithelial cells, even 
after inflammation has subsided; which suggests that intestinal organoids derived 
from CD patient colonic crypts may have been conditioned to inflammatory 
conditions, regardless of biopsy collection from macroscopically non-inflamed tissues. 
Furthermore, it is common for macroscopically non-inflamed tissues to have evidence 
of inflammation-mediated pathology upon histological analysis, which may have led 
to the collection of inflamed biopsies[284]. It is possible that CD patient organoids 
were stressed from chronic or previous exposure to inflammation, which was further 
exacerbated by dissociation and seeding as monolayers. Cell stress induced by 
inflammatory conditioning could explain why IBD patient monolayers had 
deleterious interactions with F. prausnitzii. Therefore, it cannot be ruled out that these 
deleterious interactions were an artefact of the monolayer model. However, 
heterogeneity in growth and development in both non-IBD and CD patient 3D 
organoids suggests a wide range of organoid health and survivability in in vitro 
culture. The consistent degradation of CD patient monolayers in co-culture, compared 
to the consistent resistance to degradation in non-IBD control monolayers, provided 
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evidence that these differences in response to co-culture were biologically relevant to 
intestinal interactions. 
These data provide insight into possible initiating factors for intestinal epithelial 
barrier dysfunction in patients with CD. The monolayer model is a single layer of cells 
derived from intestinal organoids; therefore, this model does not fully represent the 
complexities of the intestinal milieu. However, these data showed consistent 
differences between non-IBD and CD patient responses to co-culture with F. 
prausnitzii. Together, these data suggest that deleterious interactions between CD 
patient intestinal cells and commensal bacteria may be an initiating factor in the 
disease. Epithelial dysfunction subsequently leads to increased permeability, allowing 
migration of luminal antigens into the lamina propria. It is possible that this influx of 
luminal contents leads to inflammation and chronic exposure of intestinal immune 
cells to commensal bacteria, which may contribute to further loss of tolerance. It is also 
possible that these inflammatory events cause inflammatory conditioning in 
associated cells, leaving patients susceptible to recurrence of disease after resolution.  
 
6.6 Future directions 
Replication of experiments conducted in this thesis using intestinal mucosa immune 
cells would increase the biological relevance of the model. Peripheral blood is easily 
collected and non-invasive; however, intestinal immune cells are more relevant to 
disease but more difficult to obtain and culture. Comparison of PBMC and intestinal 
immune cell data would provide valuable insight into the biological relevance of data 
in this model. Furthermore, if similarities are drawn between these cells, PBMCs could 
continue to be used for further use in the development of personalised assays. 
It would be interesting to further investigate potential abnormal CD PBMC responses 
to other types of commensal bacteria. T-bet deficiency led to the development of 
spontaneous colitis-like disease in mice[236]. Co-housing of these mice resulted in the 
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transmission of colitis-like disease to wild-type mice, indicating the development of 
an inflammation-inducing microbiome. It is possible that inflammatory responses, in 
patients with CD, shape a microbiome more hospitable to pathogenic microbes. 
Therefore, it would be interesting to co-culture non-IBD and CD patient immune cells 
with microbes isolated from faecal content from both non-IBD and CD patients.  
The generation of a monolayer model in this thesis proved the accessibility of 
organoid technology for small laboratory groups. To the best of my knowledge, this 
is the first intestinal monolayer system used to investigate immune responses to 
commensal bacteria in CD. It is possible to further optimise this model to become a 
clinical assay for personalised identification of disease mechanisms in patients. 
Although this first iteration of the monolayer model did not detect differences in 
immune responses, the model itself may be highly adaptable. 
Here, the intestinal monolayer model was able to accommodate T lymphocyte subsets. 
Other studies have shown intestinal monolayers can accommodate macrophages[133, 
285]. Valuable information about cellular interactions in CD could be obtained from 
further optimisation of the monolayer system, and inclusion of multiple types of 
immune cells. Furthermore, individual immune cells subsets could be sorted and 
added to monolayer cultures to investigate their specific role in disease pathogenesis. 
As immune cells often do not function in isolation from other cells, recombinant 
proteins could be added to supplement cell survival and activation. To further 
investigate the pathogenicity of IBD patient immune cells, immune cells from CD 
patients could be cultured with non-IBD control monolayers, and vice versa. 
To improve the monolayer model, future experiments should seek to improve the 
uniformity of epithelial monolayers. Due to a restriction of time and samples, it was 
not possible to fully optimise monolayer growth between individual patients. As a 
result, monolayers cultured from different patients lacked uniformity. This result 
could be partially due to patient heterogeneity, but further optimisation of the culture 
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protocol and careful monitoring of seeding numbers and spheroid:colonoid ratios 
could improve uniformity.  
The addition of recombinant or blocking proteins could provide insight into the 
mechanisms of intestinal pathology, immune response, and immune interactions with 
intestinal cells. As evidence by data in this thesis, T lymphocytes induced epithelial 
degradation when stimulated with anti-CD3/28 beads. Therefore, it is possible to 
titrate this stimulation to induce various intensities of inflammation or stimulate cells 
via other pathways. In this way, multiple diseases and various CD pathology 
mechanisms could be investigated using patient tissues. 
Regarding data in this thesis, future experiments should observe the mechanism of 
epithelial degradation in CD patient monolayers. It is possible that low TEER in CD 
patient monolayers allowed migration of microbial components, allowing interaction 
with basolateral PRRs on the intestinal cells. Supernatants from apical and basal 
compartments should be examined for F. prausnitzii proteins. Furthermore, future 
experiments should co-culture F. prausnitzii in the basal compartment of non-IBD 
control monolayers. This experiment would help elucidate whether the epithelial 
dysregulation is due to abnormal responses from CD patient monolayer cells, or the 
consequence of bacterial component migration into the basal compartment. Future 
experiments should expand the scope of detected cytokines and cell types. Further, 
experiments should aim to include live bacteria, possibly through the use of air-liquid 
interface monolayer models[286].  
This thesis focused on T lymphocytes phenotypes in CD; however, PBMCs are also 
comprised of other immune cell types. Data in this thesis did not implicate T 
lymphocytes as inducers of epithelial degradation; however, it is possible that 
unobserved immune cell types played a role in monolayer degradation. If certain 
immune cell subsets are implicated in monolayer degradation, blocking antibodies 
could be used to elucidate mechanisms of pathology. 
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6.7 Clinical relevance  
In recent years, a variety of treatment options for patients with IBD have become 
available. However, IBD heterogeneity and treatment variety causes difficulty in 
identification of which treatment option is the optimal choice for an individual. This 
leads to the administration of treatments on a trial and error basis. Biologics, such as 
immune response targeting mAb, have paved the way for more precise manipulation 
of the immune system. Biologic treatments are prime candidates for inclusion in 
personalised monolayer assays, as they mediate their effects through direct binding 
to immune cytokines and proteins. 
 
6.7.1 Anti-TNF biologics 
Anti-TNF biologics, such as Infliximab, Adalimumab, and Golimumab, target and 
block TNF, a potent inducer of inflammation[287-289]. Macrophages are a major 
source of TNF, however, other innate cells, as well as IFNγ+ T lymphocytes, can also 
produce TNF[290]. TNF, an activator of NF-κB, is a pyrogen, which upon binding with 
its receptors TNFR1 or TNFR2, can induce a range of cellular responses, which often 
result in cellular differentiation, proliferation, and eventual cell death[291]. Blockade 
of TNF has been successful in reducing the severity of other diseases, such as 
rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Anti-TNF treatments have 
seen major success in the treatment of CD; however, not all patients with CD respond 
to anti-TNF treatment, and 23-46% of responders develop resistance to treatment over 
time, often due to the development of treatment-targeting antibodies[5, 292]. More 
concerning is the number of primary responders, who, in the absence of treatment-
targeting antibodies, still develop resistance to treatment over time, suggesting CD 
mechanisms of pathology may change in individuals over time.  
CD patient PBMCs in this thesis produced higher concentrations of TNF than non-IBD 
control PBMCs, in response to stimulation with anti-CD3/28 beads. Furthermore, CD 
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patient PBMCs were more susceptible to differentiation into IFNγ+ T lymphocytes and 
IL-17A+ T lymphocytes, had a higher proliferation index, and higher precursor 
frequency, than non-IBD control PBMCs. These data suggest CD patient PBMCs have 
a higher inflammatory capacity upon stimulation than non-IBD control PBMCs. 6/10 
CD patient PBMCs produced TNF concentrations above the detection limit, however, 
4/10 produced TNF at a similar level to non-IBD control PBMCs. Therefore, it is 
possible that TNF treatment would not be optimal for all patients in this cohort. 
Interestingly, PBMCs from patients in this cohort, who treated with Humira (anti-
TNF), secreted TNF at concentrations above the limit of detection. These data suggest 
that anti-TNF treatment does not inhibit the production of TNF ex vivo; however, 
conclusive results cannot be determined due to the low number of samples. As anti-
TNF biologics directly influence immune cell inflammatory capacity, anti-TNFs could 
theoretically be used in intestinal monolayer assays to validate the appropriateness of 
administration for individual patients. 
 
6.7.2 Anti-integrin biologics 
Anti-integrin biologics, such as Natalizumab (α4-integrin) and Vedolizumab (α4β7-
integrin) prevent the migration of immune cells to the intestinal mucosa[172, 226]. 
Phase II trials of Natalizumab and Vedolizumab showed both treatments can induce 
remission in CD patients[173]. DCs present antigen to T lymphocytes in intestinal 
MALT, which induces the expression of α4β7-integrin on the T lymphocyte 
surface[293]. These DCs can migrate to mesenteric lymph nodes to present antigen to 
peripheral T lymphocytes, inducing expression of α4β7-integrin[294]. As α4β7+ T 
lymphocytes circulate the body in peripheral blood, they are captured by the cell 
surface-α4β7 ligand, MadCAM-1. MAdCAM-1-expressing cells are highly localised to 
intestinal high endothelial venules and facilitate capture and trafficking of circulating 
α4β7+ to the intestinal mucosa[295]. Thus, anti-integrin biologic treatments broadly 
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reduce gut inflammation by reducing the trafficking of peripheral immune cells into 
the intestinal mucosa.  
α4β7-integrin was not analysed in this thesis. However, α4β7 is upregulated on 
peripheral T lymphocytes upon induction of inflammation, and subsequently 
trafficked to the site of inflammation. Data in this thesis analysed PBMCs, a pool of 
immune cells that could be recruited to the site of intestinal inflammation in CD, thus, 
their responses to stimulation and bacteria are relevant to intestinal biology. Anti-
α4β7-integrin functions by preventing immune cell trafficking to sites of 
inflammation, as opposed to preventing inflammation by direct inhibition of cell-
mediated inflammation; therefore, it is unlikely that this biologic would be 
appropriate for the monolayer model.  
 
6.7.3 Anti-inflammatory T lymphocyte biologics 
Ustekinumab is a mAb which targets and neutralises the p40 subunit of IL-12 and IL-
23[296]. IL-23 is a pro-inflammatory cytokine which induces the differentiation and 
survival of IL-17A+ T lymphocytes. Patients with CD often have high concentrations 
of IL-23 in blood and intestinal mucosa[297]. Ustekinumab treatment is effective for 
patients with high numbers of IL-17A+ T lymphocytes in the intestinal mucosa and 
non-responders to anti-TNF therapy. A 2012 Phase IIb trial of Ustekinumab showed 
that, in CD patients resistant to anti-TNF therapy, 36.6 - 39.7% achieved clinical 
response at six weeks, compared to 23.5% of the placebo group[227]. Risankizumab, 
an anti-IL-23A mAb is an effective treatment for reducing psoriasis severity index but 
is still being investigated for use in CD[298]. A Phase II trial was conducted, in which 
93% of active CD participants had previous treatment with at least one anti-TNF 
treatment. 31% of patients who received Risankizumab experienced clinical remission, 
compared to 15% of patients receiving placebo[299]. 
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CD patients in this thesis had higher frequencies of CD4+IL-17A+ T lymphocytes than 
non-IBD control PBMCs. Furthermore, CD patient PBMCs produced higher IL-17A 
and IL-6, a key cytokine in IL-17A+ T lymphocyte differentiation. However, 5/12 CD 
patient PBMCs had similar frequencies of CD4+IL-17A+ T lymphocytes compared to 
non-IBD control PBMCs, and 4/10 CD patient PBMCs secreted similar concentrations 
of IL-17A to that of non-IBD control PBMCs. These data again, highlight the 
heterogeneous nature of pathological mechanisms in IBD. As anti-inflammatory T 
lymphocyte biologics directly inhibit inflammatory function and polarisation of IL-
17A+ T lymphocytes, these treatments could be tested using the monolayer model for 
appropriateness of administration to patients. 
 
6.7.4 JAK-STAT inhibitor biologics 
Recently developed treatment options for CD are Filgotinib and Tofacitinib. Filgotinib 
and Tofacitinib are Janus Kinase (JAK) inhibitors, which inhibit JAK-Signal transducer 
and activator of transcription (STAT) signalling pathways. JAK and STAT signalling 
proteins interact with membrane-bound cytokine receptors on the cell surface. 
Binding of a cytokine receptor and its ligand induces dimerization of receptors and 
subsequent recruitment of JAK and STAT proteins to the cytokine receptor, inducing 
a signalling cascade. Induction of JAK-STAT signalling has various effects but are 
broadly associated with immune cell activation and initiation of inflammatory 
pathways. In the FITZROY Phase II Filgotinib trail, 47% of patients treated with 
Filgotinib achieved clinical remission after 10 weeks, compared to 23% of patients 
receiving placebo[300]. Phase II Tofacitinib trials have shown limited efficacy. In one 
trial, 43% of patients who received Tofacitinib achieved clinical remission, compared 
to 36.7% of patients who received placebo. In a different trail,  14-31% of patients 




As described above, CD patient PBMCs in this thesis had a higher capacity for 
inflammation and proliferation upon stimulation with anti-CD3/28 beads. JAK-STAT 
signalling was not observed in this thesis. However, JAK-STAT inhibitors mediate 
their effects through direct immune inhibition, suggesting they are ideal candidates 
for inclusion in monolayer assays. 
 
6.7.5 Conclusions 
Each of these treatments comes with variable efficacy and a range of side-effects that 
reduce patient quality of life. Currently, identification of which treatment is 
appropriate for an individual is conducted step-wise – increasing time to remission, 
reducing patient quality of life, and exponentially increasing cost of treatment and 
care. Observational studies have shown that patients who receive scheduled biologic 
interventions (such as Infliximab, 25.7%) are less prone to requiring hospitalisation or 
surgery in the immediate years after the onset of remission, compared to patients 
receiving episodic treatment (46.7%) and patients who had to prematurely stop 
Infliximab treatment (62.7%)[303]. Analyses of patient data from the past 60 years 
have shown the requirement of surgery for patients with CD has decreased over 
time[304, 305]. Multiple factors have contributed to the decrease in required surgeries 
for patients with IBD: earlier diagnosis, improved medical assistance, improved access 
to treatments, and the advent of biologic treatments. Biologic treatments often work 
for some subgroups of IBD patients but not others, suggesting that the mechanism of 
disease is different in each individual and stepwise treatment administration is not 
ideal. Biologic treatments have provided a range of options for individual patients to 
use but the ability to optimally apply these treatments is limited. Intestinal organoids 
and personalised intestinal monolayer models could reduce the burden of treatment 
by modelling disease in vitro, allowing the potential development of individualised 




6.8 Stratification of Crohn’s disease patient data 
Stratification of patient data using EarlyBird highlighted the usefulness of tracking 
patient data across multiple parameters. Indeed, outliers were easily identified and 
observed to have high expression of cytokines across multiple parameters. 
Stratification by age provided a possible explanation for the presences of high- and 
low-IFNγ secreting PBMCs in CD patients. Stratification by cytokine expression 
elucidated possible association between IFNγ and IL-2, and also IL-6 and IL-1β.  
Stratification data were highly speculative due to the low numbers of patients per 
group. However, EarlyBird and stratification of patient data provided useful tools to 
speculate potential mechanisms of pathology in CD patient PBMCs. Ideally, to 
improve the accuracy of stratification, future experiments would have a larger cohort 
and less medication variety. 
 
6.9 A model of Crohn’s disease pathogenesis 
Combined data from the various in vitro models in this thesis provided the basis for 
a model of the induction of intestinal inflammation in CD. CD patient PBMCs a had 
higher capacity for proliferation, production of inflammatory cytokines, and were 
more susceptible to differentiation, compared to non-IBD control PBMCs. CD patient 
PBMC Tregs increased in frequency in the presence of F. prausnitzii, whereas non-IBD 
control Tregs did not respond. This effect was not seen in co-culture with B. fragilis, 
signifying that this response may be specific to certain commensal species. Upon 
exposure to F. prausnitzii, non-IBD control IFNγ+ T lymphocytes reduced in frequency, 
whereas CD patient PBMCs maintained their frequencies. Upon exposure to B. fragilis, 
non-IBD control IFNγ+ T lymphocytes and IL-17A+ T lymphocytes reduced in 
frequency, whereas CD patient PBMCs did not. Together, these data suggest CD 
patient PBMCs have abnormal responses to commensal bacteria and may avoid the 
development of commensal tolerance.  
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CD patient monolayers had lower TEER than non-IBD control monolayers, suggesting 
heightened permeability. Furthermore, CD patient monolayers had deleterious 
interactions with F. prausnitzii, resulting in reduced TEER, which was exacerbated by 
the presence of PBMCs. However, PBMCs alone did not induce TEER reduction in CD 
patient monolayers, suggesting an external stimulus is required for deleterious 
immune response. 
Together, these data suggest that patients with CD may be more susceptible to initial 
inflammatory insult due to deleterious interactions between commensal bacteria and 
the intestinal epithelial barrier. Consequently, elevated permeability in CD patient 
intestinal epithelial barriers may promote the local expansion of Tregs in regions of 
intestinal tissue, creating immune ‘cold spots’. These cold spots could promote 
bacterial success, leading to an influx of bacterial migration into the lamina propria, 
resulting in an inflammatory response. Aligning with the patchy development of CD 
intestinal lesions, local region cold spots could be the result of the migration of certain 
commensal species, such as F. prausnitzii, across the epithelial barrier in discreet 
regions of intestinal tissue. Frequent exposure to commensal microbes in the lamina 
propria could promote commensal-specificity and a subsequent loss of tolerance to 
invading bystander microbes. Data in this model suggest that abnormal interactions 
between epithelial cells and intestinal commensals may be the cause of initial insult, 
and the subsequent immune response may be the consequence of epithelial 
disruption. However, it is clear from data in this thesis, that abnormalities in both 





Figure 6.1 Theory of intestinal cold spots. Cartoon of an intestinal epithelium split 
into a ‘warm spot’ (left) and a ‘cold spot’ (right). Warm spot refers to an area with an 
active immune response. In this case, IFNγ+ and IL-17A+ T lymphocytes were 
presented luminal antigens by a DC. T lymphocytes initiate an inflammatory 
response, and bacteria are cleared upon entry and eventual resolution. Cold spot 
refers to an area with a Treg bias. 1) Data in this thesis showed CD patient PBMCs 
increased in frequency upon exposure to the commensal F. prausnitzii, whereas non-
IBD control Tregs did not. 2) Treg-biased zones may promote bacterial success, 
leading to dysbiosis in regions of the intestine. 3) Bacterial success allows migration 
through the intestinal barrier, into the immune dampened tissues. 4) Mass migration 
of luminal microbes into intestinal tissues results in a large immune infiltration and 
subsequent inflammation. Immune damage may leave intestinal regions susceptible 




The ‘cause or consequence’ of CD pathology has been a constant debate in the field of 
CD research for decades. CD represents a range of manifestations of disease and 
mechanisms of pathology. Data in this thesis reaffirmed the notion that patients with 
CD are heterogeneous, and a mechanism for CD cannot be found by observing 
immune profiles alone. CD is an intestinal pathology, which facilitates the 
dysregulation and breakdown of the intestinal epithelial barrier in all patients. Thus, 
treatment and re-establishment of the intestinal epithelial barrier should be the 
primary objective in CD rehabilitation. The intestinal monolayer model in this thesis 
provided valuable insight into the aetiology of pathology in patients with CD. Within 
the monolayer model, CD patients had deleterious interactions with commensal 
bacteria, exacerbated by the presence of immune cells. Thus, within this model, 
pathology was a combination of both abnormal epithelial and immune response to 
commensal bacteria. These data provided evidence which suggested that a 
dysregulated epithelium was the initial cause of disease, and the subsequent immune 
response was a consequence of that dysregulation. However, debate on what is a 
‘cause or consequence’ of the disease remains largely irrelevant, due to the 
heterogeneity of the disease and various mechanisms of pathology. What is clear, is 
that each patient with IBD has unique mechanisms of disease and unique treatment 
requirements; therefore, the debate should be focused on the selection and 
development of in vitro tools for personalised assays for improved identification of 
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Supplementary Figure 1: Expression of CD3 in non-IBD and CD patient PBMCs visualised 
by SPADE analysis. Peripheral blood mononuclear cells (PBMC) were isolated from non-
inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples 
were processed as described in the Materials and Methods, then analysed by flow cytometry. 
Plot shows CD3 expression across live CD3+ PMBCs from concatenated data from 5 non-IBD 
controls (a) and 5 CD patients (b). CD3 expression is relative to mean CD3 MFI within this 





Supplementary Figure 2: Expression of CD4 in non-IBD and CD patient PBMCs visualised 
by SPADE analysis. Peripheral blood mononuclear cells (PBMC) were isolated from non-
inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples 
were processed as described in the Materials and Methods, then analysed by flow cytometry. 
Plot shows CD4 expression across live CD3+ PMBCs from concatenated data from 5 non-IBD 
controls (a) and 5 CD patients (b). CD4 expression is relative to mean CD4 MFI within this 





Supplementary Figure 3: Expression of CD8 in non-IBD and CD patient PBMCs visualised 
by SPADE analysis. Peripheral blood mononuclear cells (PBMC) were isolated from non-
inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples 
were processed as described in the Materials and Methods, then analysed by flow cytometry. 
Plot shows CD8 expression across live CD3+ PMBCs from concatenated data from 5 non-IBD 
controls (a) and 5 CD patients (b). CD8 expression is relative to mean CD8 MFI within this 





Supplementary Figure 4: Expression of IFNγ in non-IBD and CD patient PBMCs visualised 
by SPADE analysis. Peripheral blood mononuclear cells (PBMC) were isolated from non-
inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples 
were processed as described in the Materials and Methods, then analysed by flow cytometry. 
Plot shows IFNγ expression across live CD3+ PMBCs from concatenated data from 5 non-IBD 
controls (a) and 5 CD patients (b). IFNγ expression is relative to mean IFNγ MFI within this 





 Supplementary Figure 5: Expression of IL-2 in non-IBD and CD patient PBMCs visualised 
by SPADE analysis. Peripheral blood mononuclear cells (PBMC) were isolated from non-
inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples 
were processed as described in the Materials and Methods, then analysed by flow cytometry. 
Plot shows IL-2 expression across live CD3+ PMBCs from concatenated data from 5 non-IBD 
controls (a) and 5 CD patients (b). IL-2 expression is relative to mean IL-2 MFI within this data 





Supplementary Figure 6: Expression of IL-17A in non-IBD and CD patient PBMCs 
visualised by SPADE analysis. Peripheral blood mononuclear cells (PBMC) were isolated 
from non-inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). 
Samples were processed as described in the Materials and Methods, then analysed by flow 
cytometry. Plot shows IL-17A expression across live CD3+ PMBCs from concatenated data 






Supplementary Figure 7: Expression of CD25 in non-IBD and CD patient PBMCs visualised 
by SPADE analysis. Peripheral blood mononuclear cells (PBMC) were isolated from non-
inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). Samples 
were processed as described in the Materials and Methods, then analysed by flow cytometry. 
Plot shows CD25 expression across live CD3+ PMBCs from concatenated data from 5 non-IBD 
controls (a) and 5 CD patients (b). CD25 expression is relative to mean CD25 MFI within this 





Supplementary Figure 8: Expression of FOXP3 in non-IBD and CD patient PBMCs 
visualised by SPADE analysis. Peripheral blood mononuclear cells (PBMC) were isolated 
from non-inflammatory bowel disease (IBD) controls and patients with Crohn’s disease (CD). 
Samples were processed as described in the Materials and Methods, then analysed by flow 
cytometry. Plot shows FOXP3 expression across live CD3+ PMBCs from concatenated data 
from 5 non-IBD controls (a) and 5 CD patients (b). FOXP3 expression is relative to mean 





















Supplementary Figure 9: Time course optimisation of PBMC cytokine analysis. Peripheral 
blood mononuclear cells (PBMC) were isolated from non-inflammatory bowel disease (IBD) 
controls. Samples were processed as described in the Materials and Methods, then 80,000 
PBMCs were cultured with anti-CD3/CD28 beads at a 1:1 ratio for either 24, 48, or 72 hours. 
Cytokine supernatants were then analysed by flow cytometry. 48 hours was chosen as some 
cytokine expression was delayed until 48 hours (a); whereas expression of other cytokines 
were above limit of detection at 72 hours (b). Data are shown as the mean concentrations 
(pg/mL) of the indicated cytokine and the lines represent the range. Non-IBD (n=3). The dotted 








Supplementary Figure 10: CFSE staining did not resolve proliferation peaks. a) non-
inflammatory bowel disease (IBD) control peripheral blood mononuclear cells were sorted 
into Tconv (CD3+CD4+CD25lo-intCD127+) and Treg (CD3+CD4+CD25HICD127-) populations. a) 
Lymphocytes were validated by size, granularity, CD4, and viability dye, after 3 or 6 days 
culture Tconvs were stained with CFSE before stimulation then cultured with a 1:1 cell:bead 
ratio of anti-CD3/28 beads for 3 (b) or 6 (c) days.  Individual proliferation peaks were gated 
and labelled by division number and the frequency of total Cell Trace Violet+ (CTV) events. 






Supplementary Figure 11: Validation of sorted Tregs for expression of CD25 and FOXP3. 
a-c) Tregs (CD3+CD4+CD25HICD127-) were sorted from human peripheral blood mononuclear 
cells. Dot plots are pre-gated on CD3+CD4+ T lymphocytes. a) CD25 fluorescence minus one 
(FMO) with gate indicating CD25 positivity. (b) FOXP3 FMO with gate indicating FOXP3 
positivity. (c) Dot plot shows sorted Tregs and CD25 and FOXP3 expression. Data are 




Supplementary Figure 12: Non-IBD control intestinal monolayers maintained TEER in all 
bacterial conditions. Peripheral blood mononuclear cells (PBMC) were isolated from non-
inflammatory bowel disease (IBD) controls. Samples were processed as described in the 
Materials and Methods. 106 PBMCs were added to the basal compartment of confluent 
intestinal monolayers, cultured with apical MOI 10 or 50 F. prausnitzii, basal anti-CD3/28 (1:1 
bead:cell ratio), or alone, for 72 hours, then processed for H&E staining. H&E image shows 
intestinal cells lining a 0.4 μm Transwell® membrane. All conditions maintained 
transepithelial electrical resistance over the 72 hours [except with the addition of anti-CD3/28 
beads]. Gaps between monolayer cells in this image were likely due to post-processing events. 
This monolayer was derived from patient C149. Failed to scan data not available at hand-in 






Supplementary Figure 13: Non-IBD control intestinal monolayers maintained TEER in all 
bacterial conditions. Peripheral blood mononuclear cells (PBMC) were isolated from non-
inflammatory bowel disease (IBD) controls. Samples were processed as described in the 
Materials and Methods. 106 PBMCs were added to the basal compartment of confluent 
intestinal monolayers, cultured with apical MOI 10 or 50 F. prausnitzii, basal anti-CD3/28 (1:1 
bead:cell ratio), or alone, for 72 hours, then processed for H&E staining. H&E image shows 
intestinal cells lining a 0.4 μm Transwell® membrane. All conditions maintained 
transepithelial electrical resistance over the 72 hours [except with the addition of anti-CD3/28 
beads]. Gaps between monolayer cells in this image were likely due to post-processing events. 




Supplementary Figure 14: Non-IBD control intestinal monolayers maintained TEER in all 
bacterial conditions. Peripheral blood mononuclear cells (PBMC) were isolated from non-
inflammatory bowel disease (IBD) controls. Samples were processed as described in the 
Materials and Methods. 106 PBMCs were added to the basal compartment of confluent 
intestinal monolayers, cultured with apical MOI 10 or 50 F. prausnitzii, basal anti-CD3/28 (1:1 
bead:cell ratio), or alone, for 72 hours, then processed for H&E staining. H&E image shows 
intestinal cells lining a 0.4 μm Transwell® membrane. All conditions maintained 
transepithelial electrical resistance over the 72 hours [except with the addition of anti-CD3/28 
beads]. Gaps between monolayer cells in this image were likely due to post-processing events. 




Suppl  ementary Figure 15: Non-IBD control intestinal monolayers maintained TEER in all 
bacterial conditions. Peripheral blood mononuclear cells (PBMC) were isolated from non-
inflammatory bowel disease (IBD) controls. Samples were processed as described in the 
Materials and Methods. 106 PBMCs were added to the basal compartment of confluent 
intestinal monolayers, cultured with apical MOI 10 or 50 F. prausnitzii, basal anti-CD3/28 (1:1 
bead:cell ratio), or alone, for 72 hours, then processed for H&E staining. H&E image shows 
intestinal cells lining a 0.4 μm Transwell® membrane. All conditions maintained 
transepithelial electrical resistance over the 72 hours [except with the addition of anti-CD3/28 
beads]. Gaps between monolayer cells in this image were likely due to post-processing events. 
This monolayer was derived from patient C158. 
 




Supplementary Figure 16: Non-IBD control intestinal monolayers maintained TEER in all 
bacterial conditions. Peripheral blood mononuclear cells (PBMC) were isolated from non-
inflammatory bowel disease (IBD) controls. Samples were processed as described in the 
Materials and Methods. 106 PBMCs were added to the basal compartment of confluent 
intestinal monolayers, cultured with apical MOI 10 or 50 F. prausnitzii, basal anti-CD3/28 (1:1 
bead:cell ratio), or alone, for 72 hours, then processed for H&E staining. H&E image shows 
intestinal cells lining a 0.4 μm Transwell® membrane. All conditions maintained 
transepithelial electrical resistance over the 72 hours [except with the addition of anti-CD3/28 
beads]. Gaps between monolayer cells in this image were likely due to post-processing events. 




Supplementary Figure 17: CD patient intestinal monolayers maintained TEER in all 
bacterial conditions. Peripheral blood mononuclear cells (PBMC) were isolated from patients 
with Crohn’s disease. Samples were processed as described in the Materials and Methods. 106 
PBMCs were added to the basal compartment of confluent intestinal monolayers, cultured 
with apical MOI 10 or 50 F. prausnitzii, basal anti-CD3/28 (1:1 bead:cell ratio), or alone, for 72 
hours, then processed for H&E staining. H&E image shows intestinal cells lining a 0.4 μm 
Transwell® membrane. All conditions maintained transepithelial electrical resistance over the 
72 hours [except with the addition of anti-CD3/28 beads]. Gaps between monolayer cells in 




Supplementary Figure 18: CD patient intestinal monolayers maintained TEER in all 
bacterial conditions. Peripheral blood mononuclear cells (PBMC) were isolated from patients 
with Crohn’s disease. Samples were processed as described in the Materials and Methods. 106 
PBMCs were added to the basal compartment of confluent intestinal monolayers, cultured 
with apical MOI 10 or 50 F. prausnitzii, basal anti-CD3/28 (1:1 bead:cell ratio), or alone, for 72 
hours, then processed for H&E staining. H&E image shows intestinal cells lining a 0.4 μm 
Transwell® membrane. All conditions maintained transepithelial electrical resistance over the 
72 hours [except the with addition of anti-CD3/28 beads]. Gaps between monolayer cells in 






Supplementary Figure 19: CD patient intestinal monolayers maintained TEER in all 
bacterial conditions. Peripheral blood mononuclear cells (PBMC) were isolated from patients 
with Crohn’s disease. Samples were processed as described in the Materials and Methods. 106 
PBMCs were added to the basal compartment of confluent intestinal monolayers, cultured 
with apical MOI 10 or 50 F. prausnitzii, basal anti-CD3/28 (1:1 bead:cell ratio), or alone, for 72 
hours, then processed for H&E staining. H&E image shows intestinal cells lining a 0.4 μm 
Transwell® membrane. All conditions maintained transepithelial electrical resistance over the 
72 hours [except with the addition of anti-CD3/28 beads]. Gaps between monolayer cells in 
this image were likely due to post-processing events. This monolayer was derived from 




Supplementary Figure 20: No difference between non-IBD and IBD cytokines produced in 
response to co-culture conditions in intestinal monolayer model. Supernatants were 
collected from apical (left) and basal (right) compartments of experiments conducted in Figure 
5.8. Cytokines from supernatants were labelled using a LegendPlex cytokine analysis kit, then 
analysed by flow cytometry. Data are shown as individual patients and the bar represents the 
median concentration (pg/mL). Non-inflammatory bowel disease (n=3), Crohn’s disease (n=3). 
Statistical analyses were calculated using the Wilcoxon matched-pairs ranked test. 
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Supplementary Figure 21: No difference between non-IBD and IBD cytokines produced in 
response to co-culture conditions in intestinal monolayer model. Supernatants were 
collected from apical (left) and basal (right) compartments of experiments conducted in Figure 
5.8. Cytokines from supernatants were labelled using a LegendPlex cytokine analysis kit, then 
analysed by flow cytometry. Data are shown as individual patients and the bar represents the 
median concentration (pg/mL). Non-inflammatory bowel disease (n=3), Crohn’s disease (n=3). 
Statistical analyses were calculated using the Wilcoxon matched-pairs ranked test. 
252 
 
Supplementary Figure 22: No difference between non-IBD and IBD cytokines produced in 
response to co-culture conditions in intestinal monolayer model. Supernatants were 
collected from apical (left) and basal (right) compartments of experiments conducted in Figure 
5.8. Cytokines from supernatants were labelled using a LegendPlex cytokine analysis kit, then 
analysed by flow cytometry. Data are shown as individual patients and the bar represents the 
median concentration (pg/mL). Non-inflammatory bowel disease (n=3), Crohn’s disease (n=3). 
Statistical analyses were calculated using the Wilcoxon matched-pairs ranked test. 
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Supplementary Figure 23: No difference between non-IBD and IBD cytokines produced in 
response to co-culture conditions in intestinal monolayer model. Supernatants were 
collected from apical (left) and basal (right) compartments of experiments conducted in Figure 
5.8. Cytokines from supernatants were labelled using a LegendPlex cytokine analysis kit, then 
analysed by flow cytometry. Data are shown as individual patients and the bar represents the 
median concentration (pg/mL). Non-inflammatory bowel disease (n=3), Crohn’s disease (n=3). 







Supplementary Figure 24: No difference between non-IBD and IBD cytokines produced in 
response to co-culture conditions in intestinal monolayer model. Supernatants were 
collected from apical (left) and basal (right) compartments of experiments conducted in Figure 
5.8. Cytokines from supernatants were labelled using a LegendPlex cytokine analysis kit, then 
analysed by flow cytometry. Data are shown as individual patients and the bar represents the 
median concentration (pg/mL). Non-inflammatory bowel disease (n=3), Crohn’s disease (n=3). 
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research project. 
2. I have had sufficient time to talk with other people of my choice about participating in the 
study.   
3. I confirm that I meet the criteria for participation which are explained in the Information 
Sheet. 
4. All my questions about the project have been answered to my satisfaction, and I understand 
that I am free to request further information at any stage.  
5. I know that my participation in the project is entirely voluntary, and that I am free to 
withdraw from the project at any time without disadvantage. 
6. I know that as a participant I will be required to provide a 50 mL blood sample 
7. I know that the consent process will explore my health status and that if the line of 
questioning  develops in such a way that I feel hesitant or uncomfortable I may decline to 
answer any particular question(s) , and /or may withdraw from the project without 
disadvantage of any kind.  
8. I understand the nature and size of the risks of discomfort or harm which are explained in 
the Information Sheet. 
9. I know that when the project is completed, all personal identifying information will be 
removed from the paper records and electronic files which represent the data from the 
project, and that these will be placed in secure storage and kept for at least ten years.  
10. I understand that the results of the project may be published and be available in the 
University of Otago Library, but that either (i) I agree that any personal identifying 
256 
 
information will remain confidential between myself and the researchers during the study, 
and will not appear in any spoken or written report of the study . 
11. I know that there is no remuneration offered for this study, and that no commercial use will 
be made of the data.  
12. I understand that the blood samples will be potentially stored at -80oC in a dedicated human 
tissue storage facility for future use in only this study.   
13. I request that my sample is disposed of with a karakia  
14. I would like to receive a copy of the results of this study at completion  
Email address for results:………………………………………………………………………. 
Signature of participant:  Date: 
   
   
 
Name of person taking consent  Date: 
   
 
This study has been approved by the University of Otago Human Ethics Committee (Health: 
H17/117). If you have any concerns about the ethical conduct of the research, you may contact 
the Committee through the Human Ethics Committee Administrator (phone +64 3 479 8256 or 
email gary.witte@otago.c.nz). Any issues you raise will be treated in confidence and 
investigated, and you will be informed of the outcome. 
